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1
INTRODUCTION

CELL DIFFERENTIATION
The majority of chemotherapeutic agents in clinical use exert their antitumor activity
through the production of cytotoxic lesions in the malignant cell population. This concept
o f tumor cell kill has been the driving philosophy behind the development of most
anticancer compounds in the last few decades. However, such agents also produce similar
cytodestructive lesions in normal cells, and the efficacy of clinically useful anticancer drugs
is achieved only through the greater susceptibility o f neoplastic cells to the agents’ cytotoxic
effects (1). The difference in drug susceptibility between tumor cells and normal cells is
often small, and this narrow therapeutic index limits the amount of drug which can be given
to the patient. While such chemotherapeutic agents have been responsible for significant
advances in the treatment o f several types of cancers, notably childhood leukemias, this
therapeutic response is often achieved at the expense o f significant toxicity to normal cells
and considerable morbidity to the patient. Furthermore, conventional cytotoxic regimens
have been much less successful in the treatment of most adult malignancies, and few of the
currently available drugs have any clinically effective activity against the most common
forms of adult cancer (2,3).
Continued development of new cytotoxic agents has not led to significant
therapeutic improvement over available anticancer drugs, and the generation of cytotoxic
compounds currently under clinical investigation offers few prospects of broader antitumor
activity (3). Because of the clinical limitations of cytodestructive drugs, it is necessary to
develop new kinds of therapeutic agents which do not require cytodestruction for antitumor
action. One such alternative approach envisions the use of pharmacological inducers of
tumor cell maturation as a possible new therapy (1,4-6).
Differentiation of neoplastic cells. The maturation of tumor stem cells to terminally
differentiated forms has been shown to be inhibited or abnormally regulated in both
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hematological malignancies and solid tumors (5, 7-9). This loss o f control o f cell
differentiation contributes to an increased population o f self-renewing stem cells and to
consequent tumor growth. In normal proliferating tissues, such as bone marrow, testes
and skin, the process by which fully differentiated mature cells are continuously lost and
replaced by a pool of self-renewing stem cells is tightly regulated (10). The pool of
pluripotent stem cells is capable of self-renewal or differentiation to transitional, committed
progenitor forms. Mitotic division of a stem cell can yield two new stem cells (self-renewal
or proliferation), two progeny cells committed to the maturation pathway (differentiation),
or one new stem cell and one cell committed to maturation. In normal proliferating tissues,
tight regulation of this delicate balance between self-renewal and differentiation is necessary
for both growth control and continuous production o f mature, functional end-stage cells.
Committed progenitor cells are restricted to one lineage of development and have limited
self-renewal potential.

These progenitor, or precursor, cells can undergo further

differentiation and give rise to end-stage cells of that specific lineage. Mature end-stage
cells are terminally differentiated and have no proliferative capability, but are functionally
effective for a finite life span (1,11).
This regulated program of differentiation, essential for physiological processes such
as hematopoiesis, is aberrant in malignancy (12). Hematopoiesis is normally mediated by
the interaction of cytokines, which include erythropoietin (EPO), colony stimulating factors
(CSFs) and interleukins (ILs). These glycoprotein molecules determine whether stem cells
undergo self-replication or commitment to the differentiation pathway. In contrast to
noimal stem cells, neoplastic stem cells display an increased probability of generating two
new stem cells upon mitotic division, with a concomitantly decreased probability of
producing daughter cells committed to the maturation pathway. Consequently, the tumor
grows as stem cells undergo increased self-renewal and proliferation, and there is a
decreased progression of stem cells to terminally differentiated, functional cells (1,11).
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However, cancer is not an irreversible process (1). Experimental evidence in a
variety of tumor types has demonstrated that malignant cells often retain the ability to
undergo a program of terminal differentiation similar to that occurring in normal tissue cells
from which they originate (13-17). The sporadically observed spontaneous remission of
cancer may be due to progression o f malignant stem cells to terminally differentiated forms
without futher proliferative potential.

For example, differentiation o f malignant

neuroblastoma cells to benign ganglioneuroma cells has been documented in pediatric
patients with stage IV-S neuroblastoma (18,19).
Pharmacological induction o f the differentiation o f neoplastic stem cells. The initial
evidence that pharmacological agents can induce the commitment of neoplastic stem cells to
a maturation pathway and progression to non-tumorgenic forms was reported twenty-five
years ago. In this first observation, colony stimulating factor (CSF) was shown to enhance
mature colony formation from murine myelomonocytic leukemia cells (17). Similar studies
later demonstrated that human spleen conditioned medium can induce the maturation of
human leukemic myeloblasts and that the polar solvent dimethylsulfoxide (DMSO) can
induce the differentiation of Friend murine erythroleukemia (MEL) cells (20). In the last
twenty-five years, a wide variety o f chemical and biological agents have been demonstrated
to induce terminal differentiation o f malignant cells in a number o f tumor cell systems.
Pharmacological induction of differentiation has been achieved in tumor cell lines derived
from all three germ layers and o f germ cell origin (1). Thus, the potential use of
physiological inducers or pharmacological agents to correct the imbalance between selfrenewing stem cells and mature end-stage cells is a potential approach to cancer therapy
which needs to be addressed.
Differentiation in vitro has been examined in a number of human and murine
leukemia cell lines, including the Friend MEL, HL-60 human acute promyclocytic leukemia
and M l murine myeloid leukemia cell lines (1, 20-23). DMSO was initially shown to
induce tumor cell maturation in these cell lines, and other polar compounds have
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subsequently been demonstrated to have similar differentiation-inducing activity (24-26).
While the ability of DMSO and similar chemical agents to induce leukemia cell
differentiation has been known for two decades, the mechanism by which these
compounds exert their activity remains unclear. Nonetheless, the ability of these agents to
induce maturation of leukemia cell lines in culture has simplified in vitro studies of cell
differentiation (1). One particular murine leukemia cell line that has been studied
extensively and that is often used to investigate tumor cell maturation is the Friend MEL cell
line (20).

FRIEND MURINE ERYTIIROLEUKEMIA CELLS
Friend murine ervthroleukemia (MEL) cells and the spleen focus-forming virus
(SFFV). Friend MEL cells were derived from proerythroblast-like cells isolated from the
spleens of mice infected with the Friend SFFV viral complex (27, 28). This retroviral
complex, commonly referred to as the "Friend virus," was discovered by Charlotte Friend
in 1957 and consists of two component viruses: the spleen focus-forming virus (SFFV), a
replication-defective retrovirus, and the Friend murine leukemia virus (F-MuLV), a
replication-competent helper virus (27,29,30). The SFFV is the component responsible
for the acute erythroleukemia induced by the Friend virus upon infection of adult mice (27,
31-34). The target cells for SFFV infection has been demonstrated to be relatively late
committed erythroid precursor cells closely associated with colony-forming unit-erythroid
(CFU-E) cells (27, 28, 35-37), as depicted in Figure 1. These committed erythroid
progenitor cells are responsive to the glycoprotein hormone erythropoietin (EPO), the
principal humoral regulator of erythrocyte production, and are dependent on EPO for both
proliferation and terminal differentiation to functional erythrocytes (38). EPO has been
shown to be necessary for colony formation from these cells in in vitro assays (28).
Two variants of the SFFV can be distinguished by their ability to induce
polycythemia (SFFVp) or a mild anemia (SFFVa) in infected adult mice (27). Mice
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Figure 1. The Friend murineervlhroleukemia (MEL) cell system for studying the
erythropoietin (EPO)-induced differentiationQtervthroitLcells
The burst-forming unit-erythroid (BFU-E) is an early, committed erythroid
progenitor cell derived from the colony-forming unit-stem (CFU-S). Interleukin-3
(IL-3) acts upon CFU-S and BFU-E cells to stimulate both self-renewal as well as
progression to more mature stages of development. IL-3 induces the differentiation
of the BFU-E to the more mature colony-forming unit-erythroid (CFU-E).
Erythropoietin (EPO) acts upon the CFU-E to induce both proliferation and
differentiation to erythrocytes, or mature red blood cells (RBCs). Infection of
CFU-E cells by Friend virus gives rise to Friend murine erythroleukemia (MEL)
cells that are independent of EPO and are blocked in EPO-induced differentiation.
Induction o f MEL cell differentiation by dimethylsulfoxide (DMSO) restores
sensitivity to the differentiating effects of EPO.
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infected with Friend SFFVp or SFFVa viral complexes develop greatly enlarged spleens
due to a massive proliferation o f proerythroblast-like cells in the spleen (27, 28).
However, whereas erythropoiesis in SFFVa-infected mice remains sensitive to normal
physiological controls, erythroid differentiation is apparently unregulated in SFFVpinfected mice. SFFVp-infected mice continue to produce mature red blood cells even in the
absence of detectable levels of EPO (28,39-41). Unlike the erythroid progenitor cells that
are the target o f SFFVp infection and EPO-dependent MEL cells derived from SFFVainfected mice, Friend MEL cells derived from mice infected with SFFVp are unresponsive
to EPO (30,42). SFFVp infection confers extensive self-renewal capacity upon erythroid
progenitor cells and abrogates their dependence on EPO (Figure 1). These transformed
Friend MEL cells can grow in the absence of EPO in culture and can form colonies in the
absence of EPO in in vitro assays (43, 44). In addition, these cells are blocked in their
differentiation and do not progress down the developmental pathway to mature erythrocytes
when exposed to EPO in culture (20,27).
Chemical induction o f the differentiation of Friend MEL cells. A variety of
chemical agents, including DMSO, can induce Friend MEL cells to undergo changes in
cellular morphology and function similar to those occurring during the differentiation of
proerythroid cells to orthochromatophilic normoblasts. These alterations include a decrease
in cell size, induction of heme and hemoglobin synthesis, expression of erythrocyte
antigens, and changes in protooncogene expression. More interestingly, the induction of
Friend cell differentiation by DMSO is accompanied by a restoration of sensitivity to both
the growth-stimulatory and differentiation-inducing effects of EPO (Figure 1). DMSOpretreated MEL cells respond to EPO in culture with both increased proliferation and
increased hemoglobin production, a marker of erythroid differentiation (20,45).
The mechanism by which DMSO induces the differentiation of MEL cells and
restores sensitivity to EPO remains unclear. A number of second messenger systems have
been implicated in the chemical induction of differentiation in MEL cells, including cAMP-
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dependent protein kinase (PKA), protein kinase C (PKC) and tyrosine dephosphorylation
(46-53). A strong body of evidence suggests that PKC plays an important role in the
chemical induction of differentiation. Depletion of cellular PKC in MEL cells by long-term
exposure to 12-O-tetiadecanoylphorbol-13-acetate (TPA) blocked the ability of the cells to
differentiate in response to hexamethylene bisacetamide (HMBA) (51). The introduction of
murine PKC-p, but not PKC-a, into permeabilized vincristine-resistant MEL cells
accelerated HMB A-induced differentiation (52). Treatment of MEL cells with TPA or PKC
inhibitors, such as H7 and sphingosine, blocked subsequent DMSO-induced
differentiation. In addition, although PKC activity declined during MEL cell maturation,
continued PKC activity was necessary for completion of the differentiation process (53).
Tyrosine dephosphorylation has also been implicated in the erythroid differentiation
o f MEL cells (48). Several protein tyrosine kinase inhibitors, including ST638 and
genistein, have been shown to effectively induce MEL cell differentiation (47,48). It was
recently reported that most cellular phosphotyrosine-containing proteins were either
decreased or disappeared very early in erythroleukemia cells induced to differentiate by
exposure to DMSO.

The phosphotyrosine phosphatase (PTP) inhibitor, sodium

orthovanadate (Na3 V0 4 ), prevented the alterations in phosphotyrosine-containing proteins,
as well as the cellular differentiation produced by DMSO (49). In addition, mutant MEL
cells resistant to the induction of differentiation by DMSO did not exhibit changes in
phosphotyrosine-containing proteins (49).

While both PKC activity and tyrosine

dephosphorylation have been implicated in the maturation o f MEL cells, the relative
importance of each event remains unclear. Thus, it is not known whether PKC activity and
tyrosine dephosphorylation are two separate, yet both necessary, pathways for the
commitment to differentiate in response to DMSO or whether both activities are part of the
same pathway, with one activity being upstream or downstream of the other. In addition, it
is not known whether the tyrosine dephosphorylation seen in MEL cells undergoing
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maturation results from a decrease in tyrosine kinase activity, an increase in PTP activity,
or a combination of both (49).

ERYTHROPOIETIN RECEPTOR
Erythropoietin (EPO). Erythropoietin (EPO) is a 34 kilodalton (kDa) glycoprotein
hormone which is the primary humoral regulator o f erythrocyte production. EPO is
produced primarily by interstitial cells adjacent to proximal convoluted tubules in the
kidney, although a small amount o f EPO production occurs in the liver (38, 54). After
synthesis and release by the kidney, EPO circulates to bone marrow where the hormone
increases red blood cell production through the stimulation o f committed erythoid
progenitor cells (55, 56). EPO primarily stimulates CFU-E cells, which are highly
responsive to EPO and give rise to erythroblast colonies (38,54). As erythroid progenitor
cells differentiate beyond the nondividing late basophilic erythoblast stage, they become
independent of EPO for continued maturation (57).
Unlike other hematopoietic growth factors, EPO production is regulated by a classic
negative feedback control system. EPO production and consequent erythrocyte production
increase in response to hypoxia, and hyperoxia acts as a negative regulator of EPO, as well
as o f erythrocyte, production (54). Recombinant human EPO (rhEPO) has been used
clinically as a pharmacological inducer of red blood cell production in anemia resulting
from renal failure with consequent inadequate production of endogenous EPO.
Administration of rhEPO to anemic patients with renal failure results in a rapid and dramatic
rise in patients’ hematocrits (58,59).
Erythropoietin receptor fEPORL The complementary deoxyribonucleic acid
(cDNA) for the murine erythropoietin receptor (EPOR) has been cloned from an MEL
cDNA library using a COS cell expression system (60). This cDNA encodes a 507 amino
acid polypeptide with a single membrane-spanning domain. The EPOR is a type I
transmembrane protein, with the amino terminus oriented on the luminal face and the
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carboxy terminus oriented on the cytoplasmic face. The human EPOR cDNA has also been
cloned and encodes a 508 amino acid polypeptide (61). The human and murine receptors
share 82% homology in both cDNA and amino acid sequences, and both polypeptides have
a predicted molecular weight o f 55 kDa based on the amino acid sequences. A newly
synthesized polypeptide of human or murine EPOR has a moleculer size o f 62 kDa as
determined by protein gel electrophoresis (57, 60, 61), and this polypeptide undergoes
post-translational glycosylation and oligosaccharide processing. The mature EPOR is
expressed on the cell surface as a 66 kDa glycoprotein, as determined by protein gel
electrophoresis.
The EPOR belongs to the cytokine receptor superfamily, which also includes the
receptors for granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophagecolony stimulating factor (GM-CSF), interleukin (IL)-2, IL-3, IL-4, IL-5, IL-6, IL-7,
interferon (IFN)-a, IFN-y, prolactin (PRL) and growth hormone (GRH) (62-69). The
members of the cytokine receptor superfamily share a conserved tryptophan-serine-Xtryptophan-serine (WSXWS) motif just proximal to the transmembrane domain, as well as
four spaced cysteine residues near the amino terminus (55). In contrast to the receptor
protein tyrosine kinases, the cytokine receptors do not contain an intrinsic protein kinase
domain. However, phosphorylation of cytoplasmic proteins seems to be important for
EPO-induced proliferation, and the membrane-proximal region of the cytoplasmic domain
of EPOR has been shown to be necessary for this proliferation (57,70-73). EPO binding
induces tyrosine phosphorylation of the EPOR and association of the receptor with the
cytoplasmic tyrosine kinase JAK2. This association leads to activation o f JAK2 kinase
activity, although it is not known whether JAK2 phosphorylates the EPOR (72,74,75).
Extensive crosslinking studies were conducted to identify the EPOR prior to
isolation o f the human and murine receptor cDNAs, and further studies have been
performed to examine proteins which may be involved in the EPOR complex. However,
the results o f these experiments have not led to a clear model of the EPOR complex.
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Radioiodinated EPO has been crosslinked primarily to 85 and 100 kDa polypeptides in a
variety of cell lines, but these proteins have not been shown to be immunologically related
to the cloned EPOR (55,76-81). It is unclear what role, if any. these two proteins play in
the EPOR complex, or if these proteins are really associated with the receptor.
Surprisingly, no immunologically related protein of 66 kDa, the known molecular weight
o f EPOR expressed from cloned cDNA, has been shown to be crosslinked to
radioiodinated EPO.
A point mutation resulting in the change of an arginine to a cysteine at residue 129
of the exoplasmic domain produces a constitutively active, ligand-independent EPOR
mutant, R129C (82).

The mutant receptors form disulfide-linked homodimers,

independent of EPO, in the rough endoplasmic reticulum (RER) and are transported to the
plasma membrane (83). The constitutive activity of these disulfide-linked homodimers of
R129C suggests that EPO-induced dimerization of wild-type EPOR may be necessary for
signal transduction to occur in response to EPO. Several other members, including the
GRH receptor, of the cytokine receptor superfamily have been shown to undergo ligandinduced homodimerization, and residue 129 of the EPOR maps to the dimer interface
region of the GRH receptor (57, 84). Thus, homodimerization of the EPOR is thought to
be necessary for the receptor to transduce its mitogenic signal.

W hether such

homodimerization is also required for transduction of the differentiation-inducing effect of
EPO is unclear.
Binding studies of the EPOR. Radioiodinated EPO has been used to examine
EPOR expression on a number of cell lines derived from the erythroid lineage, including
normal erythroid progenitors, Friend MEL cells, other murine and human erythroleukemia
cells, and cells from human fetal liver (55,76-78,80, 81, 85-92). The number of specific
binding sites per cell and the affinity constants, or dissociation constants (kds), have been
determined for many cell lines, and the values vary from cell line to cell line. The values
for a number of murine cells and cell lines are summarized in Table 1. Erythroid progenitor
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Table 1. Cell receptor numbers and binding affinities o f erythropoietin receptors
(EPORs) expressed on murine cells or cultured murine cellJings

Murine cells or cell lines

Receptor number per cell

Binding affinity (nM)

MEL 745

110-910

0.1-3.3

GM979

110-1600

0.15-0.7

707

120

0.78

B8

350-650

1.2-1.4

K -l

930

0.28

90-680

0.1-0.3

EPOindependent cell lines

EPO-responsive cell lines
TSA8

6.1
SKT6

470

0.15

Rauscherred 1

160

2.7

1200-1700

0.44

1040

0.28

20-130

0.5-1.4

20-60

0.8-1.4

20-60

0.8-1.4

180-1000

0.09 (20%)
0.60 (80%)

370

0.07 (40%)
0.81 (60%)

400-1200

0.1-0.4 (75%)
3.1 (25%)

Rauscher red 5-1.5
J2E-1
IL-3-dependent cell lines
DA-1
FDC-P2
IC-2

‘

Murine cells
Friend cells
CFU-E
Fetal liver cells

This table is taken from information presented in D’Andrea, A. D. and Zon, L. I.,
Erythropoietin receptor: subunit structure and activation, J. Clin. Invest. 8 6 :681687 (1990) and the appropriate references therein.
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and erytholeukemia cells express from 100 to over 1000 EPO receptors per cell, and
independent investigators have often reported very different numbers of receptors for the
same cell line. The relatively low number of surface receptors for EPO is also typical for
other members o f the cytokine receptor superfamily, such as the G-CSF, GM-CSF, IL-3
and IL-6 receptors (93-95).
Some cell lines express both high- and low-affinity receptors, with an affinity
constant of less than 100 pM for the high-affinity receptor and an affinity constant of 400
pM to over 1 nM for the low-affinity EPOR. Many erythroid cells, including MEL cells,
express receptors of only a single binding affinity, generally of low affinity (kd > 400 pM).
Affinity constants of 100 pM to greater than 1 nM have been determined for these
receptors, and widely varying values for several cell lines have been obtained by different
laboratory groups studying the same line. It is interesting that such a wide range o f both
receptor numbers and affinity constants have been reported for the EPOR, as only one
murine and one human receptor have been cloned to date. O f particular note are cell lines
that express receptors of two binding affinities, as only one EPOR cDNA has been isolated
in both mice and humans (60,61).
Effect o f the induction of differentiation upon expression o f the EPOR in Friend
MEL cells. As mentioned above, the induction of Friend MEL cell differentiation by
DMSO is accompanied by a restoration of sensitivity to both the growth-stimulatory and
differentiation-inducing effects of EPO. Whereas uninduced Friend cells are independent
of EPO and are blocked in their capacity to differentiate in response to EPO, DMSOpretreated Friend cells respond to EPO with increased cellular proliferation and increased
hemoglobin production (20,45). However, it remains unclear whether the expression of
the EPOR in Friend MEL cells changes with chemical induction of differentiation or
whether this induction is accompanied by expression of an EPOR of a different binding
affinity from the receptor expressed in the uninduced state. DMSO treatment of Rauscher
MEL cells, which are EPO-responsive (96), resulted in increased hemoglobin production
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and induction of a new population o f high-density receptors (2 0 ,0 0 0 per cell) that displayed
marked positive cooperativity with a Hill coefficient o f 6.75 (97, 98). This positive
cooperativity was interpreted as evidence that the receptors in Rauscher cells interact with
each other through the formation of oligomers (98).
However, such cooperativity has not been demonstrated in EPO-nonresponsive
Friend MEL cell lines. Treatment o f MEL cell clone B 8 with 1% (v/v) DMSO has been
reported to increase specific binding of radioiodinated EPO by 200% after one day of
exposure, although binding decreased to 1 0 0 % over baseline by day 2 and gradually
decreased to 50% over baseline after 4 days of exposure to DMSO (90). A single class of
EPORs with a binding affinity of 1.2-1.4 nM was observed, and DMSO induction did not
significantly change the binding affinity for EPO and did not result in positive cooperativity
or expression of a second class of higher-affinity receptors. Thus, Rauscher and Friend
MEL cells appear to have different responses in EPOR expression when induced to
differentiate with DMSO.
Despite this work, further studies are needed to examine the changes in EPOR
expression upon chemical induction o f differentiation in Friend MEL cells. It is unclear
whether the results reported with MEL cell clone B 8 can be generalized to all Friend MEL
cell lines or are specific to that particular line. Of note, the reported affinity constant of 1.3
nM for clone B 8 is a relatively high value compared to other reported dissociation constants
for the low-affinity EPOR. DMSO acts in some manner to remove the block in EPO
responsiveness of Friend cells, and it is necessary to examine whether DMSO removes this
block at the level of the cytokine receptor, rather than at a downstream signal transduction
site. If such modulation o f EPOR expression does occur, possible mechansims may
include a change in receptor number, appearance of a high-affinity receptor not present in
uninduced cells, dimerization, or oligomerization of the receptor with positive binding
cooperativity.
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ENVELOPE GLYCOPROTEIN OF THE SFFV
Unique oncogene o f the SFFV. The vast majority of acutely transforming
retroviruses carry an oncogene which is derived from a normal cellular protooncogene and
whose protein product is responsible for cellular transformation and tumorigenicity (30).
Many of these protooncogenes encode a component o f the normal cell proliferation
pathway such as a growth factor or a growth factor receptor. An activating mutation or
aberrant expression of such a protooncogene can result in uncontrolled cell growth and
malignancy. For example, leukemia in mice can arise from transforming mutations in
hematopoietic growth factor receptors such as the CSF-1 receptor and the EPOR (99,100).
However, the Friend SFFV is unique among leukemogenic retroviruses, in that its
oncogene is derived, not from a transduced cellular protooncogene but, from a viral
envelope glycoprotein (30, 101-103).

The viral envelope glycoprotein o f the

polycythemia-inducing strain of the SFFV, SFFVp gp55, binds to and constitutively
activates the EPOR in murine erythroid progenitor cells, resulting in growth independence
from EPO (104). In order to understand this crucial interaction between SFFVp gp55 and
the murine EPOR, as well as the ability of this interaction to constitutively activate the
receptor, the structure of SFFVp gp55 has been examined by a number of investigators.
Genome of the SFFV. The SFFV seems to have originated by deletion and
recombination between its natural helper virus, the F-MuLV, and endogenous murine
genetic sequences (27, 102, 105). The endogenous murine sequences contained in the
SFFV are highly homologous to the envelope (env) genes o f the mink cell focus-forming
(MCF) viruses, so that the SFFV and MCF viruses appear to have originated from a
common genetic source (27). The SFFV genome lacks a gene for a functional RNAdependent DNA polymerase, resulting in replication defectiveness and dependence upon its
helper virus (101). The SFFV does encode for a truncated gag-related protein, which
varies in size from 15 to 45 kDa, depending on the particular SFFV strain (27,42, 101).
In comparison, the prototype gag precursor has a molecular weight of 65 kDa.
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Gp55, the envelope glycoprotein of the SFFVp. The env gene o f the SFFV
encodes a 55 kDa glycoprotein, gp55, which is immunologically related to gp70, the MCF
viral envelope glycoprotein (106-108). Unlike the gag protein, whose molecular weight
varies from strain to strain and which is not even expressed in some MEL cell lines, gp55
is highly expressed in all SFFV strains and is highly conserved from strain to strain (27).
More importantly, the env gene alone is sufficient for pathogenecity o f the SFFVp,
although a replication-competent helper virus is necessary to cause actual disease in mice
(109).
As mentioned above, the SFFV env gene appears to be related to the env genes of
the MCF viruses. Several nucleotide sequences of the SFFV env gene have been
published, and these reports have shown that the amino-terminal two-thirds o f the SFFV
env gene is nonhomologous to the corresponding region of the F-MuLV env gene but does
share a high degree of homology with the env genes of the MCF viruses (110-112). The
homology between the SFFV and the Friend MCF or Moloney MCF viruses in this region
o f the env gene is more than 90-95%, and there is a 67 amino acid sequence, beginning
with amino acid residue number 60, which is identical for all SFFV and MCF viral
envelope glycoproteins (27, 113,114). In contrast, the carboxy-terminal one-third of the
SFFV env gene is homologous to the corresponding region of the F-MuLV env gene
(114).
The SFFV env gene product, gp55, has several unique characteristics which can
only be appreciated in comparison to the env gene products of other retroviruses, such as
MuLV gp70, the prototypical retroviral envelope glycoprotein. The env gene of MuLV
encodes an 80-90 kDa primary translation product which is glycosylated with high
mannose-containing oligosaccharides. This precursor polyprotein is then cleaved to yield
gp70, the envelope glycoprotein, and Prl5E, a smaller polypeptide which is further cleaved
into pl5E and an R peptide (27).
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In the SFFV, however, a 585 base pair deletion in the middle of the env gene has
removed the cleavage site between gp70 and Prl5E with resultant fusion o f the aminoterminal gp70 sequences and the carboxy-terminal p l5 E sequences. This genetic deletion
has resulted in the loss of 195 amino acids surrounding the gp70-Prl5E cleavage site and
in the generation of a unique fusion protein, gp55 (27,110-112). In addition, a single base
pair insertion near the 3' end o f the p l5 E domain has caused a frame shift with resultant
premature termination of translation. While the base pair insertion and its exact location
vary from SFFV isolate to isolate, the results in each case have been the shortening o f the
reading frame by 99 base pairs, or 33 amino acids, and the generation of a unique sequence
of 5 or 6 amino acids at the carboxy-terminus of gp55. Both the 585 base pair deletion and
the single base pair insertion are conserved in all SFFV isolates, indicating that both
mutations play a role in the pathogenecity of the virus (27).
Defective oligosaccharide processing and transport o f SFFVp gp£>. The resultant
SFFVp env gene product is a 409 amino acid polypeptide that has a molecular weight of 45
kDa and is defective in carbohydrate processing and transport to the cell surface (27, 111,
115). The large deletion in the SFFVp env gene has removed three putative asparaginelinked glycosylation attachment sites, and the carbohydrate processing that occurs at the
remaining four N-linked glycosylation sites is incomplete (27, 113, 114, 116). The
predominant form of the SFFVp env gene product that accumulates intracellularly is a 55
kDa glycoprotein which remains ir. an immature, high mannose oligosaccharide,
endoglycosidase H (endo H)-sensitive state within the RER (27,107,108,115).
This endo H-sensitive fraction, which accounts for 95% of the SFFVp env gene
product, is blocked in its passage into the Golgi apparatus, where final N-linked
oligosaccharide processing o f glycoproteins to mature glycosylation patterns occurs.
However, 2-5% of the SFFVp env gene product is transported to the cell surface, where it
exists in an endo H-resistant 65 kDa form which undergoes homodimerization through the
formation of disulfide bonds (27, 107, 115, 117). In addition, the large deletion in the
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SFFVp env gene has generated a transmembrane glycoprotein with only a two amino acid
cytoplasmic tail. Thus, SFFVp gp55 is a unique integral membrane protein that consists of
an exoplasmic domain, a putative 29 amino acid transmembrane domain, and an almost
non-existent cytoplasmic domain ( 11 1 , 112 ).
Differences between the transmembrane regions of SFFVa gp55 and SFFVp gp55.
The env genes of the SFFVa and SFFVp have been sequenced to determine differences
between the anemia- and polycythemia-inducing strains of the SFFV, as the env gene has
been shown to determine the biological activity of the SFFV (118). The major amino acid
differences between SFFVa gp55 and SFFVp gp55 reside in the transmembrane domains
of the two glycoproteins. There are 10 amino acid differences between SFFVa gp55 and
SFFVp gp55, all within or proximal to the transmembrane region, and there is also a 2
amino acid insertion in the transmembrane region o f SFFVp gp55 (115, 119). These
amino acid differences have been shown to be responsible for the differences in
responsiveness to and dependence upon EPO between MEL cells derived from mice
infected with the Friend SFFVa and SFFVp viral complexes (119,120). While MEL cells
derived from SFFVa-infected mice are EPO-dependent, Friend MEL cells derived from
SFFVp-infected mice are EPO-independent and are unresponsive to the growth-stimulatory
and differentiation-inducing properties of the cytokine (27).

GP55 AND THE NON-RESPONSIVENESS OF FRIEND MEL CELLS TO EPO
Interaction between the EPOR and SFFVp gp55. The env gene of the SFFVp has
been identified as the part of the retroviral genome that is responsible for the EPO
independence of SFFVp-infected erythroid progenitor cells (109). The initial studies were
carried out using IL-3-dependent murine Ba/F3 cells that had been stably transfected with a
plasmid expressing the cDNA for the murine EPOR. The resultant Ba/F3-EPOR cells were
able to grow in the presence of IL-3 or EPO but still required one of the two factors for cell
viability (104). Subsequent transfection of Ba/F3-EPOR cells with a retroviral vector
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expressing the cDNA for SFFVp gp55 conferred factor independence upon these cells, and
coimmunoprecipitation experiments demonstrated that gp55 and the EPOR physically
associated with resultant constitutive activation of the receptor. Transfection of Ba/F3 cells
with a retroviral vector expressing the SFFVp gp55 cDNA did not result in IL-3independent growth, and gp55 did not coimmunoprecipitate with the IL-3 receptor in these
cells (104).
These and similar studies with other members of the cytokine receptor superfamily
demonstrated the specificity o f the interaction between SFFVp gp55 and the EPOR, as
gp55 has not been shown to be physically associated with other members o f the cytokine
receptor superfamily or to induce growth independence from other cytokines (115). In
addition, somewhat different studies in an in vivo experimental system demonstrated that
expression of SFFVp gp55 was sufficient for tumorigenicity in erythroid cells and that this
tumorigenicity was specific for erythroid cells.

In these studies, transgenic mice

expressing the SFFVp env gene, but no other part of the SFFVp genome, developed
erythroleukemia but no other malignancies, confirming that the expression o f gp55 resulted
in the specific transformation of cells of the erythroid lineage (109).
Interaction between the transmembrane regions of the EPOR and SFFV p gp55.
Because the cytoplasmic tail o f SFFVp gp55 consists o f only two amino acids, the
interaction of gp55 with the EPOR must occur between the exoplasmic or transmembrane
domains o f the two proteins (115).

Mutations within either the exoplasmic or

transmembrane region can cause a loss of tumorgenicity, suggesting that both regions may
be necessary for interaction with the EPOR (121). Considerable additional evidence
suggests that interaction o f the transmembrane domains is important for the capacity of
SFFVp gp55 to constitutively activate the EPOR (115, 119, 120). The amino acid
differences between the transmembrane domains of SFFVa gp55 and SFFVp gp55 have
been previously discussed in this section. These amino acid differences have been shown
to determine the biological activity of the SFFV. In particular, the transmembrane region of
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SFFVp gp55 has been demonstrated to be necessary for growth independence from EPO in
erythroid progenitor cells infected with the SFFV genome (119).
Similarly, the transmembrane region of the EPOR has been shown to be necessary
for activation of EPO-independent growth by SFFVp gp55 in transfection studies of Ba/F3
cells expressing chimeric receptors containing regions of the EPOR and the IL-3 receptor
(70, 115). While a chimeric polypeptide containing the exoplasmic region of the EPOR
and the transmembrane and cytoplasmic regions o f the IL-3 receptor was able to physically
associate and coimmunoprecipitate with gp55, this association did not result in EPOindependent cell growth. In contrast, a chimera of the exoplasmic and transmembrane
domains of the EPOR and the cytoplasmic domain of the IL-3 receptor was bound and
constitutively activated by SFFVp gp55. Thus, while the exoplasmic domain of the EPOR
is involved in binding of the cytokine receptor to gp55, the transmembrane region is
necessary for activation of the receptor by gp55 (115). The same studies also excluded the
possibility that gp55 acts through the same binding site on the EPOR as does the natural
ligand, EPO. First, there is no homology between the amino acid sequences of gp55 and
EPO. More importantly, the first chimeric receptor was able to confer EPO-dependent
growth upon Ba/F3 cells, demonstrating the capacity of the chimera to recognize EPO, but
could not be constitutively activated by gp55.
SFFVp gp55-EPOR interaction, in the RER and at the cell surface, and activation of
the EPOR bv gp55. Interestingly, SFFVp gp55 has been shown to associate with the
EPOR primarily in the RER (122). This association in the RER interrupts normal
carbohydrate processing and intracellular transport of the EPOR. As discussed previously,
gp55 is defective in oligosaccharide processing and transport to the cell surface; instead,
95% of the viral envelope glycoprotein is retained in an endo H-sensitive form within the
RER (27, 107, 115,116). Expression of SFFVp gp55 in Ba/F3-EPOR cells resulted in
retention of the EPOR in a high mannose, endo H-sensitive 64 kDa form within the RER
and inhibited processing of the receptor to its mature, endo H-resistant 6 6 kDa form. The
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presence of gp55 also inhibited degradation of synthesized EPORs and prolonged the halflife of the cytokine receptors. Additionally, the intracellular gp55 form of the SFFVp env
gene product, and not the cell surface gp65 form of the envelope glycoprotein,
coimmunoprecipitated with the EPOR in cellular lysates of Friend MEL cells (122).
Because of these results, as well as the observation that 95% of SFFVp gp55 and, in
probable likelihood, a similar percentage of gp55-EPOR complexes remain in the RER, it
was postulated that a novel mechanism, by which a mitogenic signal was generated from
within the cell, could be responsible for the constitutive activation of the EPOR by gp55
(115, 122).
However, more recent studies have suggested that the mitogenic signal is generated
by the interaction o f SFFVp gp55 and the EPOR at the cell surface. Radioiodinated EPO
was chemically crosslinked to the cell surface gp65 form of gp55 in Friend MEL cells,
demonstrating that a detectable amount of the SFFVp env gene product is associated with
the EPOR at the cell surface of Friend cells (123). Interestingly, this set o f experiments, as
in all other reported crosslinking studies with radioiodinated EPO, did not observe
crosslinking of radiolabeled EPO to its own receptor. Secondly, five SFFVp env mutants
encoding glycoproteins that were expressed on the cell surface conferred factor
independence upon Ba/F3-EPOR cells, whereas three mutants whose products were not
transported out of the RER were not able to confer EPO independence upon Ba/F3-EPOR
cells. The presence of the five pathogenic SFFVp env mutants in EPOR complexes on the
cell surface was confirmed by crosslinking studies (124). Therefore, while the majority of
the interaction between SFFVp gp55 and the EPOR occurs intracellularly within the RER,
the small amount of interaction (2-5% of total gp55-EPOR complexes) between the fully
processed gp65 form and the EPOR at the cell surface appears to be responsible for
constitutive activation of the EPOR in Friend MEL cells.
Use ofchemical crosslinking to study SFFVp_gp55-EPQR interaction at the Friend
MEL cell surface. As summarized above, a number of investigators have demonstrated that
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SFFVp gp55(gp65) and the EPOR are expressed on the cell surface of Friend MEL cells in
very small numbers (27,55,107,115). It is possible that previous studies may have been
unable to detect the small amount of cell surface complexes between the two glycoproteins.
Because of the experimental limitations imposed by the small numbers o f EPORs and
gp55(gp65)-EPOR complexes on the cell surface of Friend cells, many of the studies that
have examined the cell surface interaction of the two proteins have employed chemical
crosslinking as an experimental tool (61, 74, 76-81, 89, 90, 123, 125). Chemical
crosslinking has often been used to identify cell surface receptor proteins for which cDNA
clones were not yet available or to characterize receptor expression in particular cell types or
culture lines (126-128). While such studies have been used to identify crosslinked proteins
as the receptors for other radiolabeled ligands, all attempts to crosslink radiolabeled EPO to
its receptor have been unsuccessful. No immunologically related protein of 6 6 kDa, the
molecular weight of the cloned mEPOR, has been reported to be crosslinked to
radioiodinated EPO.
In addition to the actual cell surface receptor, however, chemical crosslinking can
also identify proteins that are associated with the receptor. As mentioned above,
radioiodinated EPO was crosslinked to the cell surface gp65 form of gp55 in Friend MEL
cells, demonstrating that the SFFVp env gene product is associated with the EPOR at the
Friend MEL cell surface (123). Interestingly, crosslinking of labeled EPO to gp55(gp65)
was observed even in the absence of crosslinking of labeled EPO to the EPOR. These
experiments demonstrated that the cell surface form of SFFVp gp55 is in close enough
physical approximation to the EPOR to be crosslinked to radiolabeled EPO upon binding of
EPO to its receptor. The close physical proximity of gp55(gp65) to the EPOR strongly
suggests that the cell surface form of gp55 is associated with the EPOR complex at the
Friend MEL cell surface.
Use of coimmunoprecipitation to study SFFVp pp55-EPOR interaction. The other
experimental tool which has been frequently used in investigations of EPOR complexes and
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the interaction between gp55 and the EPOR is coimmunoprecipitation by antibodies which
recognize SFFVp gp55 and the murine EPOR. This method was used to report the first
evidence o f the physical association between gp55 and the EPOR (104, 122). The
intracellular location of the SFFVp gp55-EPOR association may be determined in several
ways. First, the size of the immunoprecipitated form of gp55 is informative. The RER
form of the SFFVp env gene product has a lower molecular weight, 52-55 kDa, than the
cell surface form, which has a size of 65 kDa (27, 107, 116). In contrast, the EPOR
undergoes a smaller increase in molecular size, from 62 kDa to 6 6 kDa, upon carbohydrate
processing and transport to the cell surface. Secondly, endoglycosidase H treatment may
be used to determine if the proteins in the gp55-EPOR complex have been transported
through the Golgi (122). Lastly, careful cell fractionation and purification of membranes
may allow determination o f the amounts of gp55-EPOR complex in each membrane
compartment, although this method has not been a commonly employed approach.
Coimmunoprecipitation, however, does have limitations. First, SFFVp gp55EPOR complexes in the RER are more readily detected then cell surface complexes due to
the greater number o f such complexes in the RER (122). Consequently, cell surface
complexes may be difficult to detect due to their much lower numbers. Secondly, physical
association of gp55 and the EPOR after formation of a cellular lysate can not be
distinguished from actual association within the living cell. Thus, the two glycoproteins
may be located in physically separate intracellular, or membrane, compartments in the
living cell and may only associate when the cell undergoes lysis during in vitro
manipulation of experimental cell samples. While these drawbacks should not exclude the
use of this very useful experimental tool, the inherent limitations of coimmunoprecipitation
studies must be kept in consideration when interpreting results from these types of studies.
Effect of DMSO upon the cell surface interaction of SFFVp gp55 and the EPOR.
Of particular interest to this laboratory were the role of SFFVp gp55 in blocking the EPOinduced differentiation of MEL cells and the effect of DMSO induction of MEL cell
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differentiation on the cell surface interaction between SFFVp gp55(gp65) and the EPOR.
EPO both stimulates cell growth and induces differentiation of normal committed erythroid
progenitor cells (38,54). SFFVp gp55 associates with the EPOR in Friend MEL cells, and
this association constitutively activates a mitogenic signal from the receptor but does not
result in activation of a differentiation signal (104). Moreover, although the EPOR
expressed on Friend cells can bind EPO, a signal for the cell to differentiate is not
transduced upon binding of EPO by the receptor. Thus, while activation of the EPOR by
gp55 has been shown to be responsible for EPO-independent growth, it is unclear whether
the presence of gp55 is responsible for the inability of Friend cells to differentiate in
response to EPO.
As has been previously discussed above, exposure to DMSO induces Friend MEL
cell maturation and restores EPO responsiveness to these cells (20). Given the importance
of the cell surface interaction between gp55(gp65) and the EPOR in the constitutive
activation of the cytokine receptor by gp55, it is conceivable that this interaction may also
result in a block in EPO-induced differentiation. Such a block could occur through
prevention by gp55 of an association between the EPOR and a third protein necessary for
transduction o f a differentiation signal. Alternatively, the constitutive activation of a
proliferation signal by gp55 may be sufficient to block any EPO-induced differentiation
signal. Given the importance o f the gp55-EPOR interaction, it is also conceivable that
induction of maturation by DMSO may result in an interruption or perturbation o f this
association. It would, therefore, be quite interesting to determine whether induction of
differentiation by DMSO is accompanied by dissociation of the EPOR from the cell surface
form o f gp55, thus allowing the receptor to transduce both a mitogenic and a
differentiation-inducing signal upon binding EPO.
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MATERIALS AND METHODS

Materials. Recombinant human erythropoietin (rhEPO) for use in tissue culture
studies was obtained through the generous gift of Dr. Marc Weisberg, R. W. Johnson
Pharmaceutical Research Institute, Raritan, NJ. This tissue culture-grade rhEPO (10,000
units/ml in a sterile buffered solution containing 2.5 mg/ml of human serum albumin; lot N6985) was divided into 100 pi aliquots and stored at 4°C (129-131). Purified, serum
albumin-free rhEPO for use in radioiodination and binding studies was also kindly donated
by Dr. Weisberg. This iodination-grade rhEPO (200,000 units/ml in a sterile solution of
50% [v/v] glycerol and 25 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
acid] buffer [pH 7.2]; lot N-7310) was divided into 10 pi aliquots and stored at -20°C. All
other reagents were purchased from commercial sources as noted.
Cell culture. Friend murine erythroleukemia (MEL) PC4 cells, a subclone of the
Friend MEL cell line 745, were obtained through the generous gift of Dr. David E.
Housman, Massachusetts Institute of Technology, Cambridge, MA (132). Cells were
maintained in suspension culture in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 15% (v/v) fetal bovine serum (FBS; Sigma Chemical Co., S t Louis,
MO, or GIBCO BRL / Life Technologies, Gaithersburg, MD) and 2 mM L-glutamine
(Sigma) at 37°C in a 90% air / 10% CO 2 NAPCO 6300 humidified incubator (National
Appliance Co., Portland, OR). For all experiments, as well as passages, cells were seeded
at 4 x 104 cells/ml, and passaged cells were maintained in logarithmic growth.
A dimethylsulfoxide (DMSO)-resistant subline of MEL cells, DMSO/R1, was
obtained without mutagenesis by passaging MEL cells in growth medium (DMEM, 15%
[v/v] FBS, 2 mM L-glutamine) containing progressively higher concentrations of DMSO
(Sigma), up to 1.5% (v/v) DMSO. DMSO/R1 was then cloned by single cell sorting using
a FACS IV flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA).
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Unless otherwise noted, DMSO/R1 cells were continuously passaged in growth medium
containing 1.25% (v/v) DMSO in a humidified air atmosphere containing 10% CO2 .
Ba/F3-EPOR cells were derived from murine lymphoid Ba/F3 cells (133) which
had been stably transfected with the eukaryotic expression vector p75/15-EPOR, which
contains the complementary deoxyribonucleic acid (cDNA) for the murine erythropoietin
receptor (EPOR) (60).

Unlike parental Ba/F3 cells, which are dependent upon

interleukin(IL)-3 for cellular growth, Ba/F3-EPOR cells can grow in the presence o f IL-3
or EPO (104). Ba/F3-EPOR cells were the generous gift o f Dr. Kimiko Ishiguro, Yale
University, New Haven, CT. Cells were maintained in suspension culture in R P M I1640
medium supplemented with 10% (v/v) FBS and 0.3 units/ml o f rhEPO at 37°C in a 95%
air / 5% CO2 humidified incubator. Cells were seeded at approximately 4 x 104 cells/ml for
passage, and passaged cells were maintained in exponential growth.
Chemical inducers of erythroid differentiation. Sterile filtered, tissue culture-grade
(Hybri-Max) DMSO was purchased from Sigma and divided into 500 pi aliquots, which
were stored at room temperature. A sterile stock solution o f 500 mM HMBA (N,N‘hexamethylene bisacetamide; Sigma) was made by filtering an aqueous solution through a
0.22 pm Millex filter unit (Millipore Corp., Bedford, MA). Stock HMBA solution was
wrapped in aluminum foil and stored at room temperature.
Differentiation-induced erythropoietin (EPO) responsiveness. MEL or DMSO/R1
cells were seeded at 4 x 104 cells/ml in the presence of 1.25% (v/v) DMSO, 2 mM HMBA,
4 mM HMBA, or no inducer. Cells were incubated for 3 days at 37°C in a humidified air
atmosphere containing 10% CO2 . Cell numbers were determined on day 3, and cells were
reseeded at 4 x 104 ceils/ml in the absence or presence of 0.5 unit/ml of tissue culture-grade
rhEPO in growth medium containing the same type and concentration of inducer as before.
Cells were incubated for 3 more days at 37°C in a humidified air atmosphere containing
10% CO2. Cell densities were assayed on day 6 as a measure of proliferation, and cellular
hemoglobin content was determined as a marker of erythroid differentiation (2 0 ).
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To determine whether the DMSO-resistant phenotype of DMSO/R1 was dependent
upon continuous passage in DMSO-containing growth medium, DMSO/R1 cells were
passaged for 1 week or 1 month in the absence of DMSO. Cells were then assayed for the
ability of DMSO to induce differentiation and for EPO responsiveness, as described above.
Cell density. Cell numbers were determined using a Sampling Stand II (Coulter
Corp., Hialeah, FL) and a Coulter ZM particle counter. Cell sizes were ascertained with a
Coulter Channelyzer 256 multichannel analyzer.
Determination o f hemoglobin content. A modification of a previously described
method was used to measure hemoglobin content (134). Five x 106 cells were collected by
centrifugation in an IEC Centra-7 centrifuge (International Equipment Co., Needham
Heights, MA) and washed with 1 ml of ice-cold Hanks’ balanced salt solution (HBSS;
GIBCO). Cells were lysed in 100 pi o f ice-cold extraction buffer (20 mM Tris-HCl [pH
7.5], 10 mM MgCh, 30 mM KC1,0.5% [w/v] Triton X-100), and nuclei were removed by
centrifugation at 16,000 g for 5 minutes in an Eppendorf 5415C microcentrifuge
(Brinkmann Instruments, Westbury, NY). The resulting supernatant was designated the
nuclei-free cellular lysate. Fifty pi o f nuclei-free cellular lysate were added to 2 ml of a
freshly prepared solution o f 0.033% (w/v) TMB (3,3',5,5'-tetramethylbenzidine; Aldrich
Chemical Co., Milwaukee, WI) and 0.083% (v/v) H 2 O 2 (J.T. Baker Chemical Co.,
Phillipsburg, NJ) in 10% (v/v) acetic acid (J.T. Baker), and the sample was mixed by
gentle vortexing. After incubation at room temperature for 7 minutes, the absorbance was
measured at 515 nm (OD 515 ) in a Beckman Model 25 spectrophotometer (Beckman
Instruments, Fullerton, CA). A standard curve was constructed from OD 515 measurements
of standards made with Type IV human hemoglobin (Sigma), and the hemoglobin contents
of samples were quantified using the standard curve.
Isolation of total ribonucleic acid (RNAf. Total cellular RNA was isolated by
extraction with guanidinium thiocyanate (Fluka Chemical Corp., Ronkonkoma, NY)
followed by sedimentation through a cesium chloride (CsCl; American Bioanalytical,
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Natick, MA) gradient, as previously described (135*138). Five to fifteen x 107 cells were
collected by centrifugation, and cells were resuspended in 10 ml of growth medium and
transferred to a 15 ml conical tube. Cells were collected by centrifugation, and the
supernatant was decanted. Cells were broken by vigorously vortexing the pellet at
maximum speed for 30 seconds. Four ml of homogenization buffer (4 M guanidinium
thiocyanate, 25 mM sodium citrate [pH 7.0], 0.5% [w/v] sodium lauryl sarcosinate, 100
mM 2-mercaptoeihanol) were added, and the cellular lysate was homogenized by vigorous
vortexing at maximum speed for 30 seconds.
The homogenate was carefully layered onto a 2.5 ml cushion of 5.7 M CsCl, 0.1 M
EDTA (pH 7.0) in a Beckman 14 x 89 mm polyallomer centrifuge tube, and 3.5 ml of
guanidinium thiocyanate homogenization buffer were added to the tube. The homogenate
was centrifuged for 16-18 hours at 20°C and 32,000 rpm using an SW40 swinging-bucket
rotor and a Beckman L5-75B ultracentrifuge (137). The resulting supernatant, including
protein and DNA, was carefully removed by aspiration and decantation. The pellet,
containing total cellular RNA, was washed twice with 70% (v/v) ethanol and allowed to
dry at room temperature. The pellet was resuspended in 50-150 pi of sterile water,
depending on the number of cells originally harvested. The RNA concentration of the
resulting solution was determined by measuring the ultraviolet (UV) absorbance at 260 nm
(OD 260 ) using a Beckman Model 25 spectophotometer. The UV absorbance at 280 nm
(OD 280 ) was measured, and the ratio of OD 26O to OD 28 Owas determined to ensure the
absence of protein contamination. Sterile water was added to dilute the RNA solution to
approximately 3 mg/ml, and the final RNA concentration was determined by repeating UV
absorbance measurements.
Electrophoresis of RNA through formaldehyde gels. Ten pg of total RNA were
prepared for electrophoresis as previously described (139-141). RNA was dissolved in 20
pi of a solution containing lx MOPS buffer, 2.2 M formaldehyde (J.T. Baker) and 50%
(v/v) formamide (J.T. Baker, deionized by mixing with Bio-Rad AG 501-X8 mixed resin
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beads followed by filtration). MOPS buffer (lx ) consisted of 20 mM MOPS (3-[Nmorpholino]propanesulfonic acid; American Bioanalytical), pH 7.0,5 mM sodium acetate
and 1 mM EDTA (pH 8.0). Samples were incubated at 65°C for 15 minutes to denature
RNA and were then chilled on ice. Four pi o f 6x gel-loading buffer (1 mM EDTA [pH
8.0], 0.25% [w/v] bromophenol blue, 0.25% [w/v] xylene cyanol, 40% [v/v] glycerol)
were added, and the samples were mixed. Samples were subjected to electophoresis
through a 1.0% (w/v) Agarose (American Bioanalytical) gel containing 0.66 M
formaldehye and 0.5 pg/ml of ethidium bromide (Sigma) in lx MOPS buffer. An IBI
Model MPH electrophoresis unit (International Biotechnologies, New Haven, CT) was
employed, and lx MOPS was used as the running buffer. A Model 3-3000 UV illuminator
(Fotodyne, New Berlin, WI) was used to visualize 18S and 28S ribosomal RNA (rRNA)
bands, and a photograph was taken with a Polaroid MP-4 Land Camera (Polaroid Corp.,
Cambridge, MA).
Transfer of RNA to nitrocellulose membranes. RNA was partially hydrolyzed by
soaking the gel in 0.05 N NaOH under gentle agitation on a Model G2 Laboratory Rotator
(New Brunswick Scientific Co., New Brunswick, NJ) for 20 minutes. The gel was then
soaked in lOx SSC transfer buffer (150 mM sodium citrate [pH 7.0], 1.5 M NaCl) under
gentle agitation for 15 minutes. RNA was transferred to an Immobilon-NC nitrocellulose /
cellulose acetate membrane (Millipore) using lOx SSC as the transfer buffer and a TE80
TransVac vacuum transfer unit (Hoefer Scientific Instruments, San Francisco, CA) as
previously described (142-144).

The membrane and gel were examined by UV

illumination to assess the efficiency of transfer, and transferred RNA was crosslinked to
the membrane using a Stratalinker UV crosslinker 1800 (Stratagene Cloning Systems, La
Jolla, CA).
Purification of cDNA fragments for use as Northern hybridization probes. A probe
for murine erythropoietin receptor (EPOR) messenger RNA (mRNA) transcripts was
obtained by Kpnl-digestion of pXM-EPOR. pXM-EPOR, a mammalian expression vector
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containing an ampicillin resistance {amp1) gene and the murine EPOR cDNA, was the
gracious gift o f Dr. Alan D'Andrea, Children's Hospital, Boston, MA (60).
Logarithmically growing E. coli, strain DH5a (a gift of Dr. Jianming Li, Yale University,
New Haven, CT), were collected by centrifugation and made permeable to DNA by
incubation in ice-cold 50 mM CaCl2 for 30 minutes (140,145, 146). These competent
bacteria were transformed with pXM-EPOR by incubation on ice for 30 minutes followed
by heat shock at 37°C for 5 minutes. Bacteria were plated on LB (Luria broth) agar
containing 50 pg/ml of ampicillin (Boehringer Mannheim Corp., Indianapolis, IN) and
allowed to grow overnight at 37°C. Transformants were selected for partial purification of
plasmid DNA by a previously described "mini-prep" method (147, 148), and DNA was
analyzed by digestion with the restriction endonuclease Kpnl (Boehringer Mannheim). A
large scale plasmid preparation was performed using a previously described alkaline lysis
method (137, 147).
A 1.8 kb EPOR cDNA insert was excised by digestion with Kpnl and separated
from Kpnl-linearized pXM by 1.0% Agarose gel electrophoresis using lx Tris-borate
buffer (90 mM Tris-HCl [pH 8.0], 90 mM boric acid, 2 mM EDTA) as the running buffer
(140). The EPOR cDNA insert was recovered by electrophoresis onto a diethylaminoethyl
(DEAE)-cellulose membrane (Schleicher & Schuell, Keene, NH) as previously described
(137). The membrane was washed with low-salt buffer (50 mM Tris-HCl [pH 8.0], 150
mM NaCl, 10 mM EDTA), and DNA was eluted with high-salt buffer (50 mM Tris-HCl
[pH 8.0], 1 M NaCl, 10 mM EDTA). The eluate was extracted with an equal volume of
salt-saturated (SS)-phenol (Boehringer Mannheim): chloroform: isoamyl alcohol (25:24:1,
v/v), and the aqueous layer was extracted with an equal volume o f chloroform: isoamyl
alcohol (24:1, v/v). After addition of 0.1 volume of 3 M sodium acetate (pH 5.2) and
ethanol precipitation, the DNA pellet was resuspended in TE80 buffer (10 mM Tris-HCl,
0.1 mM EDTA, pH 8.0) (140).
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A probe for mRNA transcripts of the mouse myeloblastosis oncogene c-myb was
obtained by EcoRl-digestion of pMCl (American Type Culture Collection [ATCC],
Rockville, MD) to excise a 2.5 kb murine c-myb cDNA insert. The c-myb cDNA insert
was electrophoretically separated from vector and recovered by electrophoresis onto a
DEAE-cellulose membrane as described above. A 1.4 kb probe for mRNA transcripts of
the mouse myelocytomatosis oncogene c-myc was derived from the cDNA of MEL cells
and was the generous gift of Dr. Ishiguro.
Northern hybridization. A membrane containing crosslinked, transferred total RNA
was incubated with prehybridization buffer containing 50 mM Tris-HCl (pH 7.5), 1 M
NaCl, 0.1% (w/v) sodium pyrophosphate, 0.2% (w/v) bovine serum albumin (BSA),
0.2% (w/v) polyvinyl-pyrrolidone, 0.2% (w/v) Ficoll, 1% (w/v) sodium dodecyl sulfate
(SDS), 10% (w/v) dextran sulfate, 50% (v/v) deionized formamide and 0.1 mg/ml o f heatdenatured salmon sperm DNA at 42°C for several hours. Twenty-five ng of a DNA probe
were radiolabeled using a random primer extension kit (GIBCO) and a previously
described protocol (149,150). Reaction buffer and [a-32P]-deoxycytidine 5’-triphosphate
(dCTP) (3000 Ci/mmol in 10 mM Tricine [pH 7.6], 10 mCi/ml; Du Pont NEN Research
Products, Boston, MA) were added to the heat-denatured probe to a total volume of 49 ml
containing 0.02 mM deoxyadenosine 5’-triphosphate (dATP), 0.02 mM deoxyguanosine
S'-triphosphate (dGTP), 0.02 mM deoxythymidine 5'-triphosphate (dTTP), 200 mM
HEPES, 50 mM Tris-HCl (pH 6.8), 5 mM M gCh, 10 mM 2-mercaptoethanol, 0.4 mg/ml
of BSA and 5.5 OD 26O units/ml of oligodeoxyribonucleotide primers (hexamers). One ul
o f Klenow fragment (large fragment o f DNA polymerase I, 3 units/pl in 100 mM
potassium phosphate buffer [pH 7.0], 10 mM 2-mercaptoethanol, 50% [v/v] glycerol) was
added, and the reaction mixture was incubated at room temperature for 60 minutes.
The radiolabeled probe was heat-denatured and hybridized to the membrane by
incubation at 42°C for 14-18 hours. The membrane was rinsed and then washed with 2x
SSC (30 mM sodium citrate [pH 7.0], 300 mM NaCl) containing 0.1% (w/v) SDS at room
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temperature. The membrane was then washed with 0.2x SSC (3 mM sodium citrate [pH
7.0], 30 mM NaCl), 0.1% (w/v) SDS once at room temperature and twice at 68°C. The
membrane was exposed to X-Omat RP scientific imaging Film (Eastman Kodak Co.,
Rochester, NY) at -70°C.
Radioiodination of erythropoietin. Recombinant human erythropoietin (rhEPO)
was labeled with N aI2^i using the IODO-GEN reagent (1,3,4,6-tetrachloro-3o,6odiphenylglycouril; Pierce Chemical Co., Rockford, 1L) (151-153), as previously described
(78). Four pg o f IODO-GEN were coated on the bottom of a 12 x 75 mm borosilicate
tube. Five hundred units o f pure, iodination-grade rhEPO in 45 pi of HBSS containing
0.01% (w/v) Tween 20 (Fierce) were added to the reaction tube. Five pi (500 pCi) of
Na125I (100 mCi/ml in NaOH solution, pH 7-11; Amersham Corp., Arlington Heights, IL)
were added to bring the reaction volume to 50 pi, and the mixture was incubated at room
temperature for 10 minutes. The iodination reaction was quenched by the addition of 100
pi of an aqueous solution o f 1.6 M KI (Sigma). 125I-rhEPO was purified from unreacted
N a 125[ using an Excellulose GF-5 Desalting Column (Pierce).

The column was

equilibrated with two volumes of elution buffer (HBSS, 0.1% [w/v] BSA, 0.01% [w/v]
Tween 20), and the quenched reaction mixture was applied to the column. An initial
fraction of 300 pi and subsequent fractions of 5 drops (approximately 60 pi) were collected
in 1.7 ml Eppendorf tubes. One pi was removed from each fraction, and radioactivity was
determined using an LKB 1282 Compugamma universal gamma counter (Wallac Inc.,
Gaithersburg, MD).
Analysis of radioiodination products bv sodium dodecvl sulfate-polvacrylamide gel
electrophoresis (SDS-PAGET One pi was removed from each eluted fraction and added to
19 pi of extraction buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 5 mM EDTA, 0.5%
[w/v] Nonidet P-40, 0.2 mM phenylmethanesulfonyl fluoride, 5 pg/ml of aprotinin).
Twenty pi o f 2x SDS-PAGE sample buffer (125 mM Tris-HCl [pH 6.8], 4% [w/v] SDS,
40% [v/v] glycerol, 10% [v/v] 2-mercaptoethanol, 0.002% [w/v] bromophenol blue) were
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added, and the samples were boiled for 5 minutes and then cooled (154). The samples
were subjected to 7.5% SDS-PAGE using an SE600 vertical slab electrophoresis unit
(Hoefer) and a 1.0 mm thick gel. The stacking gel consisted of 5% (w/v) acrylamide,
0.13% (w/v) N,N'-methylene-bis-acrylamide (bis), 125 mM Tris-HCl (pH 6.8), 0.1%
(w/v) SDS, 0.1% (w/v) ammonium persulfate and 0.1% (v/v) N,N,N’,N'tetramethylethylenediamine (TEMED). The resolving gel consisted o f 7.5% (w/v)
acrylamide, 0.2% (w/v) bis, 375 mM Tris-HCl (pH 8.8), 0.1% (w/v) SDS, 0.1% (w/v)
ammonium persulfate and 0.06% (v/v) TEMED. The running buffer consisted of 25 mM
Tris, 192 mM glycine and 0.1% (w/v) SDS. All reagents were molecular biology grade;
Tris buffer was purchased from American Bioanalytical, and all other materials were
purchased from Bio-Rad Laboratories, Richmond, CA.

M olecular weights were

determined using prestained SDS-PAGE standards (Bio-Rad). The gel was soaked for 60
minutes in a fixing solution of 10% (v/v) trichloroacetic acid (Brand-Nu Laboratories,
Meriden, CT), 10% (v/v) acetic acid and 30% (v/v) methanol (J.T. Baker). The fixed gel
was dried under heat and vacuum for 90 minutes using a Bio-Rad Model 443 slab dryer,
and the dried gel was exposed to X-Omat AR scientific imaging film (Eastman Kodak) at
-70°C.
Determination of the biological activity of radioiodinated erythropoietin. The
biological activity o f radioiodinated erythropoietin was assessed using a previously
described quantitative colorimetric assay for cellular proliferation (155). Ba/F3-EPOR cells
were seeded at 1 x 104 cells per well in a 96-well plate (Becton Dickinson Lab ware,
Lincoln Park, NJ) in a volume of 100 pi of RPMI 1640 medium supplemented with 10%
(v/v) FBS and varying amounts of 125I-rhEPO. Ba/F3-EPOR cells were also seeded at the
same cell density in 100 pi per well of RPMI 1640, 10% (v/v) FBS, containing varying
amounts of tissue culture-grade or iodination-grade (albumin-free) rhEPO. Cells were
incubated for 2 days at 37°C in a humidified air atmosphere containing 5% C02- Ten pi of
stock MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide; Sigma)
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solution (10 mg/ml; sterile filtered) were added to each well, and the cells were incubated at
37°C in 95% air / 5% CO 2 for 4 hours. One hundred-fifty nl o f acid-isopropanol (0.04 N
HC1 in 2-propanol) were added to each well, and the contents of each well were thoroughly
mixed to dissolve crystals of the MTT formazan product. The 96-well plate was read in a
Titertek Multiskan MCC/340 eight-channel vertical photometer (Row Laboratories,
McLean, VA), using a test wavelength of 550 nm and a reference wavelength o f750 nm.
Determination o f erythropoietin receptor (EPOR) number and binding affinity.
Logarithmically growing MEL or DMSO/R1 cells were collected by centrifugation, and the
supernatant was decanted. Cells were resuspended in binding medium (DMEM, 15% [v/v]
FBS, 2 mM L-glutamine, 20 mM HEPES, pH 7.4) at a density o f 6 x 106 cells/ml. Cells
were transferred to Eppendorf tubes by pipetting 500 pi (3 x 106 cells) into each tube.
Cells were collected by centrifugation, and the supernatant was removed by aspiration.
Cells were resuspended in the absence or presence of 50-fold excess rhEPO in 100 pi of
binding medium containing varying amounts of 12^I-rhEPO. Cells were incubated at 1012°C for 4 hours to allow binding of 12^I-rhEPO to cell surface EPO receptors. Cells and
bound ,2^I-rhEPO were collected by centrifugation and were washed twice with 500 pi of
ice-cold PBS (phosphate-buffered saline, pH 7.5). Eppendorf tube tips containing cell
pellets were severed and placed in 12 x 75 mm borosilicate tubes, and radioactivity was
determined using an LKB 1282 gamma counter.
Metabolic labeling. Cells were seeded at 4 x 104 cells/ml, or 1 x 105 cells/ml when
cells were to be labeled the next day, in growth medium containing 1.5% (v/v) DMSO, 5
mM HMBA or no inducer. Cells were incubated for 1,2 or 3 days at 37°C in a humidified
air atmosphere containing 10% CO2 . Three x 106 cells were collected by centrifugation
and washed once with 1 ml of methionine-free DMEM (GIBCO) supplemented with 15%
(v/v) FBS and 2 mM L-glutamine, which had been prewarmed to 37°C. Cells were
resuspended at a density of 1.5 x 107 cells/ml in 200 pi of methionine-free medium, and
100 pCi of L-[35S]-methionine (10 mCi/ml in an aqueous solution containing 10 mM 2-
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mercaptoethanol; Du Pont NEN) were added to attain a final concentration of 500 pCi/ml
(156-158). Cells were incubated at 37°C for 60 minutes.
Immunoprecipitation of cellular lvsates. Cells were collected by centrifugation and
washed twice with 1 ml of ice-cold HBSS. Cells were lysed in 200 pi of ice-cold
extraction buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 5 mM EDTA, 0.5% [w/v]
Nonidet P -40,0.2 mM phenylmethanesulfonyl fluoride, 5 pg/ml of aprotinin), and nuclei
were removed by centrifugation. The supernatant, designated the nuclei-firee cellular
lysate, was transferred to a new Eppendorf tube. Five pi of goat a-MuLV gp70 polyclonal
antiserum (lot # 81S000127, 86 mg/ml of protein; Quality Biotech Inc., Camden, NJ),
which cross-reacts with SFFVp gp55, were added to each cellular lysate sample for a
dilution of 1:40, and immunoprecipitation was conducted overnight at 4°C. Twenty-five pi
of Protein A-Agarose (Pierce) were added to each sample, and the samples were incubated
for 20 minutes at room temperature under agitation (159-165). The immunoglobulinProtein A complexes were washed 6 times with 500 pi of ice-cold extraction buffer.
Analysis by SDS-PAGE and autoradiography. The immunoglobulin-Protein A
complexes were resuspended in an equal volume (50 pi) of 2x SDS-PAGE sample buffer
and boiled for 5 minutes. The samples were cooled to room temperature and were then
centrifuged at 16,000 g for 30 seconds. Twenty pi of supernatant were removed from each
sample and subjected to 7.5% SDS-PAGE, and molecular weights were determined using
prestained SDS-PAGE standards (154). The gel was soaked under gentle agitation in a
fixing solution of 10% (v/v) trichloroacetic acid, 10% (v/v) acetic acid and 30% (v/v)
methanol for 60 minutes. The fixing solution was decanted, and the gel was impregnated
with EN3HANCE fluorescent autoradiography enhancer (Du Pont NEN) by soaking the
gel under gentle agitation in EN3HANCE solution for 60 minutes. The used enhancer
solution was discarded, and an excess of ice-cold water was added to precipitate the
fluorescent material inside the gel. The gel was soaked under gentle agitation in cold water
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for 60 minutes and then dried under heat and vacuum for 90 minutes. The dried gel was
exposed to Kodak X-Omat RP scientific imaging film at -70°C.
Endoglvcosidase H fendo H) treatment of metabolicallv labeled SFFVp gp55
immunoprecipitates. MEL or DMSO/R1 cells were seeded at 4 x 104 cells/ml in the
presence or absence of 1.5% (v/v) DMSO and were incubated for 2 days at 37°C in a
humidified air atmosphere containing 10% CC>2. Three x 106 cells were collected by
centrifugation, resuspended in 200 pi of methionine-free medium, and labeled with 100 pCi
of L-[35S]-methionine for 15 minutes (156-158). Cells were collected by centrifugation,
washed twice with regular growth medium containing methionine, and resuspended in 200
pi of DMEM, 15% (v/v) FBS, 2 mM L-glutamine. Cells were incubated in regular growth
medium for 0, 3 or 6 hours (chase period). Cells were then collected by centrifugation,
washed twice with ice-cold HBSS, and lysed in 200 pi of extraction buffer as described
above. The nuclei-free cellular lysates were subjected to immunoprecipitation by 5 pi of
goat a-MuLV gp70 polyclonal antiserum (1:40 dilution) as desribed above.
After washing the immunoglobulin-Protein A complexes with ice-cold extraction
buffer as described above, the immunoglobulin-Protein A complexes were resuspended in
25 pi o f endo H extraction buffer (50 mM Tris-HCl [pH 8.0], 0.5% [w/v] SDS, 0.5%
[v/v] 2-mercaptoethanol). The samples were boiled for 5 minutes, allowed to cool to room
temperature, and then centrifuged at 16,000 g for 30 seconds. Ten pi o f supernatant were
removed and added to 40 pi of endo H incubation buffer to bring the total volume of the
reaction mixture to 50 pi. The final incubation mixture consisted of 10 mM Tris-HCl (pH
8.0), 100 mM sodium citrate (pH 5.5), 0.1% (w/v) SDS, 0.7% (v/v) 2-mercaptoethanol,
and 4% (v/v) Nonidet P-40 with or without the presence of 5 mU of endoglycosidase H (1
mU/pl in 50 mM sodium phosphate, 0.05% [w/v] sodium azide, pH 7.0; Boehringer
Mannheim) (166-168). The samples were incubated overnight at 37°C, and 50 pi of 2x
SDS-PAGE sample buffer were then added (154). The samples were boiled for 5 minutes
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and allowed to cool to room temperature. Fifty pi were removed from each sample and
analyzed by 7.5% SDS-PAGE and autoradiography as described above (154).
Nuclei-free cellular lysates. Cells were seeded at 4 x 104 cells/ml, or 1 x 10s
cells/ml when cells were to be harvested the next day, in the presence or absence of 1.25%
(v/v) DMSO. Cells were incubated for 1, 2 or 3 days at 37°C in a humidified air
atmosphere containing 10% CO 2 . Three x 106 cells were collected by centrifugation and
washed twice with 1 ml o f ice-cold HBSS. Cells were lysed in 200 pi o f ice-cold
extraction buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 5 mM EDTA, 0.5% [w/v]
Nonidet P -40,0.2 mM phenylmethanesulfonyl fluoride, 5 mg/ml of aprotinin), and nuclei
were removed by centrifugation.
Determination of the protein concentrations of nuclei-free cellular lvsate samples. A
microtiter plate format based on the Bradford assay was used to determine the protein
concentrations of the nuclei-free cellular lysate samples (169-172). Ten pi of nuclei-free
cellular lysate were added to 90 pi of PBS to dilute the protein concentration ten-fold.
Twenty pi of the 1:10 dilution of cellular lysate were transferred to each of 3 wells of a 96well plate, and 180 pi of Coomassie Plus Protein Assay Reagent (Pierce) were added to
each well. The 96-well plate was read in a Titertek Multiskan MCC/340 eight-channel
vertical photometer, and the absorbance of each well was measured at 600 nm (OD600)- A
standard curve was constructed from OD600 measurements of standards made with BSA
(Sigma), and the protein concentrations of the samples were quantified using the standard
curve.
SDS-PAGE of nuclei-free cellular lvsates and electrophoretic transfer of proteins to
nitrocellulose membranes. Nuclei-free cellular lysate containing 50 pg of protein was
added to an equal volume o f 2x SDS-PAGE sample buffer, and the samples were boiled
for 5 minutes and then allowed to cool to room temperature. The samples were subjected
to 7.5% SDS-PAGE, and molecular weights were determined using prestained SDS-PAGE
standards (154). Proteins were electrophoretically transferred to an Immobilon-NC
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nitrocellulose / cellulose acetate membrane as previously described (173, 174). The
transfer buffer consisted of 82.5 mM Tris, 192 mM glycine and 20% (v/v) methanol, and
the transfer was performed using a Model TE42 Transphor electrophoresis unit with a
Model TE50 Transphor Power Lid (Hoefer).
Western blot analysis of total cellular SFFVp pp55 protein. A previously described
procedure was used to detect gp55 that had been transferred onto the Immobilon-NC
membrane (173). The membrane was soaked in Tris-buffered saline (TBS; 50 mM TrisHCl [pH 7.4], 200 mM NaCl) and then incubated under gentle agitation in a blocking
solution of 5% (w/v) nonfat dry milk (H. J. Heinz Co., Pittsburgh, PA) in TBS for 2
hours at room temperature. The blocking solution was removed, and the membrane was
incubated with goat a-MuLV gp70 polyclonal antiserum (1:250 dilution in 1% [w/v] nonfat
dry milk in TBS) overnight at 4°C. The membrane was washed 5 times at room
temperature with TBS-Tween 20 (0.05% [w/v] Tween 20 in TBS) and then once with
TBS. The membrane was blocked with 5% (w/v) nonfat dry milk for 30 minutes and then
incubated with 30 pCi of 125I-rProtein A (low specific activity 2-10 pCi/pg, 80 pCi/ml in a
50 mM sodium phosphate buffer, pH 4.0, containing 35% [v/v] ethanol; Du Pont NEN) in
30 ml of 1% (w/v) nonfat dry milk for 2 hours at room temperature. The membrane was
washed as before, and the dried membrane was exposed to Kodak X-Omat AR film at
-70°C.
Construction of the eukaryotic expression vector pRc/RSV-eo55. The SFFVp
gp55 cDNA insert was excised from pXM-gp55, a COS cell expression vector containing
the SFFVp gp55 cDNA, by digestion with the restriction endonucleases H indlll and PstI
(Boehringer Mannheim). pXM-gp55 was the generous gift of Dr. Alan D’Andrea,
Children's Hospital, Boston, MA. The SFFVp gp55 cDNA insert was then subcloned into
the multiple cloning site of HindlH-Pstl-linearized pBluescript SK (a gift of Dr. Jianming
Li, Yale University, New Haven, CT) using previously described methods (137, 140).
pBluescript SK-gp55 was then digested with the restriction endonucleases H indlll and

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

38
Xbal, and the resulting SFFVp gp55 cDNA insert was subcloned in the sense orientadon
into the multiple cloning site o f pRc/RSV (Invitrogen Corp., San Diego, CA), a
mammalian expression vector containing a neomycin resistance gene for selection in
eukaryotic cells. A large scale plasmid preparation o f pRc/RSV-gp55 was performed using
a previously described alkaline lysis method (137,147).
Construction o f the antisense gp55 cDNA expression vector pRc/RSV-antisense
gp55. The SFFVp gp55 cDNA insert was excised from pXM-gp55 by digestion with the
restriction endonucleases EagI (New England Biolabs, Beverly, MA) and Pstl, and the
insert was subcloned into the multiple cloning site o f Eagl-Pstl-lincmzed pBluescript SK
(137). The resulting plasmid was then digested with EagI and Hindlll, and the resulting
SFFVp gp55 cDNA insert was subcloned in the antisense orientation into the multiple
cloning site of pRc/RSV. A large scale plasmid preparation of pRc/RSV-antisense gp55
was performed using a previously described alkaline lysis method (137,147).
Transfection o f Friend MEL cells bv electroporation. MEL cells were transfected
with plasmids expressing the SFFVp gpSS cDNA in the sense or antisense orientation by a
previously described method for electroporation o f suspension culture cells (140, 175178). The expression vectors pRc/RSV, pRc/RSV-gp55 and pRc/RSV-antisense gp55
were digested with the restriction endonuclease B glll (New England Biolabs) to generate
linearized plasmids. The restriction digestion mixtures were extracted with equal volumes
of SS-phenol: chloroform: isoamyl alcohol (25:24:1, v/v), and the aqueous layers were
extracted with equal volumes of chloroform: isoamyl alcohol (24:1, v/v). After addition of
0.1 volumes of 3 M sodium acetate (pH 5.2) followed by ethanol precipitation, the DNA
pellets was resuspended in TE70 buffer (10 mM Tris-HCl, 0.1 mM EDTA, pH 7.0) (140).
One x 107 logarithmically growing Friend MEL cells were collected by
centrifugation, washed once with 5 ml of ice-cold PBS, and resuspended at a density of 1 x
107 cells/ml in 1 ml of ice-cold PBS (140). Eight x 106 cells (0.8 ml) were transferred by
pipette to a sterile Gene Pulser cuvette (Bio-Rad). Ten pg of linearized pRc/RSV (vector
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alone), pRc/RSV-gp55, pRc/RSV-antisense gp55, or no vector (sham transfection) were
added, and the cuvette was incubated on ice for 5 minutes. Transfection of the cells was
performed using a Gene Pulser electroporation apparatus (Bio-Rad) with a capacitance
extender (Bio-Rad). Electroporated cells were incubated on ice for 10 minutes and then
transferred to a tissue culture flask containing 30 ml of growth medium. Cells were
incubated for 48 hours at 37°C in a humidified air atmosphere containing 10% CO 2 .
Selection and cloning (bv single cell sorting) o f transfectants. A sterile stock
solution of the aminoglycoside antibiotic G-418 Sulfate (Geneticin, GIBCO) was prepared
by filtering an aqueous solution of 10 mg/ml of G-418 through a 0.22 pm Millex filter unit
(179-182). The sterile antibiotic solution was divided into aliquots and stored at -20°C.
Two x 106 cells were reseeded at a density of 8 x 104 cells/ml in 25 ml of fresh growth
medium supplemented with 800 ng/ml of G-418. Cells were incubated under antibiotic
selection at 37°C in a humidified air atmosphere containing 10% CO 2 for 2 weeks. Cells
were passaged biweekly with collection of cells by centrifugation and resuspension in fresh
growth medium containing 800 ng/ml of G-418. Cells were then cloned by single cell
sorting using a FACS IV flow cytometer with continued selection in growth medium
containing 800 ng/ml of G-418.
Screening of transfectants bv Western blotting for total cellular gr?55 protein. Three
x 106 cells were collected by centrifugation, washed twice with ice-cold HBSS, and then
lysed in 200 pi of ice-cold extraction buffer as previously described. Nuclei were removed
by centrifugation, and 40 pi of nuclei-free cellular lysate were removed and added to an
equal volume of 2x SDS-PAGE sample buffer (154). The samples were boiled, allowed to
cool to room temperature, and then subjected to 7.5% SDS-PAGE followed by
electrophoretic transfer to Immobilon-NC membranes as previously described (173,174).
The membranes were probed with goat a-MuLV gp70 polyclonal antiserum at a dilution of
1:250 in 1% (w/v) nonfat dry milk, and bound primary antibody was detected with 125IrProtein A and autoradiography as previously described (173). Because the protein
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concentrations o f the transfectant samples were not determined prior to SDS-PAGE and,
therefore, had not been normalized from sample to sample, the visualized gp55 band of
each sample was compared to the F-MuLV gp70 band of the sample to estimate the level of
total cellular gp55 protein in each transfectant clone.
Immunoprecipitation of SFFVp gp55 and the mEPOR. MEL or DMSO/R1 cells
were seeded at 4 x 104 cells/ml in the presence or absence of 1.25% (v/v) DMSO and were
incubated for 4 days at 37°C in a humidified air atmosphere containing 10% CO 2 . Cells
were split on day 2 and reseeded in fresh growth medium to achieve a cell density of
approximately 1 x 106 cells/ml upon harvesting on day 4. Cells were collected by
centrifugation, nuclei-free cellular lysates were prepared, and the protein concentrations of
the nuclei-free cellular lysates were determined as described above (169-172). Ice-cold
extraction buffer was added to cellular lysate containing 100 pg o f protein to bring the total
volume to 100 pi.
The nuclei-free cellular lysate was incubated overnight at 4°C in the presence of 4 pi
o f goat a-MuLV gp70 polyclonal antiserum (1:25 dilution), 4 pi of rabbit a-m EPO R
polyclonal antiseram (1:25 dilution), or no antibody. Rabbit polyclonal antiserum C31201
(Research Genetics, Huntsville, AL) to the murine erythropoietin receptor (mEPOR) was
generated by immunization of a New Zealand white female rabbit with a synthetic Multiple
Antigen Peptide (MAP) containing eight copies of the mEPOR N-terminal peptide
(APSPSLPDPKFESK) (183-187). SFFVp gp55 and mEPOR immunoprecipitates were
complexed to 20 pi of Protein A-Agarose and washed several times with ice-cold extraction
buffer as previously described (159-165).
Western blot analysis of coimmunoprecipitated SFFVp gp55 and mEPOR. The
nuclei-free cellular lysate samples and the SFFVp gp55 and mEPOR immunoprecipitates
were resuspended in equal volumes of 2x SDS-PAGE sample buffer and boiled for 5
minutes. The samples were subjected to 7.5% SDS-PAGE as previously described, and
molecular weights were determined using prestained SDS-PAGE standards (154).
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Proteins were electrophoretically transferred to Immobilon-NC membranes as described
above (173, 174). The membranes were soaked in TBS and then incubated with a
blocking solution of 5% (w/v in TBS) nonfat dry milk for 2 hours. The membranes were
incubated with goat a-MuLV gp70 polyclonal antiserum (1:2000 dilution in 1% [w/v in
TBS] nonfat dry milk) or rabbit a-mEPOR polyclonal antiserum (1:250 dilution in 1%
[w/v] nonfat dry milk) overnight at 4°C (173). The membranes were washed as previously
described and then blocked with 5% (w/v) nonfat dry milk for 30 minutes.
Membranes that had been probed with goat a-MuLV gp70 polyclonal antiserum
were incubated with a 1:2000 dilution (in 1% [w/v in TBS] nonfat dry milk) of rabbit anti
goat IgG (whole molecule) conjugated to horseradish peroxidase (317 purpurogallin
units/ml in 10 mM PBS, pH 7.4, containing 0.01% thimerosal, lot 091H4806; Sigma).
Membranes that had been probed with rabbit a-mEPOR polyclonal antiserum were
incubated with a 1:2000 dilution (in 1% [w/v] nonfat dry milk) o f goat anti-rabbit IgG
(whole molecule) conjugated to horseradish peroxidase (300 purpurogallin units/ml in 10
mM PBS, pH 7.4, containing 0.01% thimerosal, lot 053H4815; Sigma). The membranes
were probed with secondary antibody for 2 hours at room temperature and then washed as
described above. The bound horseradish peroxidase-conjugated secondary antibodies were
visualized using an enhanced chemiluminescence detection system (ECL; Amersham) and
Kodak RP X-Omat scientific imaging film (188,189).
Chemical crosslinkinp to radioiodinated rhEPO. Radioiodinated rhEPO was
crosslinked to cell surface proteins using a previously described method (78). Five x 106
cells were collected by centrifugation and washed with binding medium (DMEM, 15%
[v/v] FBS, 2 mM L-glutamine, 20 mM HEPES, pH 7.4). Cells were resuspended at a
density of 5 x 107 cells/ml in 100 pi of binding medium, and 0.5 pmol of ,25I-rhEPO was
added. Cells were incubated at 10-12°C for 4 hours to allow binding of 125I-rhEPO to cell
surface EPO receptors. Cells and bound 17^I-rhEPO were collected by centrifugation and
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were washed twice with 500 jxl o f ice-cold PBS. Cells and bound ,25I-rhEPO were
resuspended in 99 pi of ice-cold PBS.
One-half pi of a stock solution of 100 mM disuccinimidyl suberate (DSS; Pierce)
(126,128) and 0.5 pi of a stock solution of 100 mM disuccinimidyl tartarate (DST; Pierce)
(190, 191) were added to attain final concentrations of 0.5 mM DSS and 0.5 mM DST.
The stock solutions of 100 mM DSS and 100 mM DST were freshly prepared in DMSO
prior to their use. Cells were incubated on ice for 90 minutes, and 0.5 pi o f 100 mM DSS
and 0.5 pi o f 100 mM DST were both added after 30 and 60 minutes o f incubation.
A lte rn a tiv e ly ,

cells

w ere

in cubated

in

the

p resen ce

of

0.5

mM

bis(sulfosuccinim idyl)suberate (BS^; Pierce) (192-194) or 10 mM l-ethyl-3-(3dim ethylam inopropyl)carbodiim ide (EDC; Pierce) (195-197) and 20 mM Nhydroxysulfosuccinimide (sulfo-NHS; Pierce) (198) for 90 minutes.
Cells and bound and crosslinked I25I-rhEPO were collected by centrifugation and
were washed twice with 500 pi o f ice-cold PBS. The cell pellet was resuspended in 75 pi
of ice-cold extraction buffer, and nuclei were removed by centrifugation. Seventy-five pi
of 2x SDS-PAGE sample buffer were added to each sample, and the samples were boiled
and allowed to cool to room temperature. The samples were subjected to 7.5% SDSPAGE, and molecular weights were determined using prestained molecular weight
standards (154). The gel was soaked under gentle agitation in a fixing solution of 10%
(v/v) trichloroacetic acid, 10% (v/v) acetic acid and 30% (v/v) methanol, and the fixed gel
was dried under heat and vacuum. The dried gel was exposed to Kodak X-Omat AR
scientific imaging film at -70°C.
Radioiodination of cell surface proteins. Cell surface proteins were radiolabeled
using a previously described enzymatic method (199-203). A sterile stock solution of 1%
(w/v) {J-D-glucose (Sigma) was prepared by filtering an aqueous solution through a 0.22
pm Millex filter unit, and lyophilized Enzymobead Radioiodination Reagent (immobilized
preparation of lactoperoxidase and glucose oxidase, Bio-Rad) was rehydrated with distilled
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water. Five x 106 cells were collected by centrifugation, washed once with 1 ml of ice-cold
HBSS, and resuspended in 50 pi of HBSS. Twenty-five pi of 1% p-D-glucose, 50 pi of
Enzymobead Radioiodination Reagent, and 100 pCi of Na125I (100 mCi/ml in NaOH
solution, pH 7-11; Amersham) were added. The reaction mixture was incubated for 25
minutes at room temperature. The mixture was centrifuged, and the supernatant containing
unreacted Na125I was removed. The pellet was washed with ice-cold HBSS and lysed in
200 pi of ice-cold extraction buffer. Nuclei and Enzymobead Radioiodination Reagent
were removed by centrifugation, and the supernatant was designated the nuclei-fiee cellular
lysate. An aliquot of nuclei-free cellular lysate was removed and added to an equal volume
of 2x SDS-PAGE sample buffer, and the samples were subjected to 7.5% SDS-PAGE and
autoradiography as described above (154).
Cell surface labeling o f SFFVp gp55.

Nuclei-free cellular lysates were

immunoprccipitated with 8 pi of goat a-MuLV gp70 polyclonal antiserum (1:25 dilution) at
4°C overnight. The immunoprecipitates were complexed to 40 pi o f Protein A-Agarose
and washed several times with ice-cold extraction buffer as described above (159-165).
The samples were added to equal volumes of 2x SDS-PAGE sample buffer and subjected
to 7.5% SDS-PAGE and autoradiography as described above (154).
Statistical analyses. Experiments were performed in triplicate, and mean values and
standard errors were determined. Experimental results were expressed as tabular values or
graphical points representing the results of 3 determinations plus or minus the standard
error of measurement. The significance of the difference between two experimental groups
was evaluated using the one-tailed Student's t test. A p value less than 0.05 was
considered statistically significant.
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RESULTS

CHARACTERIZATION OF THE DMSO-RESISTANT MEL CLONE DMSO/R1
To assist in an investigation o f changes in erythropoietin receptor (EPOR)
expression during induction of Friend murine erythroleukemia (MEL) cell differentiation by
dimethylsulfoxide (DMSO), a cell line resistant to the differentiating and EPO-sensitizing
effects of DMSO was developed by selection in DMSO-containing growth medium. This
DMSO-resistant subline of MEL cells, DMSO/R1, was obtained without mutagenesis by
passaging MEL cells in growth medium containing progressively higher concentrations of
DMSO, up to 1.5% (v/v) DMSO, as described in the Materials and Methods section.
DMSO/R1 was then cloned by single cell sorting using a FACS IV flow cytometer. After
cloning, DMSO/R1 was continuously passaged in growth medium containing 1.25% (v/v)
DMSO.
Growth and differentiation of Friend MEL and DMSO/R1 cells. The growth
characteristics of Friend MEL cells and DMSO/R1 cells arc represented by growth curves
in Figure 2. Cells were seeded at a density of 4 x 104 cells/ml in the absence or presence of
1.25% (v/v) DMSO and were incubated for 4 days in a humidified air atmosphere, as
described in the Materials and Methods section. An aliquot of the cell suspension was
removed each day, and cell numbers were determined using a Coulter particle counter.
Friend MEL cells displayed logarithmic growth with a doubling time o f 10 hours, and
growth reached a plateau at day 3 at a cell density of approximately 3 x 106 cells/ml.
DMSO treatment inhibited the growth of Friend MEL cells slightly, increasing the
doubling time to 11 hours. However, DMSO-treated MEL cells reached a similar plateau
phase density o f 3 x 10® cells/ml on day 4. DMSO/R1 cells grew more slowly than
parental MEL cells in the absence o f DMSO, displaying a doubling time o f 12 hours. In
contrast to parental MEL cells, DMSO/R1 cells responded to DMSO treatment with
increased growth resulting in a doubling time of 11 hours. DMSO-treated DMSO/R1 cells
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Figure 2a. Growth curves of Friend murine erythroleukemia (MED cells incubated in the
presence or absence o f 1.25% (v/v) DMSO.
Friend murine erythroleukemia (MEL) cells were seeded on day 0 at 4 x 104
cells/ml in the presence or absence of 1.25% (v/v) DMSO. An aliquot was removed each
day, and cell numbers were determined using a Coulter particle counter. Each point
represents the results o f 3 determinations ± the standard error.

Figure 2b. Growth curves of DMSO/R1 cells incubated in the presence or absence of
1.25% (v/v) DMSO.
DMSO-resistant cells (clone DMSO/R1) were seeded on day 0 at 4 x 104 cells/ml in
the presence or absence of 1.25% (v/v) DMSO. An aliquot was removed each day, and
cell numbers were determined using a Coulter particle counter. Each point represents the
results of 3 determinations + the standard error.
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reached a similar plateau phase cell density as Friend MEL cells by day 4, but growth of
untreated DMSO/R1 cells reached a plateau of 2 x 106 cells/ml by day 4. DMSO induced
the differentiation of Friend MEL cells, as evidenced by a hemoglobin (Hb) content of 18.7
+ 2.7 pg Hb/107 cells on day 3 for DMSO-treated cells, as compared to 4.9 + 0.6 pg
Hb/107 cells for untreated cells. Exposure to DMSO had no effect on Hb production in
DMSO/R1 cells, and both untreated and DMSO-treated cells contained 4.4 ± 0.4 pg Hb/107
cells on day 3.
Induction of cell differentiation and restoration of EPO responsiveness bv DMSO in
Friend MEL cells but not in DMSO/R1 cells. The responsiveness of Friend MEL cells and
DMSO/R1 cells to EPO after pretreatment with DMSO is examined in Table 2. Cells were
incubated in culture for 3 days in the absence or presence of 1.25% (v/v) DMSO and were
then reseeded in the absence or presence of 0.5 units/ml o f recombinant human
erythropoietin (rhEPO), as described in the Materials and Methods section. After 3 days of
exposure to rhEPO, cell numbers were determined as a measure of proliferation, and Hb
content was determined as a measure o f the extent of differentiation (20,134). DMSO
inhibited the growth of Friend MEL cells (73% inhibition from day 3 to day 6) but
stimulated the growth of DMSO/R1 cells (30% stimulation from day 3 to day 6), as had
been previously demonstrated in Figure 1. In addition, DMSO induced the differentiation
of Friend MEL cells, as evidenced by a Hb content of 40.3 pg Hb/107 cells by day 6, but
not of DMSO/R1 cells, which displayed no increase in Hb content upon exposure to
DMSO.
RhEPO had no effect on Friend MEL cells that were not pretreated with DMSO
(data not shown) but stimulated both increased proliferation (+22%) and further
differentiation (+6.5 pg Hb/107 cells) in DMSO-pretreated MEL cells. Both the increase in
proliferation and differentiation were statistically significant with p values less then 0.005.
In contrast, rhEPO had no effect on either unpretreated (data not shown) or DMSO-
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Table 2. DMSO pretreatm ent restores sensitivity o f Friend m urine
erythroleukemia (MED cells, but not of the DMSO-resistant clone DMSQ/R1. to
the growth-stimuiatorv and differentiation-inducing effects of erythropoietin (EPOl

Cell line

Friend MEL

DMSO/R1

DMSO

EPO

-

-

Cells/ml x 10~6

tig Hh/107 Cells

2.72 ± 0 .2 3

8.1 ± 1.0

+

-

0.74 ± 0 .1 2

40.3 ± 1 .7

+

+

0.90 ±0.13*

46.8 ± 2 .5 *

-

-

1.51 ± 0 .1 7

8.3 ± 0 .9

+

-

1.97 ± 0 .3 2

8.4 ± 0 .9

+

+

2.02 ± 0.28

8.6 ± 0.7

Cells were seeded on day 0 at 4 x 104 cells/ml in the presence or absence
of 1.25% (v/v) DMSO. On day 3, cells were reseeded at 4 x 104 cells/ml in the
same DMSO concentration in the presence or absence o f 0.5 unit/ml of
recombinant human erythropoietin (rhEPO, R.W.J. Pharmaceutical Research
Institute). Cell numbers and hemoglobin content were determined on day 6. Each
value represents the results from 3 to 6 determinations ± the standard error.
*p<0.005
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pretreated DMS0/R1 cells, confirming that this subline was resistant to both the
differentiation-inducing and EPO-sensitizing effects of DMSO.
Stability of the DMSO-resistant ohenotvpe of DMSQ/R1 cells. Since DMSO had
been shown to stimulate the growth of clone DMSO/R1, it was necessary to determine if
DMSO/R1 cells would lose their resistance to DMSO upon removal of DMSO from their
growth medium. To determine whether the DMSO-resistant phenotype was dependent
upon continuous passage in DMSO-containing growth medium, DMSO/R1 cells were
removed from growth medium containing 1.25% (v/v) DMSO and were passaged in
DMSO-free medium for 1 week or 1 month. The same experiment was then repeated for
DMSO/R1 cells that had been continuously passaged in growth medium containing 1.25%
(v/v) DMSO or that had been passaged for 1 week or 1 month in DMSO-free medium. The
growth characteristics and DMSO-resistant phenotype of clone DMSO/R1 did not change
with removal of the cells from DMSO-containing medium for up to 1 month, as
summarized in Table 3. DMSO stimulated cell growth (a statistically significant 37 to 44%
increase from day 3 to day 6) under all three conditions but did not induce Hb production
under any condition. Additionally, DMSO pretreatment did not confer EPO responsiveness
under any of the three conditions. Thus, it appears that the DMSO-resistant phenotype of
clone DMSO/R1 is relatively stable and does not depend on continuous exposure to
DMSO.
Cross-resistance of DMSO/R1 cells to hexamethvlene bisacetamide (HMBA). To
determine if DMSO/R1 cells were also resistant to HMBA, another well-characterized
inducer of MEL cell differentiation, similar experiments were performed with two different
concentrations of HMBA (51). Cells were exposed to 1.25% (v/v) DMSO, 2 mM HMBA,
4 mM HMBA, or no inducer in culture as described above. The results are summarized in
Table 4. Exposure of Friend cells to 2 mM HMBA did not inhibit cell growth (42%
inhibition from day 3 to day 6) to the same degree as 1.25% (v/v) DMSO (63% growth
inhibition) but induced nearly the same degree of Hb production (23.1 + 0.9 pg Hb/107
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Table 3. The DMSO-resistant phenotype of DMSO/R1 cells is not dependent upon
continuous passage of the cells in growth medium containing DMSO

Time following
DMSO exposure

DMSO

EPO

Cells/ml x 10~6

tig Hh/107 Cells

-

1.41 ± 0.06

7.5 ± 2.2

-

+

1.42 ± 0.09

6.8 ± 2.1

+

-

2.04 ± 0.13

5.8 ± 2.6

+

+

2.14 ± 0 .0 9

6.1 ± 2 .1

-

1.46 ± 0 .0 6

7.1 ± 1.7

-

+

1.46 ± 0.06

7.3 ± 1.6

+

-

2.00 ± 0.14

7.3 ± 1 .7

+

+

2.01 ± 0.17

7.8 ± 1.6

-

1.45 ± 0.05

8.8 ± 1 .4

-

+

1.39 ± 0 .0 7

9.5 ± 1.2

+

-

1.98 ± 0 .1 5

9.3 ± 1.3

+

+

2.00 ± 0 .1 7

9.0 ± 1.0

None

1 week

1 month

DMSO/R1 cells were continuously passaged in growth medium containing
1.25% (v/v) DMSO or were passaged for 1 week or 1 month in DMSO-free growth
medium. Cells were seeded on day 0 at 4 x 104 cells/ml in the presence or absence
of 1.25% (v/v) DMSO. On day 3, cells were reseeded at 4 x 104 cells/ml in the
same DMSO concentration in the presence or absence of 0.5 unit/ml of recombinant
human erythropoietin (rhEPO, R.W.J. Pharmaceutical Research Institute). Cell
numbers and hemoglobin content were determined on day 6. Each value represents
the results from 3 determinations ± the standard error.
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Table 4. Cross-resistance o f DMSO/R1 cells to the differentiation-inducing and
erythropoietin fEPOVsensitizing effects of hexamethvlene bisacetamide fHMBAl
Cell line

Inducer

EPO

ug Hb/107 Cells

2.45 + 0.10
2.47 ± 0 .0 6

3.9 + 2.0
3.9 ± 1 .6

+

0.91 + 0.17
1.24 ± 0.09*

24.5 + 2.3
29.5 ± 0 .8 *

2m M HMBA
2 mM HMBA

+

1.42 + 0.09
1.61 ± 0 .1 2

23.1 + 0.9
27.1 ± 1.0

4 mM HMBA
4 mM HMBA

+

0.20 + 0.02
0.27 ± 0.02

59.1 + 4.9
65.6 ± 4 .2

-

+

1.52 + 0.13
1.42 ± 0.11

4.0 + 1.8
4.2 ± 1.8

+

2.03 + 0.13
2.15 ± 0 .1 9

3.5 + 2.0
3.6 ± 1 .8

+

1.88 ± 0 .1 0
1.97 ± 0 .2 2

2.9 + 1.0
3.9 ± 1.5

4 mM HMBA
4 mM HMBA

+

1.57 ± 0.08
1.59 ± 0 .0 5

2.5 ± 1 .1
2.9 ± 1.1

“

+

1.61 ± 0 .0 8
1.52 ± 0 .1 0

3.5 ± 1.3
3.3 ± 1 .4

+

1.99 + 0.12
2.12 ±0.11

3.7 + 1.2
3.4 ± 1 .3

2mM HMBA
2 mM HMBA

+

1.85 ± 0 .1 0
1.90 ± 0 .0 6

4.2 + 1.0
4.1 ± 1 .1

4 mM HMBA
4 mM HMBA

+

1.75 + 0.25
1.70 ± 0 .0 8

4.1 + 1.9
5.3 ± 2.4

Friend MEL
-

+

1.25% DMSO
1.25% DMSO

_

DMSO/R1
1.25% DMSO
1.25% DMSO
2 mM HMBA
2 mM HMBA

DMSO/R1
(4 weeks
following
exposure
to DMSO)

Cells/ml x 10-6

1.25% DMSO
1.25% DMSO

*

-

Cells were seeded on day 0 at 4 x 104 cells/ml in the presence or absence of 1.25%
(v/v) DMSO, 2 mM HMBA, or 4 mM HMBA. On day 3, cells were reseeded at 4 x 104
cells/ml in the same DMSO or HMBA concentration in the presence or absence of 0.5
unit/ml of recombinant human erythropoietin (rhEPO, R.W.J. Pharmaceutical Research
Institute). Cell numbers and hemoglobin content were determined on day 6. Each value
represents the results from 3 determinations ± the standard error.
*p<0.05
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cells, compared to 24.5 + 2.3 pg Hb/107 cells). Additionally, EPO treatment o f cells
pretreated with 2 mM HMBA resulted in a smaller percentage increase in cell proliferation
(+13%) than was observed with DMSO (+36%), but a similar increase in Hb content was
seen in response to EPO after DMSO or HMBA pretreatment.
An increase in HMBA concentration to 4 mM resulted in a greater inhibition o f
proliferation (92% inhibition from day 3 to day 6) and increased Hb production (59.1 +4.9
pg Hb/107 cells), indicating a stronger induction o f differentiation compared to 1.25% (v/v)
DMSO (63% growth inhibition and 24.5 + 2.3 pg Hb/107 cells). DMSO/R1 cells that had
been continuously passaged in the presence of 1.25% (v/v) DMSO as well as resistant cells
that had been passaged in DMSO-free medium for 4 weeks exhibited a resistant phenotype
to HMBA (less than 5 pg Hb/107 cells). While DMSO/R1 cells grew faster in the presence
of 2 mM or 4 mM HMBA than in the absence o f the inducer, they did not grow as well as
resistant cells incubated in the presence o f DMSO in culture. Interestingly, while the
addition of 2 mM HMBA stimulated the growth o f DMSO/R1 cells compared to untreated
cells, an increase in HMBA concentration to 4 mM resulted in a slight inhibition of cell
proliferation. DMSO/R1 cells were resistant to both the differentiation-inducing ar.d EPOsensitizing effects o f HMBA, and this cross-resistance was not dependent upon continuous
passage in the presence of an inducing agent
Expression of c-m \c and c-mvb mRNAs in Friend MEL and DMSO/R1 cells. To
determine if clone DMSO/R1 lacked characteristic transcriptional changes seen in MEL cells
in response to chemical induction of differentiation in addition to displaying a DMSOresistant phenotype, expression of messenger ribonucleic acids (mRNAs) for the nuclear
protooncogenes c-myb and c-myc was examined in the Friend MEL PC4 and DMSO/R1
cell lines. c-Myb mRNA levels have been shown to decrease to undetectable levels within
2-3 hours after DMSO exposure, return to pretreatment levels at 12-24 hours and fall again
to undetectable levels by day 3 or 4 (204). Constitutive expression of c-myb in MEL cells
blocked DMSO-induced differentiation, so the decrease in c-myb is a necessary part of
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chemically induced MEL cell maturation (204,205). Similar changes in c-myc expression
with induction of differentiation in MEL cells have also been demonstrated (206-208).
Northern blots to detect c-myb and c-myc mRNA levels are shown in Figures 3a
and 4a, respectively. A constant amount of total cellular RNA was loaded in each lane and
subjected to electrophoresis, as described in the Materials and Methods section.
Photographs of ethidium bromide-stained gels, wtih prominent 18S and 28S ribosomal
RNA (rRNA) bands, are displayed in Figures 3b and 4b to demonstrate that an equal
amount of total RNA was loaded in each lane. The nitrocellulose membranes onto which
RNA had been transferred were examined by UV illumination to confirm complete and
even transfer (data not shown). Friend MEL cells (F) and DMSO/R1 cells (R) were
incubated in the absence (-) or presence (+) o f 1.25% (v/v) DMSO for 4 days in culture.
On day 2, cells were split and reseeded in fresh growth medium in the absence or presence
of 1.25% (v/v) DMSO to allow for a cell density of 1 to 1.5 x 106 cells/ml upon harvesting
on day 4. As depicted in Figure 3a, Friend MEL and DMSO/R1 cells expressed similar
levels o f c-myb mRNA under untreated conditions. As had been previously reported
(204), c-myb mRNA was almost undetectable in Friend MEL cells after 4 days of DMSO
treatment. As expected, given its DMSO-resistant phenotype, clone DMSO/R1 did not
show a decrease in c-myb mRNA expression after exposure to DMSO.
Friend MEL cells expressed a low level of c-myc mRNA, which decreased to an
undetectable level after 4 days of treatment with DMSO, as represented in Figure 4a.
However, DMSO/R1 cells expressed an increased level of c-myc mRNA, compared to
parental Friend MEL cells, and this expression appeared to increase with DMSO treatment.
To examine the changes in c-myc mRNA expression in Friend MEL clone PC4 in response
to DMSO treatment, a Northern blot was performed with total cellular RNA isolated from
Friend MEL cells exposed to 1.25% (v/v) DMSO for 0 ,1 ,2 , or 4 days in culture. As seen
in Figure 5a, untreated Friend MEL cells expressed a low level of c-myc mRNA, which
increased after 1 or 2 days of DMSO treatment but decreased to a nearly undetectable level
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Figure 3a. Northern blot to detect c-mvft messenger ribonucleic acid (mRNA) expression
in Friend murine erythroleukemia (MED and DMSO/R1 cells.
Friend MEL cells (F) or DMSO/R1 cells (R) were incubated in the absence (-) or
presence (+) o f 1.25% (v/v) DMSO for 4 days in culture. Cells were split on day 2 and
reseeded in fresh growth medium to achieve a cell density of 1 to 1.5 x 106 cells/ml upon
harvesting on day 4. Total cellular RNA was isolated, and 10 pg o f total RNA were
prepared for electrophoresis, as described in the Materials and Methods section. RNA was
subjected to electrophoresis through a formaldehye-Agarose gel and then transferred to a
nitrocellulose membrane. The membrane was probed with a radiolabeled c-myb cDNA
fragment, as described in the Materials and Methods section.

Figure 3b. Ethidiuro bromide staining of total cellular ribonucleic acid (RNA).
The formaldehyde-Agarose gel in Figure 3a was photographed under ultraviolet
(UV) illumination to demonstrate loading of equal amounts of total RNA. 18S and 28S
ribosomal RNA bands are prominent. (The nitrocellulose membrane was examined under
UV illumination to confirm even transfer of RNA; data are not shown.)
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Figure 4a. Northern blot to detect c-mvc messenger ribonucleic acid (mRNA) expression
in Friend murine erythroleukemia (MEL) and DMSO/R1 ceils.
Friend MEL cells (F) or DMSO/R1 cells (R) were incubated in the absence (-) or
presence (+) o f 1.25% (v/v) DMSO for 4 days in culture. Cells were split on day 2 and
reseeded in fresh growth medium to achieve a cell density of 1 to 1.5 x 106 cells/ml upon
harvesting on day 4. Total cellular RNA was isolated, and 10 pg o f total RNA were
prepared for electrophoresis, as described in the Materials and Methods section. RNA was
subjected to electrophoresis through a formaldehye-Agarose gel and then transferred to a
nitrocellulose membrane. The membrane was probed with a radiolabeled c-myc cDNA
fragment, as described in the Materials and Methods section.

Figure 4b. Ethidium bromide staining of total cellular ribonucleic.acid_(R_NA).
The formaldehyde-Agarose gel in Figure 4a was photographed under ultraviolet
(UV) illumination to demonstrate loading of equal amounts of total RNA. 18S and 28S
ribosomal RNA bands are prominent. (The nitrocellulose membrane was examined under
UV illumination to confirm even transfer of RNA; data are not shown.)
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Figure 5a. Northern blot to detect changes in c-mvc messenger ribonucleic acid (mRNA)
expression during DMSO-induced differentiation of Friend murine erythroleukemia (MEL)
cells.
Friend MEL cells were incubated in the presence o f 1.25% (v/v) DMSO for 1,2 or
4 days in culture. Control cells were incubated in the absence of DMSO (day 0). Total
cellular RNA was isolated, and 10 pg of total RNA were prepared for electrophoresis, as
described in the Materials and Methods section. RNA was subjected to electrophoresis
through a formaldehye-Agarose gel and then transferred to a nitrocellulose membrane. The
membrane was probed with a radiolabeled c-myc cDNA fragment, as described in the
Materials and Methods section.

Figure 5b. Ethidium bromide staining o f total cellular ribonucleic acid (RNA).
The formaldehyde-Agarose gel in Figure 5a was photographed under ultraviolet
(UV) illumination to demonstrate loading of equal amounts of total RNA. 18S and 28S
ribosomal RNA bands are prominent. (The nitrocellulose membrane was examined under
UV illumination to confirm even transfer of RNA; data are not shown.)
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by day 4. Figure 5b depicts ethidium bromide-stained 18S and 28S rRNA bands to show
loading o f a constant amount of total RNA in each lane. Again, the nitrocellulose
membrane onto which RNA had been transferred was examined by UV illumination to
confirm complete and even transfer (data not shown).

CHARACTERIZATION OF THE EPOR ON FRIEND MEL PC4 AND DMSO/R1 CELLS
Expression of EPOR mRNA in Friend MEL and DMSO/Rl cells. To examine
EPOR mRNA expression in parental Friend MEL (F) and DMSO/R1 (R) cells in response
to DMSO exposure, Northern blots were performed with total RNA isolated from cells
incubated in the absence (-) or presence (+) of 1.25% (v/v) DMSO. As shown in Figure
6a, Friend MEL cells exhibited a low level of EPOR mRNA expression, which increased
with the induction of differentiation by DMSO. DMSO/R1 cells expressed a higher
baseline level of EPOR mRNA than parental MEL cells, and this level also increased with
exposure to DMSO. Loading of an equal amount of total cellular RNA in each lane is
demonstrated by ethidium bromide staining in Figure 6b. The nitrocellulose membrane
onto which RNA had been transferred was examined by UV illumination to confirm
complete and even transfer (data not shown).
To determine whether the presence of EPO in the culture medium resulted in the
down-regulation of the mRNA expression of its receptor, Northern blots were performed
with total RNA isolated from MEL and DMSO/R1 cells treated with or without 0.5 unit/ml
of rhEPO after pre-incubation in the absence (-) or presence (+) o f 1.25% (v/v) DMSO
(Figure 7a). Exposure to rhEPO in culture did not have a significant effect upon the levels
of EPOR mRNA in Friend MEL or DMSO/R1 cells. Similarly, exposure to rhEPO after
prctreatment with DMSO did not result in any change in EPOR mRNA expression in the
parental MEL or resistant subline. Loading of an equal amount of total cellular RNA in
each lane is demonstrated by ethidium bromide staining in Figure 7b. The nitrocellulose
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Figure 6a. Northern blot to detect erythropoietin receptor (EPOR) messenger ribonucleic
acid ('mRNA') expression in Friend murine ervthroleukemia fMELI and DMSO/R1 cells.
Friend MEL cells (F) or DMSO/R1 cells (R) were incubated in the absence (-) or
presence (+) o f 1.25% (v/v) DMSO for 4 days in culture. Cells were split on day 2 and
reseeded in fresh growth medium to achieve a cell density of 1 to 1.5 x 106 cells/ml upon
harvesting on day 4. Total cellular RNA was isolated, and 10 pg o f total RNA were
prepared for electrophoresis, as described in the Materials and Methods section. RNA was
subjected to electrophoresis through a formaldehye-Agarose gel and then transferred to a
nitrocellulose membrane. The membrane was probed with a radiolabeled EPOR cDNA
fragment, as described in the Materials and Methods section.

Figure 6b. Ethidium bromide staining o f total cellular ribonucleic add (RNA).
The formaldehyde-Agarose gel in Figure 6a was photographed under ultraviolet
(UV) illumination to demonstrate loading of equal amounts of total RNA. 18S and 28S
ribosomal RNA bands are prominent. (The nitrocellulose membrane was examined under
UV illumination to confirm even transfer of RNA; data are not shown.)
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Figure 7a. Northern blot to detect erythropoietin receptor (EPOR) messenger ribonucleic
acid (mRNAl expression in Friend murine ervthroleukemia (MEL) and DMSO/R1 cells
exposed to erythropoietin (EPO'I after pretreatment with PM SO.
Friend MEL cells or DMSO/R1 cells were incubated in the absence (-) or presence
(+) of 1.25% (v/v) DMSO for 3 days in culture. On day 3 cells were reseeded in fresh
growth medium in the same DMSO concentration and in the absence (-) or presence (+) of
0.5 unit/ml o f recombinant human erythropoietin (rhEPO, R. W. J. Pharmaceutical
Research Institute). On day 5, total cellular RNA was isolated, and 10 pg of total RNA
were prepared for electrophoresis, as described in the Materials and Methods section.
RNA was subjected to electrophoresis through a formaldehye-Agarose gel and then
transferred to a nitrocellulose membrane. The membrane was probed with a radiolabeled
EPOR cDNA fragment, as described in the Materials and Methods section.

Figure 7b. Ethidium bromide staining of total cellular ribonucleic add (RNA).
The formaldehyde-Agarose gel in Figure 7a was photographed under ultraviolet
(UV) illumination to demonstrate loading of equal amounts of total RNA. 18S and 28S
ribosomal RNA bands are prominent. (The nitrocellulose membrane was examined under
UV illumination to confirm even transfer of RNA; data are not shown.)
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membrane onto which RNA had been transferred was examined by UV illumination to
confirm complete and even transfer (data not shown).
Radioiodination of rhEPO using the IOPO-GEN method. To determine whether
differences in EPOR mRNA expression resulted in changes in functional cell surface
receptor expression, binding assays using radioiodinated EPO were performed to measure
receptor numbers and affinity constants in Friend MEL and DMSO/R1 cells treated with or
without DMSO. Purified, serum albumin-free rhEPO was labeled with Na125I by the
IODO-GEN method (78, 151-153), and iodination products were separated on an
excellulose column as described in the Materials and Methods section. Twenty-four eluate
fractions were collected, and the radioactivity o f each collected fraction was determined
using a gamma counter. The results are depicted in graphical form in Figure 8a. A peak of
radioactivity, likely representing 125I-rhEPO, was eluted primarily in fractions 6 to 11, and
unreacted Na125I was eluted beginning at fraction 18.
To determine that 125I-rhEPO was, in fact, eluted with the peak of radioactivity
seen in Figure 8a, eluate fractions were analyzed by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) as described in the Materials and Methods section (154).
As demonstrated in Figure 8b, the primary product of the radioiodination procedure was
125I-rhEPO; this band was shown to comigrate with both pure, serum albumin-free rhEPO
and tissue culture-grade rhEPO on SDS-PAGE (data not shown). Radioiodination
produced a small amount o f labeled product o f higher molecular weight, which was
originally thought to be labeled albumin due to inadequate quenching o f the iodination
reaction. However, this second product did not comigrate with serum albumin on SDSPAGE (data not shown) and was interpreted to be to a radioiodinated dimer of rhEPO, as
its molecular weight was consistent with the expected size of such a dimer. In addition,
SDS-PAGE and silver staining (209,2i0) of rhEPO used in radioiodination revealed only
a single protein band comigrating with the labeled product seen in Figure 8b, and there was
no other band which might have represented a contaminant (data not shown).
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Figure 8a. Radioactivity of eluate fractions collected after application o f iodination
products onto an excellulose column.
Recombinant human erythropoietin (rhEPO) was radiolabeled with Na125I using
the IODO-GEN reagent, as described in the Materials and Methods section. The iodination
reaction was quenched with excess KI, and the radioiodination products were applied onto
a Pierce Excellulose GF-5 Desalting Column. An initial fraction of 300 pi and subsequent
fractions of 5 drops (approximately 60 pi) were collected. One pi was removed from each
fraction, and radioactivity was determined using an LKB 1282 universal gamma counter.

Figure 8b. Analysis o f radioiodination products bv sodium dodecvl sulfatepolvacrvlamide gel electrophoresis (PAGE! and autoradioeraphv.
Recombinant human erythropoietin (rhEPO) was radiolabeled with Na125I using
the IODO-GEN reagent, and the radioiodination products were applied to an excellulose
column, as described in the Materials and Methods section. Fractions o f eluate were
collected as described in Figure 8a, and 1 pi was removed from each fraction and subjected
to 7.5% SDS-PAGE. The gel was fixed and then dried under heat and vacuum, and the
dried gel was exposed to Kodak X-Omat AR film.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

67
600000-1

400000-

200000-

0

10

5

15

20

25

Eluate fraction

Fractions:

6

7

8

9

10 11

12

14 16

18 20 21

22 24

106
80

49.5

32.5

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

68
To ensure that only the band corresponding to I2^I-rhEPO would bind to cells,
preliminary binding assays were performed and the binding proteins were analyzed by
SDS-PAGE and autoradiography (data not shown). Only a single band corresponding to
125I-rhEPO was shown to bind to Friend MEL and DMSO/R1 cells. If the higher
molecular weight band was, in fact, a radiolabeled dimer o f rhEPO, cell surface EPORs did
not possess a high enough binding affinity for the dimer for the presence of the dimer to
contaminate subsequent binding assays.
Determination of the biological activity of the radioiodination product. Fractions 6
to 10 were combined and used in subsequent binding assays. As can be seen from Figure
8b, however, 12^l-rhEPO was not eluted from the column in a sharp, clean peak. An
unknown but significant amount of 125I-rhEPO was not eluted during collection of
fractions 6 to 10, and 125I-rhEPO was still eluted with the last collected fraction (fraction
24). In order to confirm the biological activity of the radiolabeled 125I-rhEPO product and
to determine the actual quantity of 125I-rhEPO collected in fractions 6 to 10, the biological
activity of the combined fractions was assessed using a quantitative colorimetric assay for
cellular proliferation, as described in the Materials and Methods section (155). Ba/F3EPOR cells, which are dependent upon interleukin (IL)-3 or EPO, were used in this assay
(104). The biological activities of tissue culture-grade and iodination-grade rhEPO were
first assessed to confirm that the two sources of rhEPO possessed equal biological activity.
As shown in Figure 9a, both sources of rhEPO demonstrated equal bioactivity, with 50%
maximal biological response occurring at approximately 0.04 units/ml o f rhEPO. Figure
9b depicts the bioactivity curve in response to 125l-rhEPO in combined fractions 6 to 10;
from this curve, the amount of 125I-rhEPO in the combined fractions was determined and
used in subsequent binding assays.
Binding studies o f the EPOR of Friend MEL and DMSO/R1 cells. Whole cell
binding assays were performed as described in the Materials and Methods section (78), and
the results are shown in Figures 10 to 14. Friend MEL cells were incubated in the absence
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Figure 9a. Comparison of biological activities of two sources o f erythropoietin (EPO).
Tissue culture-grade recombinant human erythropoietin (rhEPO, stabilized with
serum albumin) was obtained from R.W. Johnson Pharmaceutical Research Institute, and
iodination-grade recombinant human erythropoietin (rhEPO, albumin-free) was obtained
from Amgen (or R.W.J.) as described in the Materials and Methods section. Biological
activity was determined by an MTT reduction assay, as described in the Materials and
Methods section, and the results are expressed as % o f maximum cell growth (of tissue
culture grade rhEPO). Each point represents the results of 3 determinations + the standard
error.

Figure 9b. Biological activity of radioiodinated erythropoietin.
Recombinant human erythropoietin (rhEPO) was radioiodinated as described in the
Materials and Methods section. The biological activity of the radioiodination product was
determined by an MTT reduction assay, as described in the Materials and Methods section,
and the results are expressed as % o f maximum cell growth. Each point represents the
results of 3 determinations + the standard error.
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Figure 10a. Binding o f radioiodinated erythropoietin to Friend murine ervthroleukemia
(MED cells.
Binding experiments using radioiodinated erythropoietin were performed as
described in the Materials and Methods section. Total binding and nonspecific binding
were determined in the absence or presence, respectively, of greater than 40-fold excess of
unlabeled erythropoietin. Specific binding was obtained by subtraction o f nonspecific
binding from total binding. Each point represents the results of 3 determinations + the
standard error. The standard error for specific binding represents the sum o f the standard
errors for total and nonspecific binding.

Figure 10b. Scatchard plot for binding of radioiodinated erythropoietin to Friend murine
ervthroleukemia (M ED cells.
Binding experiments using radioiodinated erythropoietin were performed as
described in the Materials and Methods section. Values for bound and free radioiodinated
erythropoietin were determined from the amount o f radioiodinated erythropoietin
specifically bound to cells and the amount of radioligand added to the binding mixture.
Each point represents the results of 3 determinations.
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Figure 11a. Binding o f radioiodinated erythropoietin to Friend murine ervthroleukemia
(MEL) cells treated with 1.25% (v/v) DMSO for 2 davs.
Friend murine erythroleukemia (MEL) cells were incubated in the presence of
1.25% (v/v) DMSO for 2 days. Binding experiments using radioiodinated erythropoietin
were performed as described in the Materials and Methods section. Total binding and
nonspecific binding were determined in the absence or presence, respectively, of greater
than 40-fold excess o f unlabeled erythropoietin. Specific binding was obtained by
subtraction of nonspecific binding from total binding. Each point represents the results of
3 determinations ± the standard error. The standard error for specific binding represents
the sum o f the standard errors for total and nonspecific binding.

Figure 1lb . Scatchard plot for binding of radioiodinated erythropoietin to Friend murine
ervthroleukemia (MEL) cells treated w ith 1.25% (v/v) DMSO for 2 davs.
Friend murine erythroleukemia (MEL) cells were incubated in the presence of
1.25% (v/v) DMSO for 2 days. Binding experiments using radioiodinated erythropoietin
were performed as described in the Materials and Methods section. Values for bound and
free radioiodinated erythropoietin were determined from the amount of radioiodinated
erythropoietin specifically bound to cells and the amount o f radioligand added to the
binding mixture. Each point represents the results of 3 determinations.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

74

300 T
Erythropoietin binding (molecules/cell)

Total binding
Nonspecific
Specific binding

200 -

100-

0

2

1

3

Erythropoietin (nM)

8

Bound / free, x 1000

6

4

2

0
0

2

4

6

Bound Erythropoietin, pM

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

75

Figure 12a. Binding o f radioiodinated erythropoietin to Friend murine erythroleukemia
(MEL-) cells treated with 1.25% (v/v) DMSO for 4 davs.
Friend murine erythroleukemia (MEL) cells were incubated in the presence o f
1.25% (v/v) DMSO for 4 days. Binding experiments using radioiodinated erythropoietin
were performed as described in the Materials and Methods section. Total binding and
nonspecific binding were determined in the absence or presence, respectively, of greater
than 40-fold excess o f unlabeled erythropoietin. Specific binding was obtained by
subtraction of nonspecific binding from total binding. Each point represents the results of
3 determinations ± the standard error. The standard error for specific binding represents
the sum o f the standard errors for total and nonspecific binding.

Figure 12b. Scatchard plot for binding of radioiodinated em hropoietinto Friend_ro\irine
ervthroleukemia (MEL) cells treated with 1.25% (v/v) DMSO for 4 davs.
Friend murine erythroleukemia (MEL) cells were incubated in the presence of
1.25% (v/v) DMSO for 4 days. Binding experiments using radioiodinated erythropoietin
were performed as described in the Materials and Methods section. Values for bound and
free radioiodinated erythropoietin were determined from the amount of radioiodinated
erythropoietin specifically bound to cells and the amount of radioligand added to the
binding mixture. Each point represents the results of 3 determinations.
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Figure 13a. Binding of radioiodinated erythropoietin to PMSO/R1 ceils passaged in the
continuous presence o f ! ,2g% (v/v) d m § q .
DMSO-resistant cells (clone DMSO/R1) were passaged in the continous presence of
1.25% (v/v) DMSO. Binding experiments using radioiodinated erythropoietin were
performed as described in the Materials and Methods section. Total binding and
nonspecific binding were determined in the absence or presence, respectively, of greater
than 40-fold excess o f unlabeled erythropoietin. Specific binding was obtained by
subtraction of nonspecific binding from total binding. Each point represents the results of
3 determinations + the standard error. The standard error for specific binding represents
the sum o f the standard errors for total and nonspecific binding.

Figure 13b. Scatchard plot for binding of radioiodinated erythropoietin to DMSO/R1 cells
passaged in the continuous presence of 1.25% (vM DMSO.
DMSO-resistant cells (clone DMSO/R1) were passaged in the continous presence of
1.25% (v/v) DMSO. Binding experiments using radioiodinated erythropoietin were
performed as described in the Materials and Methods section. Values for bound and free
radioiodinated erythropoietin were determined from the amount o f radioiodinated
erythropoietin specifically bound to cells and the amount of radioligand added to the
binding mixture. Each point represents the results o f 3 determinations.
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Figure 14a. Scatchard plot for binding of radioiodinated erythropoietin to DMSO/R1 cells
passaged in the continuous presence of 1.25% (v/v) DMSO.
DMSO-resistant cells (clone DMSO/R1) were passaged in the continous presence of
1.25% (v/v) DMSO. Binding experiments using radioiodinated erythropoietin were
performed as described in the Materials and Methods section. Values for bound and free
radioiodinated erythropoietin were determined from the amount o f radioiodinated
erythropoietin specifically bound to cells and the amount o f radioligand added to the
binding mixture. Each point represents the results of 3 determinations.

Figure 14b. Scatchard plot for binding of radioiodinated erythropoietin to DMSO/R1 cells
passaged in the absence ofDM SO for 2 weeks.
DMSO-resistant cells (clone DMSO/R1) were passaged in the absence ofDMSO for
2 weeks. Binding experiments using radioiodinated erythropoietin were performed as
described in the Materials and Methods section. Values for bound and free radioiodinated
erythropoietin were determined from the amount o f radioiodinated erythropoietin
specifically bound to cells and the amount of radioligand added to the binding mixture.
Each point represents the results of 3 determinations.
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(Figure 10) or presence of 1.25% (v/v) DMSO for two (Figure 11) or four days (Figure
12) in culture. Cells were split at day 2 to allow for logarithmically growing cells at day 4.
Total binding and nonspecific binding were determined from measurements o f radioactivity
contained in cell pellets after binding and washing, and specific binding was determined
from the difference between total binding and nonspecific binding. Results of binding
measurements are represented in part a of the figures, and Scatchard plots are depicted in
part b o f the figures.
A similar binding assay was performed with DMSO/R1 cells that had been
continuously passaged in growth medium containing 1.25% (v/v) DMSO, and the results
are shown in Figure 13. Because DMSO is a polar solvent with known membranepermutating effects, the presence of a small amount o f DMSO in the medium used to
maintain DMSO/R1 cells had the potential to influence EPO binding (211). Consequently,
DMSO/R1 cells were removed from growth medium supplemented with DMSO and were
passaged in DMSO-free medium for 2 weeks, and the binding assay was repeated. The
Scatchard plots for DMSO/R1 cells passaged in the presence (part a) or absence (part b) of
DMSO are represented in Figure 14.
The results o f several binding assays are summarized in Table 5, which shows
affinity constants and receptor numbers per cell for the experiments represented in Figures
10 to 14. In contrast to a previously reported study with MEL cell clone B8, which had
demonstrated a two-fold increase in EPORs per cell but no change in binding affinity over
5 days of DMSO treatment, induction of differentiation of Friend MEL cell clone PC4 by
DMSO resulted in a decrease in EPOR number followed by an increase in binding affinity.
Untreated Friend MEL cells expressed 180 receptors of a single class with an affinity
constant o f 1.0 nM, classifying these receptors in the low-affinity range of described
EPORs. The values for both receptor number and affinity constant are within the range of
previously reported values (55). Exposure to 1.25% (v/v) DMSO for 2 days resulted in
basically no change in binding affinity (0.9 nM) and a decrease in receptor number from
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Table 5. Affinity constants and receptor numbers per cell for Friend murine
ervthroleukemia cells and DMSO-resistant clone DMSO/R1.

Cell line

KnfnMl

Receptors per cell

Control

1.0

180

2 days DMSO

0.9

130

4 days DMSO

0.6

110

Maintained in DMSO

0.46

62

10 days out of DMSO

0.41

61

MEL (clone PC4)

DMSO/R1

Binding experiments using radioiodinated erythropoietin were performed
as described in the Materials and Methods section. Values for affinity constants
and receptors numbers were determined from Scatchard plots.
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180 to 130 receptors per cell. Exposure to DMSO for 2 more days (4 days total) resulted in
a small decrease in receptor number from 130 to 110 receptors per cell. A single class of
EPOR with increased binding affinity (0.6 nM) was observed, and no receptors of affinity
constant 0.9-1.0 nM were seen. Despite the increased binding affinity, the affinity constant
remained in the low-affinity range. No positive cooperativity was seen with DMSO
induction of differentiation.
DMSO/R1 cells maintained in DMSO-containing growth medium expressed 62
receptors per cell of a single class with an affinity constant of 0.46 nM. The presence of
DMSO in the growth medium was of great concern, as the decreased EPOR number and
higher binding affinity seen in DMSO/R1 cells could be due to the presence of DMSO,
rather than intrinsic properties of the subline. The decrease in receptor number and affinity
constant seen with DMSO treatment of Friend MEL cells added to this concern. To address
this issue, DMSO/R1 cells were passaged in DMSO-free growth medium for 2 weeks, and
the binding assay was repeated. The removal ofDMSO from the growth medium resulted
in no change in binding affinity (0.41 nM) or receptor number (61 receptors per cell).
Thus, the changes in EPOR characteristics in DMSO/R1 did not appear to be dependent on
the presence ofDMSO in culture.

INCREASED EXPRESSION OFGP55 PROTEIN IN DMSO/R1 CELLS
Synthesis of gp55 protein in Friend MEL and DMSO/Ri cells. Metabolic labeling
with L-[35S]-methionine (156-158) followed by cell lysis and immunoprecipitation with an
antiserum recognizing both F-MuLV gp70 and SFFVp gp55 was employed to examine the
synthesis of gp55 protein in Friend MEL cells induced to differentiate by 1.5% (v/v)
DMSO or 5 mM HMBA. Immunoprecipitates from a constant number of cells were loaded
in each lane for 7.5% SDS-PAGE (154). As depicted in Figure 15, the synthesis of both
F-MuLV gp85-90, the precursor of gp70, and SFFVp gp55 (marked by arrow) in Friend
cells decreased over a period of 3 days in culture, likely due to a saturation of cell density
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Figure 15. 35S;Metabolic labeling of F-MuLV gp7J and SFFVp gp55 in Friend
murine ervthroleukemia (MEL) ceils induced to differentiate with 1.5% (v/v)
DMSO or 5 mM HMBA
Friend murine erythroleukemia (MEL) cells were seeded at day 0 in the
absence (Friend) or presence of 1.5% (v/v) DMSO or 5 mM HMBA. After 1,2 or
3 days in culture, cells were labeled with L-[35S]-methionine for 1 hour. Cellular
lysates were immunoprecipitated with a goat polyclonal antiserum to F-MuLV gp70
that also recognizes SFFVp gp55 (marked by arrow), and immunoprecipitates were
subjected to 7.5% SDS-PAGE and autoradiography.
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with a plateau in cell growth. Induction of differentiation by DMSO resulted in no apparent
change in F-MuLV gp85-90 synthesis but appeared to result in increased synthesis of gp55
on day 3. In contrast, HMBA treatment resulted in decreased synthesis of SFFVp gp55
and a more marked decrease in F-MuLV gp85-90 synthesis over the same time period. In
addition, HMBA-treated cells exhibited almost undetectable levels of actin synthesis; actin
was nonspecifically immunoprecipitated by goat whole serum (data not shown) and
migrated as a 42-44 kDa protein on SDS-PAGE.
To determine if DMSO/R1 cells demonstrated changes in gp55 synthesis compared
to parental MEL cells, the metabolic labeling experiment was repeated with both Friend
MEL (F) and DMSO/R1 cells (R) that were grown in the absence (-) or presence (+) of
1.25% (v/v) DMSO for 1, 2 or 3 days in culture (Figure 16). As observed before, the
synthesis of both F-MuLV gp85-90 and SFFVp gp55 (marked by arrow) in Friend cells
decreased over 3 days in culture. Exposure o f Friend cells to DMSO increased both FMuLV gp85-90 and SFFVp gp55 synthesis compared to uninduced cells on the same day.
However, the level o f synthesis in DMSO-induced cells of both envelope glycoproteins
also decreased slightly over 3 days in culture. DMSO/R1 cells appeared to exhibit a higher
ratio of gp55 synthesis to gp85-90 synthesis, compared to parental MEL cells. This
increase was particularly evident on day 3. In contrast to its effect upon parental MEL
cells, DMSO treatment did not induce as much of an increase in envelope glycoprotein
synthesis, particularly of F-MuLV gp85-90, in DMSO/R1 cells.
Western blot analysis of total cellular go55 protein content. Friend MEL and
DMSO/R1 cells were grown in the absence or presence of 1.25% (v/v) DMSO for 1,2 or 3
days in culture. Total cellular gp55 protein content was examined by Western blot analysis
using a goat polyclonal antiserum recognizing both F-MuLV gp70 and SFFVp gp55, as
described in the Materials and Methods section (Figure 17). In contrast to metabolic
labeling experiments, which demonstrated synthesis of gp55 equal to or greater than that of
F-MuLV gp85-90, Western blot analysis detected a much greater amount of F-MuLV gp85
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Figure 16. 35S-Metabo1ic labeling o f F-MuLV pp70 and SFFVp gp55_in_Friend

muring. grythrplguKgmia (MEL) gglls and PMSO/P) cells treated with PMSO
Friend murine erythroleukemia (MEL) cells (F) or DMSO/R1 cells (R) were
seeded at day 0 in the absence (-) or presence (+) o f 1.5% (v/v) DMSO. After 1,2
or 3 days in culture, cells were labeled with L-[35S]-methionine for 1 hour.
Cellular lysates were immunoprecipitated with a goat polyclonal antiserum to FMuLV gp70 that also recognizes SFFVp gp55 (marked by arrow).
Immunoprecipitates were subjected to 7.5% SDS-PAGE and autoradiography.
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Figure 17. Western blotting of F-MuLV gp70 and SFFVp gp55 in Friend murine

grythroleukemia (MEL) gglls.and.PMSQ/Rl cells treated with PM SQ
Friend murine erythroleukemia (MEL) cells (Friend) or DMSO/R1 cells
(Resistant) were seeded at day 0 in the absence or presence (+DMSO) of 1.5%
(v/v) DMSO. After 1, 2 or 3 days in culture, cellular lysates were subjected to
7.5% SDS-PAGE, and proteins were transferred to an Immobilon-NC membrane.
The membrane was probed with a goat polyclonal antiserum to F-MuLV gp70 that
also recognizes SFFVp gp55 (marked by arrow). Proteins were detected using
125I-Protein A.
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than of SFFVp gp55 (marked by arrow) in Friend cells. Both total cellular gp85 and gp55
decreased from day 2 to day 3, and it appeared that the level of total cellular SFFVp gp55,
but not of F-MuLV gp85, decreased in Friend cells exposed to DMSO, compared to
uninduced cells. DMSO/R1 cells exhibited a large increase in the amount of total cellular
gp55, compared to parental MEL cells, and a smaller increase in the amount o f F-MuLV
gp85. A band corresponding to F-MuLV gp70, the processed form o f the gp85 precursor,
was also observed in the resistant subline. As with MEL cells, the amounts o f F-MuLV
gp85 (and gp70) and SFFVp gp55 in DMSO/R1 cells decreased over 3 days in culture, and
exposure to DMSO appeared to decrease the level o f gp55 protein. However, the amount
of gp55 protein observed in DMSO/R1 cells exposed to DMSO was still considerably
increased over the level observed in uninduced parental MEL cells.
Eulse-chase metabolic labeling and endoglvcosidase H treatment of SFFVp gp55
immunoprecipitates. To determine if slower degradation of synthesized gp55 in DMSO/R1
cells was responsible for the observed increase in the level of total cellular gp55 protein in
the resistant subline, pulse-chase experiments using endoglycosidase H (endo H) treatment
of gp55 immunoprecipitates were performed (166-168). Friend MEL cells (Figure 18) and
DMSO/R1 cells (Figure 19) were metabolically labeled with L-[35S]-methionine for 15
minutes, and incorporated label was chased for up to 6 hours. In Friend cells, F-MuLV
gp70 was synthesized as an immaturely glycosylated, endo H-sensitive polypeptide of a
molecular size of 80-85 kDa (Figure 18). Endo H treatment decreased the molecular
weight of the F-MuLV envelope glycoprotein to two bands of 60-62 kDa and 67-68 kDa.
After a 3 hour chase period, the maturely glycosylated, endo H-resistant 70 kDa form was
the primary band seen on SDS-PAGE, indicating that F-MuLV gp70 had undergone
oligosaccharide processing and passed through the Golgi complex. In addition, most of
the radiolabeled F-MuLV envelope glycoprotein had undergone degradation within 3 hours
after synthesis, as evidenced by the decreased intensities of the gp70 bands at 3 hours. The
results after 6 hours were essentially unchanged from the observations at 3 hours.
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Figure 18. Pulse-chase metabolic labeling and endoelvcosidase H treatment o f FMuLV go70 and SFFV p gp55 in Friend murine ervthroleukemia (MEL) cells
induced to differentiate with 1.25% (v/v) DMSO
Friend murine erythroleukemia (MEL) cells were seeded in the absence or
presence of 1.25% (v/v) DMSO. After 2 days in culture, cells were labeled with L[35S]-methionine for 15 minutes. Cells were washed twice and then incubated in
growth medium for 0, 3 or 6 hours (chase). Cellular lysates were
immunoprecipitated with a goat polyclonal antiserum to F-MuLV gp70 that also
recognizes SFFVp gp55 (marked by aiTOWs). Immunoprecipitates were incubated
in the absence (-) or presence (+) o f endoglycosidase H (endo H) and then
subjected to 7.5% SDS-PAGE and autoradiography.
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Figure 19. Pulse-chase metabolic labeling and endoglvcosidase H treatment o f FMnLV pp70 and SFFVp gp55 in DMSO/R1 ceils incubated in culture in the absence

QLBressncg.Qf 1,25% (v/v) DMSQ
DMSO/R1 cells were seeded in the absence or presence of 1.25% (v/v)
DMSO. After 2 days in culture, cells were labeled with L-[35S]-methionine for 15
minutes. Cells were washed twice and then incubated in growth medium for 0 ,3
or 6 hours (chase). Cellular lysates were immunoprecipitated with a goat polyclonal
antiserum to F-MuLV gp70 that also recognizes SFFVp gp55 (marked by arrows).
Immunoprecipitates were incubated in the absence (-) or presence (+) of
endoglycosidase H (endo H) and then subjected to 7.5% SDS-PAGE and
autoradiography.
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In contrast, the primary form of the SFFVp envelope glycoprotein that was
observed at all time points was the immaturely glycosylated, endo H-sensitive 55 kDa form
(marked by upper arrow). Endo H treatment decreased the size of SFFVp gp55 to the
unglycosylated 45 kDa polypeptide chain (marked by lower arrow). Interestingly, a
significant amount o f gp45 was observed in the absence o f endo H after 3 and 6 hour chase
periods, suggesting that a fraction of synthesized gp55 undergoes deglycosylation in
Friend cells. In contrast to the observed degradation o f gp70, the intensities o f the gp45
and gp55 bands did not diminish after 3 or 6 hour chase periods, indicative o f the longer
half-life of gp55. DMSO-treated Friend cells demonstrated faster degradation of newly
synthesized F-MuLV gp70, as the intensities o f the gp70 decreased more rapidly than in
uninduced cells. It also appeared that synthesized SFFVp gp55 underwent a small degree
of degradation after 6 hours, as the intensities of the gp45 and gp55 bands at this time point
seemed slightly diminished. In vivo deglycosylation o f synthesized gp55 appeared to
occur more slowly in DMSO-treated cells.
Similar results were observed with DMSO/R1 cells (Figure 19). Essentially no
degradation of synthesized gp55 was seen over a 6 hour chase period. In contrast to
parental MEL cells, exposure of resistant cells to DMSO resulted in no diminution o f gp45
and gp55 band intensities at the 6 hour timepoint. As was observed in DMSO-treated MEL
cells, however, DMSO treatment of DMSO/R1 cells delayed the appearance o f gp45 in
untreated immunoprecipitates, again suggesting that DMSO somehow retards the in vivo
deglycosylation of synthesized gp55.
Transfection of pRc/RSV-gp55 and pRc/RSV-antisense tro55 into Friend ceils. To
determine whether SFFVp gp55 is responsible for the block in EPO-induced differentiation
of Friend cells and whether the increase in gp55 protein observed in DMSO/R1 cells is
responsible for the subline's resistant phenotype, expression vectors containing the SFFVp
gp55 cDNA in both sense and antisense configurations were transfected into Friend MEL
cells (140). The SFFVp gp55 cDNA insert was ligated in the sense or antisense orientation
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into the multiple cloning site of the stable eukaryotic expression vector pRc/RSV (Figure
20). The vector alone, pRc/RSV, was introduced into cells by electroporation (140,176,
177), and a clone (FI) was derived from vector-transfected cells. FI cells demonstrated no
significant difference in cell growth characteristics or in sensitivity to the effects of DMSO
from parental MEL cells (Table 6). DMSO inhibited cell growth, induced differentiation,
and restored responsiveness to EPO to the same degrees in both parental MEL and FI cells.
DMSO treatment of MEL cells resulted in a 73% growth inhibition and an increase
in Hb content to 40.3 + 1.7 pg Hb/107 cells, and EPO stimulated cell proliferation by 22%
and Hb production by an additional 6.5 pg Hb/107 cells. In comparison, DMSO treatment
of FI cells resulted in a 74% growth inhibition and an increase in Hb content to 34.8 + 1.4
pg Hb/107 cells, and EPO stimulated cell proliferation by 27% and Hb production by an
additional 9.2 pg Hb/107 cells. pRc/RSV-gp55 and pRc/RSV-antisense gp55 transfectants
were selected in medium containing 800 ng/ml o f G-418 (180-182), and clones were
screened by Western blot analysis to measure the level of total cellular gp55 protein (data
not shown). Sense-transfected clones expressing increased total gp55 content and
antisense-tranfected clones expressing decreased gp55 content were chosen for further
examination of their biological responsiveness to the differentiation-inducing and EPOsensitizing effects of DMSO.
A clone derived from MEL cells transfected with gp55 cDNA expressed in the
sense orientation (Tf-gp55), which exhibited a level of total cellular gp55 protein similar to
the relatively high level observed in DMSO/R1 cells, was selected for further study (Figure
21). Tf-gp55 cells exhibited similar growth characteristics as parental MEL cells (Table 7).
Exposure of clone Tf-gp55 to 1.25% (v/v) DMSO resulted in a 77% inhibition of cell
growth and an increase in cellular Hb content to 33.2 + 1.3 pg Hb/107 cells. The
magnitudes of growth inhibition and differentiation were similar to those produced by
DMSO in parental MEL cells (81% growth inhibition and 39.7 ± 2 .0 p g Hb/107 cells).
However, in contrast to parental MEL cells, DMSO treatment did not sensitize Tf-gp55
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Figure 20. Construction of plasmids to express SFFVp gp55 cPNA in the sense or
antisense orientation in Friend murine ervthroleukemia (MED cells
The cDNA insert for SFFVp gp55 was subcloned, in either the sense or
antisense configuration, into the multiple cloning site o f the stable eukaryotic
expression vector pRc/RSV. Expression o f the insert cDNA was under the
transcriptional control o f a Rous sarcoma virus promoter (RSV LTR), and the
vector also contained a neomycin resistance gene (Neo) under control of the SV40
early promoter.
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Table 6. Effects o f erythropoietin fEPO! on proliferation and hemoglobin (Hb)
content of Friend MEL cells and pRc/RSV-transfected MEL cells (clone FI) treated
with DMSO

Cell line

DMSO

EPO

Cells/ml x 10~6

n f Hb/107 Cells

-

2.72 ± 0.23

8.1 ± 1.0

+

-

0.74 ± 0 .1 2

40.3 ± 1.7

+

+

0.90 ±0.13*

46.8 ± 2.5*

-

2.56 ± 0.39

7.6 ± 0 .5

-

+

2.60 ±0.33

8.2 ± 0 .5

+

-

0.66 ±0.07

34.8 ± 1 .4

+

+

0.84 ± 0.07

44.0 ± 2.3*

Friend MEL

FI

Cells were seeded on day 0 at 4 x 10* cells/ml in the presence or absence of
1.25% (v/v) DMSO. On day 3, cells were reseeded at 4 x 104 cells/ml in the same
DMSO concentration in the presence or absence of 0.5 unit/ml o f recombinant
human erythropoietin (rhEPO, R.W.J. Pharmaceutical Research Institute). Cell
numbers and hemoglobin content were determined on day 6. Each value represents
the results from 3 to 6 determinations ± the standard error.
*p<0.005
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Figure 21. Western blotting of F-MuLV gp70 and SFFVp gp55 in pRc/RSV-gp55transfected MEL clone Tf-gn55
Friend murine erythroleukemia (MEL) cells (Friend), DMSO/R1 cells
(Resistant), or pRc/RSV-gp55-transfected MEL cells (clone Tf-gp55) were seeded
at day 0 in the absence or presence (+DMSO) o f 1.25% (v/v) DMSO. After 1,2 or
3 days in culture, cellular lysates were subjected to 7.5% SDS-PAGE, and proteins
were transferred to an Immobilon-NC membrane. The membrane was probed with
a goat polyclonal antiserum to F-MuLV gp70 that also recognizes SFFVp gp55
(marked by arrows). Proteins were detected using ,25I-Protein A.
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Table 7. Effects o f erythropoietin CEpo") on proliferation and hemoglobin (Hh-)
CQntenLflLEriend MEL cells and pRc/RSV-fgp55 cDNAVtransfected MEL cells
(clone Tf-gp55) treated with DMSO

Cell line

DMSO

Friend MEL

EPO

Cells/ml x 10~6

ug Hb/107 Cells

-

2.40 ± 0 .1 7

6.8 ± 0.4

-

+

2.44 ± 0.19

7.0 ± 0 .7

+

-

0.45 ± 0 .0 4

39.7 ± 2.0

+

0.57 ± 0.02

46.1 ± 2.3*

-

2.29 ± 0.20

5.0 ± 1.1

-

+

2.30 ± 0 .1 8

5.6 ± 1 .3

+

-

0.53 ± 0.03

33.2 ± 1.3

+

+

0.69 ± 0.05

32.5 ± 1.6

Tf-gp55

Cells were seeded on day 0 at 4 x 104 cells/ml in the presence or absence of
1.25% (v/v) DMSO. On day 3, cells were reseeded at 4 x 104 cells/ml in the same
DMSO concentration in the presence or absence of 0.5 unit/ml o f recombinant
human erythropoietin (rhEPO, R.W.J. Pharmaceutical Research Institute). Cell
numbers and hemoglobin content were determined on day 6. Each value represents
the results from 3 to 6 determinations ± the standard error.
*p<0.0005
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Figure 22. Western blotting of F-MuLV pp70 and SFFVp cd55 in dR c/RSVantisense gp55-transfected MEL clone B7
Friend murine erythroleukemia (MEL) cells (clone PC4), DMSO/R1 cells
(R l)f pRc/RSV-antisense gp55-transfected MEL cells (clone B7), or pRc/RSVgp55-transfected MEL cells (TO were seeded at day 0 in the absence (-) or presence
(+) of 1.25% (v/v) DMSO. After 2 days in culture, cellular lysates were subjected
to 7.5% SDS-PAGE, and proteins were transferred to an Immobilon-NC
membrane. The membrane was probed with a goat polyclonal antiserum to FMuLV gp70 that also recognizes SFFVp gp55. Proteins were detected using 125IProtein A.
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Table 8. Increased sensitivity of pRc/RSV-fantisense e p 55 cPNAVtransfected
MEL-Clone B7 to both the differentiation-inducing and erythropoietin fEPOV
sensitizing effects o f DMSO

Cell line

DMSO

Friend MEL

EPO

Cells/ml x IQ-6

up Hb/107 Cells

-

3.26 + 0.31

6.8 ± 0.4

-

+

3.22 + 0.31

7.0 ± 0.7

+

-

1.00 ± 0.09

39.7 ± 2.0

+

+

1.26 ± 0.03

46.1 ± 2.3*

-

3.15 ± 0.26

6.0 ± 0.7

-

+

3.04 ± 0 .2 8

7.8 ± 1.4

+

-

0.37 ± 0.06

59.5 ± 4 .0

+

+

0.60 ± 0.05

78.3 ± 5.3*

B7

Cells were seeded on day 0 at 4 x 104 cells/ml in the presence or absence of
1.25% (v/v) DMSO. On day 3, cells were reseeded at 4 x 10* cells/ml in the same
DMSO concentration in the presence or absence of 0.5 unit/ml o f recombinant
human erythropoietin (rhEPO, R.W.J. Pharmaceutical Research Institute). Cell
numbers and hemoglobin content were determined on day 6. Each value represents
the results from 3 to 6 determinations ± the standard error.
*p<0.001
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cells to the differentiating effects of EPO, although EPO stimulated cell proliferation by
30% (compared to 27% in MEL cells). While the increased level of SFFVp gp55 protein in
Tf-gp55 cells did not result in resistance to the differentiating effects o f DMSO, the
increased amount o f gp55 appeared to render these cells nonresponsive to the
differentiating effects o f EPO.
A clone derived from MEL cells transfected with SFFVp gp55 cDNA in the
antisense orientation (B7) exhibited a decreased level of gp55 protein compared to parental
MEL cells (Figure 22). B7 cells showed growth characteristics similar to those o f parental
MEL cells in the absence of DMSO, but exhibited increased sensitivity to both the growth
inhibitory and differentiating effects o f DMSO (Table 8). DMSO treatment o f B7 cells
resulted in an 88% growth inhibition and an increase in Hb content to 59.5 + 4.0 pg
Hb/107 cells. In comparison, DMSO treatment of parental MEL cells resulted in a 69%
growth inhibition and an increase in Hb content to 39.7 ± 2.0 pg Hb/107 cells. In addition,
EPO caused a greater percentage increase in cell number, as well as a greater increase in Hb
production, in DMSO-treated B7 cells (62% growth stimulation and +18.8 pg Hb/107
cells) than in parental MEL cells (26% growth stimulation and +6.4 pg Hb/107 cells).
Thus, transfection with a vector expressing gp55 cDNA in the antisense orientation resulted
in greater sensitivity to both the differentiation-inducing and EPO-sensitizing effects of
DMSO.

INTERACTION BETWEEN GP55 AND THE EPOR
Chemical crosslinking to radioiodinated EPO. 125I-rhEPO was crosslinked to
Friend MEL and DMSO/R1 cells using 0.5 mM disuccinimidyl suberate (DSS) as
described in the Materials and Methods section, and the results are shown in Figure 23
(126-128). Bound 125I-rhEPO migrated at an approximate size of 40 kDa by SDS-PAGE,
and specific binding of the radiolabeled ligand was competed by an excess of cold EPO
(lane 1). Radioiodinated EPO was crosslinked to a protein of 60-65 kDa in both Friend
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Figure 23. Chemical crosslinking of radioiodinated erythropoietin to Friend murine
ervthroleukemia (MEL’) cells and DMSO/R1 cells hv disuccinimidvl suberate fDSS)
Friend murine erythroleukemia (MEL) cells (F) or DMSO/R1 cells (R) were seeded
at 4 x 104 cells/ml in the absence (-) or presence (+) of 1.25% (v/v) DMSO. After 2 days
in culture, cells were collected, and ,25I-rhEPO was allowed to bind to cells in the absence
or presence (+) o f excess cold EPO for 4 hours at 10-12°C. 125I-rhEPO was crosslinked
to cellular proteins for 90 minutes at 4°C using 0.5 mM disuccinimidyl suberate (DSS).
Cellular lysates were subjected to 7.5% SDS-PAGE and autoradiography.
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MEL and DMSO/R1 cells, and crosslinking to this protein was not observed in the
presence of excess cold EPO. Exposure o f Friend MEL or DMSO/R1 cells to DMSO
appeared to increase the intensity of the crosslinked protein band but did not result in the
appearance of any new bands. In both cell lines, only a small amount o f bound 125IrhEPO was crosslinked to protein, as evident by the much stronger signal intensity of the
125I-rhEPO band compared to the crosslinked band.
To determine if the use of different chemical reagents would result in more efficient
crosslinking or in crosslinking of different proteins, radioiodinated EPO was crosslinked to
Friend MEL cells using a variety of reagents (Figure 24). Cells were incubated with 12^IrhEPO in the presence of 0.5 mM DSS (lane 1), 0.5 mM disuccinimidyl tartarate (DST)
and 0.5 mM DSS (lane 2), 10 mM l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)
and 20 mM N -hydroxysulfosuccinim ide (sulfo-NHS) (lane 3), or 0.5 mM
bis(sulfosuccinimidyl)suberate (BS3) (lane 4). No crosslinking was observed with the
combination o f EDC and sulfo-NHS (195-198), and BS3 (192-194) proved to be a less
efficient crosslinker than DSS. However, the combination o f DSS (126-128) and DST
(190,191) resulted in more efficient crosslinking of 123I-rhEPO to the 60-65 kDa protein
than did DSS alone.
The combination of DSS and DST was used to crosslink radiolabeled EPO to
Friend MEL and DMSO/R1 cells, and the results are shown in Figure 25. As observed
above, crosslinking of bound 125I-rhEPO was very inefficient, with the intensities of the
crosslinkcd protein bands being of much lower intensities than the radiolabeled ligand
alone. However, a second protein of approximately 120 kDa appeared to be crosslinked to
125I-rhEPO, in addition to the aforementioned 60-65 kDa protein, which remained the
primary crosslinked band. The intensities of both crosslinked protein bands did not appear
to significantly change with exposure of either cell line to DMSO.
CelLsurface labeling of SFFVp gp55. Cell surface labeling was used to examine
the expression of the SFFVp envelope glycoprotein at the surface of Friend MEL and
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Figure 24. Chemical crosslinking of radioiodinated erythropoietin to Friend murine

gmhrolguRgroia.(M EU cclls
Friend murine erythroleukemia (MEL) cells were crosslinked to ,25I-rhEPO for 90
minutes at 4°C using 1) 0.5 mM disuccinimidyl suberate (DSS), 2) 0.5 mM DSS and 0.5
mM disuccinimidyl tartarate, 3) 10 mM l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
and 20 mM N-hydroxysulfosuccinimide, or 4) 0.5 mM bis(sulfosuccinimidyl)suberate.
Cellular lysates were subjected to 7.5% SDS-PAGE and autoradiography.
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Figure 25. Chemicalcrossl inking of radioiodinated erythropoietin to Friend MEL cells and
DMSQ/R1 cells bv disuccinimidyl suberate (DSS) and disuccinimidyl tartarate (DST)
Friend murine erythroleukemia (MEL) cells (F) orDMSO/Rl cells (R) were seeded
at 4 x 104 cells/ml in the absence (-) or presence (+) o f 1.25% (v/v) DMSO. After 2 days
in culture, cells were collected, and 125I-rhEPO was allowed to bind to cells for 4 hours at
10-12°C. 125I-rhEPO was crosslinked to cellular proteins for 90 minutes at 4°C using a
combination of 0.5 mM disuccinimidyl suberate (DSS) and 0.5 mM disuccinimidyl tartarate
(DST). Cellular lysates were subjected to 7.5% SDS-PAGE and autoradiography.
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DMSO/R1 cells and to determine if exposure to DMSO or EPO changed this expression.
Cells were incubated in the absence (-) or presence (+) o f 1.25% (v/v) DMSO in culture,
and cell surface proteins were labeled with NaI25I using an immobilized preparation of
lactoperoxidase and glucose oxidase, as described in the Materials and Methods section
(199-203). Total labeled cell surface proteins are shown in Figure 26. In both parental
MEL and DMSO-resistant cells, exposure to DMSO resulted in an increase in radiolabeling
of cell surface proteins, although this increase appeared to be more pronounced in DMSOtreated Friend cells. In both cell lines, the predominant labeled protein migrated at a
molecular weight of approximately 47-48 kDa, with less intense bands migrating at
approximately 35 k D a, 65 kDa and 80 kDa.
Labeled cell surface F-MuLV gp70 and SFFVp gp55 proteins are depicted in Figure
27. Immunoprecipitation of the cellular lysates of cell surface labeled Friend MEL cells
with goat a-MuLV gp70 polyclonal antiserum primarily detected an approximately 70 kDa
band corresponding to F-MuLV gp70 that had been processed and transported to the cell
surface. In addition, a very faint band was seen at approximately 60-65 kDa, which
presumably represented SFFVp gp55 which had undergone carbohydrate processing and
transport to the cell surface. Also observed was a 47-48 kDa band that comigrated with the
primary band seen with total labeled cell surface proteins; this band probably represented
nonspecific binding to the goat antiserum. DMSO/R1 cells exhibited a markedly decreased
amount of labeled F-MuLV gp70, compared to parental MEL cells, and no detectable
amount of labeled gp55.
Exposure to DMSO greatly increased cell surface labeling of F-MuLV gp70 in both
cell lines, and the degree of increase in band intensity exceeded the increase in band
intensities observed in total cell surface proteins (Figure 26). DMSO treatment of both cell
lines also increased labeling of the 47-48 kDa protein thought to nonspecifically bind to the
goat antiserum. Additionally, DMSO treatment of both cell lines markedly increased cell
surface labeling of the 60-65 kDa protein thought to be the maturely glycosylated envelope
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Figure 26. Labeling of total cell surface proteins in Friend murine ervthroleukemia
(M ED cells and DMSO/R1 cells treated with DMSO
Friend murine erythroleukemia (MEL) cells or DMSO/R1 cells were seeded
at day 0 at 4 x 104 cells/ml in the absence (-) or presence (+) of 1.25% (v/v)
DMSO. On day 2, cells were reseeded at 4 x 104 cells/ml. On day 4, cell surface
proteins were labeled with Na,25I using immobilized lactoperoxidase and glucose
oxidase (Enzymobead Reagent). Cellular lysates were subjected to 7.5% SDSPAGE and autoradiography.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

106

Cells:

Friend

DMSO:

-

+

DMSO/R1

-

+

106
80

49.5

33

Figure 27. Labeling o f cell surface F-MuLV gp70 and SFFVp en55 in Friend
murine erythroleukemia (MEL) cells and PMSO/R1 cells treated with DMSO
Friend murine erythroleukemia (MEL) cells or DMSO/R1 cells were seeded
at day 0 at 4 x 104 cells/ml in the absence (-) or presence (+) of 1.25% (v/v)
DMSO. On day 2, cells were reseeded at 4 x 104 cells/ml. On day 4, cell surface
proteins were labeled with Na,25I using immobilized lactoperoxidase and glucose
oxidase (Enzymobead Reagent). Cellular lysates were immunoprecipitated with a
goat polyclonal antiserum to F-MuLV gp70 that also recognizes SFFVp gp55.
Immunoprecipitates were subjected to 7.5% SDS-PAGE and autoradiography.
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form of SFFVp gp55 (Figure 27). Interestingly, a labeled protein of 52-55 kDa was
observed in DMSO-treated MEL cells but not in DMSO-resistant cells exposed to DMSO.
This protein band was not seen in uninduced MEL cells nor in DMSO-treated DMSO/R1
cells, even upon longer exposure of the dried gel to radiographic film (data not shown).
Cell surface labeling of SFFVp gp55 in pRc/RSV-gp55 and oRc/RSV-antisense
gp55-transfected cell lines. Cell surface labeling studies were performed to examine
expression of the SFFVp env gene product at the cell surface of cells derived from
pRc/RSV-gp55 cDNA-transfected MEL cells (clone Tf-gp55) and pRc/RSV-antisense gp55
cDNA-transfected MEL cells (clone B7). The results are shown in Figure 28. Similar to
the results observed in parental MEL cells, immunoprecipitation of the cellular lysates of
cell surface labeled Tf-gp55 cells and B7 cells detected primarily F-MuLV gp70 and a very
small amount of a 60-65 kDa protein corresponding to the mature, cell surface form of
SFFVp gp55. A small amount of the 47-48 kDa protein was observed in all three cell
lines, but no 52-55 kDa protein was seen. DMSO treatment o f Tf-gp55 and B7 cells, as
well of Friend and DMSO/R1 cells, resulted in markedly increased labeling of F-MuLV
gp70 as well as of the 60-65 kDa protein. Exposure to DMSO also resulted in the
appearance of the 52-55 kDa band, which was readily detectable in the parental MEL lines
and the two transfected cell lines, but faintly detectable in the resistant subline. The
increase in labeling of the 47-48 kDa band was less pronounced than the increases in the
other three bands.
Attempts to detect cell surface EPOR by immunoprecipitation of cellular lysates of
lactoperoxidase-glucose oxidase labeled cells with a rabbit polyclonal o-mEPOR antiserum
were unsuccessful. This lack of success appeared to be due to the low cell surface
expression of EPORs on MEL cells, as demonstrated by the results of the binding assays,
and the poor ability of the rabbit a-mEPOR antiserum to precipitate EPOR in cellular lysate
samples. Similarly, attempts to detect mctabolically labeled EPOR by immunoprecipitation
also proved disappointing.
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Figure 28. Labeling of cell surface F-MuLV pp70 and SFFV p gp55 in murine
erythroleukemia (MEL) cell lines treated with erythropoietin following pretreatment
with DMSO
Friend murine erythroleukemia (MEL) cells, DMSO/R1 cells (Resist),
pRc/RSV-gp55-transfected MEL cells (clone Tf-gp55), or pRc/RSV-antisense
gp55-transfected MEL cells (clone B7) were seeded at day 0 at 4 x 104 cells/ml in
the absence (-) or presence (+) o f 1.25% (v/v) DMSO. On day 3, cells were
reseeded at 4 x 104 cells/ml in the absence (-) or presence (+) of 0.5 unit/ml of
erythropoietin (EPO). On day 5, cell surface proteins were labeled with Na125I
using immobilized lactoperoxidase and glucose oxidase (Enzymobead Reagent).
Cellular lysates were immunoprecipitated with a goat polyclonal antiserum to FMuLV gp70 that also recognizes SFFVp gp55. Immunoprecipitates were subjected
to 7.5% SDS-PAGE and autoradiography.
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Western .blot analysis o f coimmunoprecipitated SFFV p gp55 and mEPOR. To
directly determine if induction of differentiation by DMSO resulted in dissociation of gp55
from the EPOR, coimmunoprecipitation studies of unlabeled cellular lysates of Friend MEL
and DMSO/R1 cells were performed. Nuclei-free cellular lysates of Friend MEL cells (F)
and DMSO/R1 cells (R) were obtained as described above. The lysates were subjected to
immunoprecipitation by a rabbit antiserum to the mEPOR (anti-EpoR) or by a goat
antisemm to F-MuLV gp70 which also recognizes SFFVp gp55 (anti-gp70). Samples of
cellular lysates and of the immunoprecipitates were resolved by SDS-PAGE and transferred
to nitrocellulose membranes (173, 174). The membranes were probed with antiserum
against gp55/gp70 (Figure 29) or the mEPOR (Figure 30) to detect both
immunoprecipitated and coimmunoprecipitated proteins, and bound primary antibodies
were detected with the appropriate peroxidase-conjugated secondary antibodies (188,189).
The Western blot of gp55/gp70 is shown in Figure 29. In Friend MEL cells (F),
the F-MuLV env gene product existed primarily in the maturely glycosylated, cell surface
gp70 form; however, a small fraction o f the immature 80 kDa form of the glycoprotein was
detected. The env gene product o f the SFFVp existed primarily in the immaturely
glycosylated 55 kDa form in the RER, although a small amount underwent oligosaccharide
processing to the mature 65 kDa form. Similar amounts of F-MuLV gp70 and gp80 were
observed in DMSO/R1 cells (R), but the resistant cells exhibited increased levels of gp55
and, in particular, gp65. Western blotting of anti-gp55/gp70 immunoprecipitates (lanes 3
and 4) showed that the polyclonal antiserum against F-MuLV gp70 bound the F-MuLV and
SFFVp envelope glycoproteins with different affinities under immunoprecipitation and
Western blot conditions. A much smaller proportion of gp70 was seen by Western blotting
in lanes 3 and 4 than in lanes 1 and 2, indicating a lower affinity for gp70 under
immunoprecipitation conditions. Western blotting of anti-EpoR immunoprecipitates (lanes
5 and 6) demonstrated that the gp55 and gp65 forms of SFFVp, but not the gp70 and gp80
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Figure 29. Western blotting of SFFVp gp55 coimmunoprecipitated with the
erythropoietin receptor in Friend murine ervthroleukemia (MEL) cells and
PMSO/R1 cells
Cellular lysates of Friend murine erythroleukemia (MEL) cells (F) or
DMSO/R1 cells (R) were subjected to immunoprecipitation with a goat polyclonal
antiserum to F-MuLV gp70 that also recognizes SFFVp gp55 (anti-gp70) or with a
rabbit polyclonal antiserum to the murine erythropoietin receptor (anti-EpoR).
Cellular lysates and immunoprecipitates were subjected to 7.5% SDS-PAGE, and
proteins were transferred to an Immobilon-NC membrane. The membrane was
probed first with goat anti-gp70 antiserum (primary andbody) and then with rabbit
anti-goat IgG conjugated to horseradish peroxidase (secondary andbody). Proteins
were detected using an enhanced chemiluminescence (ECL) system.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Ill
forms o f F-MuLV, physically associated with the EPOR. This association was seen in
both Friend (F) and DMSO/R1 (R) cells.
Immunoprecipitated and coimmunoprecipitated mEPOR was more difficult to detect
by this assay (Figure 30). The antiserum to the mEPOR primarily recognized a protein of
approximately 105 kDa, but fainter bands o f approximately 60 and 65 kDa were also
observed in both Friend (F) and DMSO/R1 (R) cell lines (lanes 1 and 2). Western blotting
of anti-gp55/gp70 immunoprecipitates demonstrated that the 60 and 65 kDa forms of the
EPOR, but not the 105 kDa protein, associated with SFFVp gp55 and gp65 (lanes 3 and 4)
in both cell lines. Western blotting of anti-EpoR immunoprecipitates resulted in a very
dense band of approximately 55 kDa.
To determine whether this band was the result of secondary antibody recognizing
antibody in the immunoprecipitation that had been subjected to SDS-PAGE and transferred
to the membrane, a Western blot was performed in which a membrane was probed only
with the secondary antibody. Goat anti-rabbit IgG conjugated to horseradish peroxidase
was used to probe a membrane, as shown in Figure 31. The antibody was probed against
Friend MEL cell lysate (lane 1), goat anti-gp70 immunoprecipitate of lysate (lane 2), rabbit
anti-EpoR immunoprecipitate o f lysate (lane 3), goat anti-gp70 antiserum alone (lane 4),
and rabbit anti-EpoR antiserum alone (lane 5). The secondary antibody readily detected a
band o f approximately 55 kDa in lanes 3 and 5, indicating that the goat anti-rabbit
secondary antibody bound to the rabbit antiserum used to immunoprecipitate the mEPOR.
A similar experiment determined that the rabbit anti-goat secondary antibody did not bind to
the goat antiserum used to immunoprecipitate SFFVp gp55 (data not shown).
Effect of DMSO upon the association of SFFVp gp55 and the EPOR. Friend MEL
and DMSO/R1 cells were incubated for 4 days in culture in the absence (-) or presence (+)
of 1.25% (v/v) DMSO, and nuclei-free cellular lysates were obtained as described in the
Materials and Methods section. The lysates were immunoprecipitated with goat antiserum
to F-MuLV gp70 (anti-gp70) or with rabbit antiserum to the mEPOR (anti-EpoR). The
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Figure 30. Western blotting of ervthropoietin.receDtor coimmunoprecipitated with
SFFVp gp55 in Friend murine ervthroleukemia (MEL) cells and DMSQ/R1 cells
Cellular lysates of Friend murine erythroleukemia (MEL) cells (F) or
DMSO/R1 cells (R) were subjected to immunoprecipitation with a goat polyclonal
antiserum to F-MuLV gp70 that also recognizes SFFVp gp55 (anti-gp70) or with a
rabbit polyclonal antiserum to the murine erythropoietin receptor (anti-EpoR).
Cellular lysates and immunoprecipitates were subjected to 7.5% SDS-PAGE, and
proteins were transferred to an Immobilon-NC membrane. The membrane was
probed first with rabbit anti-EpoR antiserum (primary antibody) and then with goat
anti-rabbit IgG conjugated to horseradish peroxidase (secondary antibody).
Proteins were detected using an enhanced chemiluminescence (ECL) system.
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Figure 31. Western blotting with anti-rabbit secondary antibody alone
Cellular lysate of Friend murine erythroleukemia (MEL) cells was subjected
to immunoprecipitation with a goat polyclonal antiserum to F-MuLV gp70 that also
recognizes SFFVp gp55 (anti-gp70) or with a rabbit polyclonal antiserum to the
murine erythropoietin receptor (anti-EpoR). Cellular lysate (lane 1), anti-gp70
immunoprecipitate (lane 2), anti-EpoR immunoprecipitate (lane 3), anti-gp70 alone
(lane 4), and anti-EpoR alone (lane 5) were subjected to 7.5% SDS-PAGE.
Proteins were transferred to an Immobilon-NC membrane. The membrane was
probed with goat anti-rabbit IgG conjugated to horseradish peroxidase. Proteins
were detected using an enhanced chemiluminescence (ECL) system.
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Figurc 32. Western blotting of SFFVp gp55 coimmunoprecipitated with the
erythropoietin receptor in Friend muiine ervthroleukemia (MEL) cells and
DMSO/R1 cells treated with DMSO
Friend murine erythroleukemia (MEL) cells or DMSO/R1 cells (Resist)
were seeded at day 0 at 4 x 104 cells/ml in the absence (-) or presence (+) or 1.25%
(v/v) of DMSO. On day 2, cellular lysates were subjected to immunoprecipitation
with a goat polyclonal antiserum to F-MuLV gp70 that also recognizes SFFVp
gp55 (anti-gp70) or with a rabbit polyclonal antiserum to the murine erythropoietin
receptor (anti-EpoR). Immunoprecipitates were subjected to 7.5% SDS-PAGE,
and proteins were transferred to an Immobilon-NC membrane. The membrane was
probed first with goat anti-gp70 antiserum (primary antibody) and then with rabbit
anti-goat IgG conjugated to horseradish peroxidase (secondary antibody). Proteins
were detected using an enhanced chemiluminescence (ECL) system.
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Figure 33. _Westem_blotting of erythropoietin reccotor coimmunoprecipitated with
SEEyp-gp55_in_Eriendjnurine ervthroleukemia (MEL) cells and PM SQ/RLcells
treated with PMSO
Friend murine erythroleukemia (MEL) cells or DMSO/R1 cells (Resist)
were seeded at day 0 at 4 x 104 cells/ml in the absence (-) or presence (+) or 1.25%
(v/v) of DMSO. On day 2, cellular lysates were subjected to immunoprecipitation
with a goat polyclonal antiserum to F-MuLV gp70 that also recognizes SFFVp
gp55 (anti-gp70). Cellular lysates and anti-gp70 immunoprecipitates were
subjected to 7.5% SDS-PAGE, and proteins were transferred to an Immobilon-NC
membrane. The membrane was probed first with rabbit polyclonal antiserum to the
murine erythropoietin receptor (primary antibody) and then with goat anti-rabbit
IgG conjugated to horseradish peroxidase (secondary antibody). Proteins were
detected using an enhanced chemiluminescence (ECL) system.
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immunoprecipitates were subjected to SDS-PAGE and transferred to nitrocellulose
membranes. The membranes were probed with goat anti-gp70 antiserum (Figure 32) or
rabbit anti-EpoR antiserum (Figure 33). Western blotting with antiserum to gp55/gp70
(Figure 32) confirmed the results observed in Figure 29; immunoprecipitation with
antiserum to mEPOR coprecipitated the gp55 and gp65 forms o f the SFFVp envelope
glycoprotein in both Friend and DMSO/R1 cells. DMSO treatment of Friend cells appeared
to increase the amount o f SFFVp gp65 coimmunoprecipitated with the EPOR, whereas
DMSO treatment appeared to decrease the amounts o f SFFVp gp55 and gp65
coimmunoprecipitated with the EPOR.
Western blotting with antiserum to the mEPOR (Figure 33) demonstrated cleaner
results than were shown previously in Figure 30. Immunoprecipitation with antiserum to
gp55/gp70 coprecipitated mEPOR with an apparent molecular weight of approximately 60
kDa by SDS-PAGE. The same amount of EPOR was coimmunoprecipitated in both Friend
MEL and DMSO/R1 cells, and exposure o f both cell lines to DMSO did not appear to
change the amount o f EPOR that was associated with SFFVp gp55 and gp65.
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DISCUSSION

The focus of the first part of these investigations has been the examination of
changes in the expression of erythropoietin receptor (EPOR) messenger ribonucleic acid
(mRNA) and protein during induction of Friend murine erythroleukemia (MEL) cell
differentiation by the polar solvent dimethylsulfoxide (DMSO). Friend MEL cells, which
are derived from proerythroblast-like cells isolated from the spleens of mice infected with
the Friend SFFVp viral complex, are independent of erythropoietin (EPO), the principal
humoral regulator of erythropoiesis (27,28, 30, 38). Unlike normal committed erythroid
progenitor cells, Friend cells are blocked in their differentiation and are unresponsive to
EPO (27,30,42). As has been previously reported, DMSO induces Friend MEL cells to
undergo changes in cellular morphology and function similar to those occurring during
differentiation of proeiythroid cells to orthochromatophilic normoblasts (20, 45). More
importantly to these investigations, however, induction of MEL cell differentiation by
DMSO is accompanied by restoration of sensitivity to both the growth-stimulatory and
differentiation-inducing effects of EPO. These studies have attempted to examine whether
this restoration of sensitivity to EPO is mediated through an increase in cell surface EPORs,
through the expression o f a new class of high-affinity receptors, or through the induction
of positive cooperativity among the receptors.

CHARACTERIZATION OF THE DMSO-RESISTANT MEL CLONE DMSO/R1
Measurement o f EPO responsiveness of MEL cells pretreated with DMSO. A
concentration of 1.25% (v/v) DMSO was chosen to induce MEL cell differentiation after
careful preliminary screening o f a wide range, from 0.25% (v/v) to over 2% (v/v), of
DMSO concentrations (data not shown). A range of concentrations of DMSO was tested to
determine the level of inducer necessary to optimize studies of the restoration by DMSO of
both the proliferation- and differentiation-inducing effects of EPO (20). A dose o f 1.25%

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

118
(v/v) DMSO was selected because pretreatment of MEL cells with this concentration of the
agent resulted in maximal increases in cell growth and Hb content by EPO (data not
shown). Lower concentrations resulted in smaller increases in cell growth and Hb content,
due to dilution of EPO's effects on differentiating cells by the larger pool of
nondifferentiated MEL cells.
Higher concentrations also resulted in smaller measured increases in growth and Hb
production, as these doses appeared to induce MEL cells to mature beyond the stage of
EPO sensitivity. EPO primarily stimulates CFU-E cells; however, as erythroid progenitor
cells differentiate beyond the nondividing late basophilic erythoblast stage, they become
independent o f EPO for terminal maturation (38,54,57). At higher doses of DMSO, the
DMSO-iesponsive population o f cells progressed far enough down the differentiation
pathway that they had no remaining proliferative capacity or had become independent of
EPO for further differentiation.
Measurement of MEL cell differentiation. A well-characterized spectrophotometric
assay to determine cellular Hb content by measuring the amount of Hb contained in several
million cells was the method chosen to measure the degree of MEL cell differentiation in
these studies (134). Benzidine staining, another commonly used assay o f MEL cell
differentiation that measures the number of cells staining positively for Hb (20), was not
performed for several reasons. Although benzidine staining yields valuable information
about the percentage of cells that are induced to differentiate, the assay is highly dependent
upon the subjective judgment o f the human observer. Experimental reproducibility of
results with the benzidine staining assay was of concern. O f particular concern was the
ability to replicate results between different observers, or interobserver reproducibility.
The degree of staining varies subtly along a continuum from individual cell to cell, and
there is no clear demarcation between a "negative" and a "positive" cell. Unlike the
benzidine staining assay, the spectrophotometric assay depends, not on a human observer
but, on an instrument that generates objective measurements (134). Additionally, the
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spectrophotometric assay yields quantitative results, and interobserver reproducibility is
excellent.
The one disadvantage of the spectrophotometric assay, however, is its inability to
provide information about the percentage of the cell population undergoing differentiation
and the amount o f Hb production in those cells that actually differentiate. This limitation
must be considered in the interpretation of any results generated from this assay, as only a
certain percentage of cells differentiate in response to a particular concentration of inducer,
as has been demonstrated by careful use of the benzidine staining assay (20). The
spectrophotometric assay can not distinguish between a situation in which the entire cell
population differentiates and produces Hb and a situation in which a smaller subpopulation
differentiates and produces a greater amount of Hb per individual cell. Both conditions
would yield the same result in the spectrophotometric assay.
Cell numbers and determination of the amount of growth inhibition in the presence
of a differentiation inducer compensate, at least to some degree, for this limitation of the
spectrophotometric assay. Cells which enter the differentiation pathway eventually lose
their capacity to proliferate (1), so that cell counts can theoretically serve as crude estimates
of the relative numbers of cells that have not differentiated and still possess proliferative
capacity. For example, an equal increase in the Hb content of two populations of MEL
cells in response to DMSO can be accompanied by a lesser or greater degree of growth
inhibition. A lesser degree of growth inhibition suggests that a smaller percentage of cells
undergoes differentiation but produces more Hb per individual cell. In contrast, greater
growth inhibition suggests that a larger percentage of cells differentiates but produces less
Hb per cell, as a larger number of cells in the overall population produce the same amount
of total Hb.
Growth and_differentiation of Friend MEL and PM SO/Rl_cells. In order to
facilitate these investigations, a Friend MEL subline resistant to the differentiating and
EPO-sensitizing effects of DMSO was developed by passaging MEL cells in progressively
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higher concentrations of DMSO and then cloning resistant cells by single cell sorting. This
DMSO-resistant subline, DMSO/R1, was used in all subsequent studies. Clone DMSO/R1
displayed somewhat slower growth in the absence of DMSO in culture than did the parental
Friend MEL clone PC4, with a doubling time of 12 hours compared to 10 hours for the
parental line (Figure 2). In addition, DMSO/R1 cells reached plateau phase at a lower
density than did parental MEL cells, with a plateau phase density o f 2 x 10® cells/ml
compared to 3 x 10® cells/ml for Friend cells. However, the growth of Friend MEL and
DMSO/R1 cells in the presence of 1.25% (v/v) DMSO was similar for the first 4 days of
tissue culture growth, with similar doubling times and plateau phase cell densities for both
lines. In contrast to Friend MEL cells, in which DMSO inhibited growth and induced
increased Hb production, DMSO/R1 cells responded to DMSO with increased proliferation
but no differentiation, as evidenced by no change in Hb production in DMSO-treated cells.
Thus, clone DMSO/R1 was demonstrated to be resistant to the differentiationinducing effect of DMSO. Clone DMSO/R1 was then further characterized to determine if
resistance to the maturation-inducing effect of DMSO was accompanied by resistance to the
EPO-sensitizing effect of DMSO (20). Unlike parental Friend MEL cells, in which DMSO
pretreatment restored EPO responsiveness, DMSO-treated DMSO/R1 cells showed no
change in cell proliferation or Hb content in response to EPO (Table 2). Therefore, clone
DMSO/R1 was resistant to both the differentiating and EPO-sensitizing properties of
DMSO.
Stability o f the DMSO-resistant phenotype o f clone DMSO/R1. O f concern,
however, was the observation that DMSO stimulated the growth o f DMSO/R1 cells,
especially given that this subline was being continuously passaged in the presence of
1.25% (v/v) DMSO. Since clone DMSO/R1 had been developed without the use of a
mutagenizing agent, the possibility that the resistant phenotype was not stable and was, in
fact, dependent upon constant exposure to DMSO had to be considered. O f additional,
though less likely, concern was the possibility that clone DMSO/R1 had become dependent
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upon DMSO and would not be able to grow in the absence of the polar solvent To address
these two concerns, DMSO/R1 cells were removed from DMSO-supplemented growth
medium and were passaged in DMSO-free growth medium for 1 week or 1 month. The
cellular responses to DMSO treatment and to EPO exposure following DMSO pretreatment
were then assessed (Table 3).
Clone DMSO/R1 exhibited a DMSO-resistant phenotype that was stable for at least
1 month and maintained resistance to both the maturation-inducing and EPO-sensitizing
properties of DMSO over this month. In addition, while DMSO/R1 cells were able to grow
in the absence o f DMSO during the month, DMSO still exerted a growth-stimulatory effect
on DMSO/R1 cells that had not been exposed to the polar solvent for 1 month. The degree
of growth stimulation seen with DMSO in these cells was similar to that observed with
DMSO/R1 cells continuously passaged in DMSO-containing medium, and DMSO/R1 cells
exhibited nearly identical growth characteristics whether they were passaged in the constant
presence of DMSO or after 1 month in culture without DMSO. These results indicated that
the DMSO-resistant property of DMSO/R1 cells was inherent to the subline and was not a
transient response to the presence of DMSO.
However, it is unclear whether this population o f DMSO-resistant cells was
achieved through the selection of a preexisting subpopulation of parental Friend MEL cells
already resistant to the action of DMSO or through the induction o f changes, whether
genetic or cellular, in the parental line which then generated a resistant subline upon further
selection in DMSO. The first explanation is certainly plausible, as there is a distribution of
sensitivities to DMSO among any population o f Friend MEL cells (20). A very small
fraction of this population may be resistant to the concentration of inducer used to generate
DMSO-resistant cells and may eventually account for the entire MEL cell population, as
DMSO-sensitive cells differentiate and lose all proliferative potential. An increasing
concentration of DMSO was used, instead of mutagenesis, to develop a resistant subline in
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this hope that selection and expansion of a preexisting, resistant subpopulation could be
achieved.
Cross-resistance of DMSO/R1 cells to hexamethvlene bisacetamide (HMBA). As
summarized in Table 4, exposure of Friend MEL cells to 2 mM HMBA resulted in a
comparable amount of Hb production (23.1 + 0 .9 pg Hb/107 cells) as did exposure to
1.25% (v/v) DMSO (24.5 ± 2 .3 pg Hb/107 cells), but 2 mM HMBA inhibited cell growth
to a lesser extent (42% inhibition) than did DMSO (63% inhibition). This statistically
significant difference in growth inhibition suggested that 2 mM HMBA induced a smaller
percentage o f MEL cells to enter the differentiation pathway than did 1.25% (v/v) DMSO.
However, 2 mM HMBA appeared to induce a greater amount o f Hb production in
differentiation-induced cells than did DMSO. Thus, while HMBA (51) and DMSO (20) are
both commonly used as inducers of the differentiation of MEL cells, they have similar, but
not equivalent, biological effects in these cells. An increase in the HMBA concentration to
4 mM resulted in both increased inhibition o f cell growth (92% inhibition) as well as
increased Hb production (59.1 + 4 .9 pg Hb/107 cells. The increased Hb production may
have resulted from an increased percentage of differentiated cells in culture, increased Hb
production by individual differentiated cells, or a combination of both effects.
DMSO/R1 cells were shown to be resistant to both the differentiation-inducing and
EPO-sensitizing effects of HMBA. DMSO/R1 cells were resistant to 4 mM HMBA, which
induced cellular Hb content in parental MEL cells to increase to an amount 2.4-fold the
level induced by 1.25% (v/v) DMSO. Exposure to 4 mM HMBA induced a greater
percentage o f parental MEL cells to differentiate or stimulated higher production of Hb
within the same percentage of cells, compared to 1.25% (v/v) DMSO or 2 mM HMBA. It
is thought that DMSO and HMBA may induce MEL cell differentiation through similar
mechanisms (1), so it was not surprising that DMSO/R1 cells also expressed a resistant
phenotype to the differentiating effects of HMBA. It was somewhat surprising that, while
both 2 mM and 4 mM HMBA stimulated the growth of DMSO/R1 cells, the increase
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observed with 4 mM was less than that seen with 2 mM HMBA. From preliminary studies
in this laboratory, HMBA appeared to have more cytotoxic effects than DMSO in culture,
and it is possible that these cytotoxic effects had a larger effect on cell growth at the higher
concentration of HMBA.
A possibility which had to be considered, however, was that DMSO/R1 cells were
being induced to differentiate in response to DMSO but were deficient in the synthetic
machinery to generate Hb, which has been widely used as the marker for erythroid
maturation (20). Cells treated with imidazole and DMSO failed to activate iron transport,
synthesize heme, or produce globin mRNA, but they underwent all the other cellular
changes, such as a decrease in cell size and nuclear condensation, characteristic o f terminal
differentiation. Thus, imidazole inhibited Hb synthesis but did not disrupt other maturation
processes in MEL cells exposed to DMSO (132,206,212). The possiblity that the method
in use was not detecting differentiation was addressed by examining clone DMSO/R1 for
other cellular changes which are known to occur in response to induction o f MEL cell
differentiation by DMSO.
Expression o f c-mvc and c-mvb mRNAs in Friend MEL and DMSO/R1 cells. The
nuclear protooncogenes c-myb and c-myc have been implicated in MEL cell maturation,
and mRNA levels o f these two protooncogenes are known to undergo characteristic
changes during chemically induced differentiation (204-208). c-Myb and c-myc mRNA
levels decrease almost immediately in response to DMSO and then return to baseline levels
by day 1 or 2 before undergoing a second, final decrease by day 3 or 4. This final decrease
to nearly undetectable levels is necessary for maturation to occur and is a hallmark of MEL
cell differentiation.
Friend MEL and DMSO/R1 cells were incubated for 4 days in culture in the absence
or presence of 1.25% (v/v) DMSO, and c-myb and c-myc mRNA levels were examined by
Northern blotting. While Friend MEL cells exhibited a characteristic decrease in c-myb
mRNA to an almost undetectable level after 4 days' exposure to DMSO, DMSO treatment
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o f DMS0/R1 cells had no effect on c-myb mRNA expression (Figure 3). A similar
decrease in c-myc mRNA expression was observed in Friend MEL cells after exposure to
DMSO, but DMSO/R1 cells displayed an increased baseline level of c-myc mRNA
compared to parental Friend cells (Figure 4). This level o f c-myc mRNA appeared to
increase in DMSO/R1 cells upon DMSO treatment.
Thus, DMSO/R1 cells were resistant to DMSO on a transcriptional, as well as on a
functional, level, and the resistant phenotype seen in biological assays was not due only to
a block in the functional enzymes being measured for assessment of maturation. While
increased c-myc expression may be a possible mechanism for the DMSO-resistant
phenotype of clone DMSO/R1, it is impossible to conclude that this increase was causally
related to the phenotype of this subline. This question may be addressed, however, by
overexpressing c-myc in parental Friend MEL cells and assessing whether such increased
expression results in a DMSO-resistant phenotype.

CHARACTERIZATION OF THE EPOR ON FRIEND MEL PC4 AND DMSO/R1 CELLS
Unfortunately, studies of EPOR protein expression and transport have been limited
by the extremely low level of cell surface receptors exhibited on erythroid cell lines (1001000 receptors per cell) (55). Because o f this limitation, much o f the work to date on the
EPOR has been conducted on non-erythroid cells transfected with vectors to overexpress
the receptor (104,122). The EPOR is easier to study in such transfected lines due to the
high number o f receptors which are expressed in these lines. A sizeable body of data on
the activation o f cell growth through the EPOR has been obtained through studies of such
transfected cell lines. However, it must be kept in mind that the findings from such
investigations in non-erythroid lines may not necessarily reflect the cellular processes
involved with the native EPOR in erythroid cells. This caveat is especially true if the goal
is the investigation of erythroid differentiation, as non-erythroid cells seem an even less
appropriate system in which to conduct such studies. Thus, while studying the EPOR in
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erythroid cells is technically difficult due to the low number of receptors on these cells,
such investigations are necessary for a better understanding o f the EPOR and its role in
inducing the differentiation of erythroid progenitor cells.
Expression o f EPOR mRNA in Friend MEL and PMSO/R1 cells. Having
characterized the DMSO-resistant phenotype of the DMSO/R1 subline, a Northern blot was
performed to determine whether changes in EPOR mRNA expression occurred after 4 days
o f DMSO treatment in parental Friend and DMSO/R1 cells (Figure 6a). DMSO/R1 cells
exhibited a higher baseline level of EPOR mRNA expression than parental MEL cells, but
the level of EPOR mRNA increased with DMSO exposure in both cell lines. This increase
was not surprising in the Friend MEL line, as the cells became EPO-responsive with
DMSO-induced maturation. Additionally, it had been shown in B8 cells that the number of
specific binding sites for EPO increased with induction o f differentiation (90).
However, DMSO/R1 cells were resistant to DMSO and did not express the changes
in nuclear protoonogene expression and Hb production normally observed during
maturation. Thus, it was intriguing to detect an increase in EPOR mRNA in a subline
which exhibited no other expected change o f maturation and which remained EPOunresponsive after treatment with DMSO. The increase in EPOR mRNA expression
observed with DMSO treatment of clone DMSO/R1 suggested that the subline’s resistance
to the EPO-sensitizing effects of DMSO was dependent on a cellular change or event
subsequent to transcription of EPOR mRNA. The level of EPOR mRNA was not
downregulated by exposure of uninduced or DMSO-treated Friend MEL or DMSO/R1 cells
to EPO (Figure 7a).
To better examine the changes in EPOR expression during chemical induction of
differentiation, binding assays were performed (78, 88). While Nonhem blots are often
used to assess gene expression, a biochemical assay to measure protein expression is
desirable, as a knowledge of the level of end product is more informative. Measurements
such as enzyme assays or binding studies are often more informative than Western blots of
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total protein or metabolic labeling studies of protein synthesis, as the former measurements
yield information on functional expression. Although both Friend MEL and DMSO/R1
cells had been shown to respond to DMSO treatment with increased expression of EPOR
mRNA, it was important to determine if such an increase at the mRNA level translated into
increased expression of functional receptor at the cell surface.
Radioiodination o f rhEPO and determination of the biological activity of the
radioiodination product. Recombinant human erythropoietin (rhEPO) was radioiodinated
using a well-accepted IODO-GEN procedure (151-153), which is the commonly used
method to label EPO for binding or crosslinking studies (78). As can be observed from
Figure 8, it was impossible to determine how much rhEPO was recovered in the form of
125I-rhEPO from the results o f gamma counting or SDS-PAGE analysis of fraction
samples. Clearly, a large but unmeasurable amount o f 125I-rhEPO remained on the column
or was collected in eluate fractions which were not included in the pooled fractions used in
subsequent binding assays (fractions 6 to 10). It addition, it was necessary to ensure that
125I-rhEPO generated by this radioiodination possessed biological activity, as iodination of
more than one tyrosine residue per EPO molecule destroys biological function o f the
hormone (88).
To address this issue and to determine the amount o f 125I-rhEPO that was
recovered from the excellulose column in fractions 6 to 10, the combined radioiodination
fractions (6 to 10) were tested for bioactivity using a quantitative colorimetric assay (Figure
9) (155). This assay employed Ba/F3-EPOR cells, murine lymphoid cells which had been
stably transfected with an expression vector containing MEL EPOR cDNA and which are
dependent upon interleukin (IL)-3 or EPO for growth in culture (104). While these
transfected lymphoid cells have been commonly employed to study the murine EPOR, it
must be emphasized that Ba/F3 cells, being of lymphoid rather than erythroid lineage, may
not possess all the requisite cellular machinery to transduce an identical signal in response
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to EPO as do erythroid cells. However, the Ba/F3-EPOR cell line was quite suitable for
the purpose for which it was being used in these investigations.
Effect of DMSO upon receptor number and binding affinity of_the EPOR of Friend
MEL cells. After determination o f the biological activity of 125I-rhEPO and quantitation of
125I-rhEPO present in the pooled eluate fractions, binding assays were performed to
examine possible changes in EPOR protein expression on the cell surface in response to
DMSO-induced differentiation. Binding experiments were conducted with both Friend
MEL and DMSO/R1 cells, and the results are represented in Figures 10 to 14 and
summarized in Table 5. Friend MEL cells growing in culture expressed approximately 180
receptors of a single class with an affinity constant of 1.0 nM, placing these receptors
within the Iow-affinity range o f described EPORs. The values for both receptor number
and affinity constant are within the range of previously reported values (55).
Exposure to 1.25% (v/v) DMSO for 2 days produced no significant change in
binding affinity (0.9 nM), but the receptor number decreased from 180 to 130 receptors per
cell. Continued exposure to DMSO for 2 more days (4 days total) produced a small
decrease in receptor number from 130 to 110 receptors per c e ll. A single class of EPOR
with increased binding affinity (0.6 nM) was observed after 4 days of DMSO treatment,
but no receptors of the original affinity constant of 0.9-1.0 nM were seen. While these
receptors exhibited somewhat higher affinity for EPO, the affinity constant remained in the
low-affinity range (55). No positive cooperativity was seen in Friend cells with DMSO
induction of differentiation.
These results were surprising for several reasons. First, a previous report had
shown that DMSO treatment o f MEL cell clone B8 resulted in a two-fold increase in
receptor number but no change in binding affinity (90). Secondly, Friend MEL cells had
been shown, during these investigations, to regain EPO responsiveness after 3 days o f
exposure to DMSO (Table 2). Thirdly, these investigations had demonstrated increased
EPOR mRNA expression in response to DMSO treatment (Figures 6 and 7). However,
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binding assays demonstrated that this increased level of mRNA did not result in increased
expression of functional receptor at the cell surface. Several possible explanations could
account for this observation.
Possible explanations for the decreased number and increased binding affinity .of
EPORs on Friend MEL cells exposed to DMSO. First, the increased level o f EPOR
mRNA in DMSO-treated MEL cells may be translated at a slower rate than in untreated
cells, resulting in a decreased synthetic rate of the protein. Alternatively, the protein may
be synthesized at an equal or faster rate, but newly synthesized EPORs may be retained in
the rough endoplasmic reticulum (RER) or degraded at a faster rate, resulting in a shorter
half-life and increased EPOR protein turnover. Pulse-chase metabolic labeling experiments
followed by immunoprecipitation with antibodies against the EPOR could address these
questions, as such studies would provide information about EPOR protein synthesis and
subsequent degradation. Treatment with endoglycosidase H or fractionation of the plasma
membrane from total cell extracts could provide information about the processing and
transport o f EPORs to the cell surface.
O f interest was the increase in EPOR binding affinity observed during day 2 to 4 of
DMSO treatment, which had not been previously reported in MEL cells. The detection of
only a single class of receptors of a different binding affinity on day 4 was surprising, as
induction o f a new class of receptors during the time interval from day 2 to day 4 would be
expected to produce two classes of EPORs in the Scatchard plot. Two explanations may
account for this observation. First, MEL cells may stop all cell surface expression of the
first class of EPOR (kd of 0.9-1.0 nM) and express only receptors of a new, second class
(kd of 0.6 nM) from day 2 to 4 o f DMSO treatment. However, the biological utility of
expressing a new class of EPOR with only a 60-80% increase in binding affinity is not
obvious. Secondly, the presence of DMSO in the culture medium may perturb the cell
membrane to such an extent that the conformation of the EPOR is altered to such a degree
that the binding affinity of the receptor for its ligand is changed somewhat. Of particular
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concern was the possibility that the observed change in binding affinity in response to
DMSO was due, not to induction of differentiation but rather, to perturbation of membrane
properties (211).
Decreased number and increased binding affinity of EPORs on PMSO/R1 cells. To
help address these questions, binding assays were performed with DMSO/R1 cells.
DMSO/R1 cells maintained in DMSO-containing growth medium expressed 62 receptors
per cell of a single class with an affinity constant of 0.46 nM. Thus, the DMSO-resistant
subline expressed approximately a third of the number o f receptors exhibited by the
parental Friend MEL cell line, and these receptors exhibited twice the binding affinity of the
parental line's EPORs. These results were surprising, given the higher level of EPOR
mRNA expression in DMSO/R1 cells compared to Friend MEL cells. As has been
discussed above, a number of mechanisms may play a role in the decrease in cell surface
EPORs despite an increased EPOR mRNA level.
An additional possibility is that increased SFFVp gp55 in DMSO/R1 cells may
retain EPOR within the RER and retard transport of the receptor to the cell surface. Gp55,
the viral envelope glycoprotein o f SFFVp, has been demonstrated to associate with the
EPOR and cause retention o f the receptor within the RER (30,103, 109-111, 122). The
association of gp55 with the EPOR has also been shown to confer factor independence
upon Ba/F3 cells cotransfected with vectors expressing cDNAs for both gp55 and EPOR
(104). This possibility will be further addressed in a later part of the Discussion section.
The presence of DMSO in the growth medium used to passage DMSO/R1 cells was
of concern, as the decreased EPOR number and particularly the higher binding affinity of
DMSO/R1 cells could be due to the presence of DMSO, rather than intrinsic properties of
the subline. This concern was increased by the observation that DMSO treatment of Friend
MEL cells resulted in both decreased cell surface receptor and affinity constant. It was
necessary to determine if the results seen with clone DMSO/R1 were due to continual
exposure to a polar solvent or if they reflected stable differences in this subline. Such
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information was also necessary to help determine if the changes in receptor number and
affinity constant seen with DMSO treatment of Friend cells resulted from induction of
differentiation or from the presence of the solvent
To address this issue, DMSO/R1 cells were passaged in DMSO-free growth
medium for 2 weeks, and the binding assay was repeated. The removal o f DMSO from
growth medium resulted in no change in binding affinity (0.41 nM) or receptor number (61
receptors per cell) compared to DMSO/R1 cells which were continuously exposed to
DMSO in culture. Thus, the changes in EPOR number and binding affinity in DMSO/R1
cells, as compared to parental MEL cells, did not appear to be dependent on the constant
presence of DMSO in culture. It can also be inferred, since the presence of DMSO did not
affect the values determined for DMSO/R1 cells, that the changes in the cell surface
expression and binding affinity of the EPOR observed with DMSO treatment o f Friend
MEL cells were due to induction of cell differentiation, rather than to the physical presence
of the chemical agent. However, it is entirely unclear whether the decreased receptor
number and affinity constant of the EPOR had any causal relationship with the DMSOresistant phenotype of DMSO/R1 cells.
It was interesting to note again that a change in EPOR mRNA expression was not
reflected by a similar change in cell surface receptor expression. Removal of DMSO/R1
cells from DMSO-containing medium resulted in a decreased level of EPOR mRNA, but no
change resulted in receptor binding assays. These results indicate that post-transcriptional
controls are important in regulation of the expression of the EPOR on the surface of MEL
cells. Such controls, as discussed above, may involve translational control or posttranslational regulation, such as protein transport or degradation.
Proposed future binding studies of the EPOR on Friend MEL and DMSO/R1 cells.
The first part of these investigations, unfortunately, have not led to a clear model of EPOR
expression during the DMSO-induced differentiation of Friend MEL cells, but they have
raised intriguing questions. While DMSO induction resulted in decreased cell surface
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expression of the EPOR, Friend MEL cells became responsive to EPO upon this induction.
Thus, DMSO must act upon some mechanism downstream of the EPOR, as the decreased
number of receptors in DMSO-treated cells are able to respond to EPO. One attractive
hypothesis is that DMSO causes dissociation of the EPOR from SFFVp gp55 in Friend
MEL cells, allowing the cytokine receptor to transduce its signal upon binding of EPO.
This possible explanation must be considered, as SFFVp gp55 has been shown to be the
part of the Friend viral genome required to confer tumorigenicity (30, 103, 213). This
hypothesis will be addressed in a later part of the Discussion section.
Such a model of DMSO’s actions is conceivable, given the membrane-perturbing
effects of DMSO (211). However, a major problem with DMSO or any other polar
compound used to examine leukemia cell differentiation is the degree of nonspecific activity
with any o f these chemical agents. These compounds induce tumor cell maturation in a
wide number of, but not in all, leukemia cell lines, and their polar properties endow them
with a variety of membrane- and cell-disrupting effects (211). Unfortunately, they remain
the most useful group of agents with which to study leukemia cell differentiation and will
remain so, until new, more specific inducers of differentiation are discovered.
Two useful sets of additional binding experiments may help to address whether the
changes in EPORs observed in MEL cells after exposure to 1.25% (v/v) DMSO for 2 or 4
days resulted from cell differentiation or from the physical presence o f a polar solvent The
first set of studies involves treatment of MEL cells with a lower concentration of DMSO, to
which approximately equal numbers of cells do and do not respond by entering the
differentiation pathway. Two populations of MEL cells, one differentiating and the other
not, should arise in culture after treatment with this lower concentration of DMSO. If MEL
cell differentiation was responsible for the aforementioned changes in EPOR expression,
binding studies of the entire cell population should theoretically observe two discrete
population of EPORs, one from each population of MEL cells, with different affinity
constants. If solvent effects were responsible for the changes in EPOR expression,
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however, the same changes in EPOR number and binding affinity should theoretically
occur in both differentiating and nondifferentiating cells, as these changes would be due to
membrane perturbation effects of DMSO and would not be specific for one or the other
group o f cells. In this latter case, a single population of EPORs with a single binding
affinity should theoretically be observed in both cell populations.
The second set of studies involves treatment o f Friend MEL cells and DMSO/R1
cells with a differentiation inducer that has fewer membrane perturbation effects.
Unfortunately, the other commonly used inducer of MEL cell differentiation, HMBA (51),
also alters membrane potential (211). However, the amount of HMBA used to induce
MEL cell differentiation in vitro is smaller than the concentrations of DMSO (1-2%, v/v)
necessary to induce differentiation. Thus, solvent effects on the cell membrane may be less
of a problem with HMBA than at the conentration of 1.25% (v/v) DMSO used in these
studies. If similar changes in the EPOR number and binding affinity were observed with
treatment with an inducer that exhibited fewer membrane disrupting effects, such results
would suggest that the receptor changes seen with DMSO resulted from the induction of
differentiation. Alternatively, if no changes were seen with the new inducer, such results
would suggest that membrane perturbation effects of DMSO were responsible.
It remains puzzling that so many different values for the binding affinity of the
mEPOR have been reported, when only one murine EPOR cDNA has been cloned to date
(60). These differences may reflect differences in methodology or errors in measurement,
or they may reflect slightly different post-translational modifications o f the receptor by
different murine cell types expressing the EPOR. Alternatively, other cellular proteins may
be important in the mEPOR complex needed to bind EPO, and the absence or presence of
these proteins may affect the affinity of the cytokine receptor for EPO. It is quite
conceivable that these accessory proteins may be different from cell line to cell line. In a
way, values from one report can not be compared to results from another report, as
investigators have used different cell lines and binding conditions to obtain their results.
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The binding o f EPO to its receptor and the changes in this binding with induction o f MEL
cell differentiation remain areas which need further investigation.

INCREASED EXPRESSION OF GP55 PROTEIN IN DMSO/R1 CELLS
The hypothesis that DMSO causes dissociation o f the EPOR from SFFVp gp55 in
Friend MEL cells, allowing the receptor to transduce its signal upon binding of EPO, was
discussed earlier in this section. This hypothesis proposes that the envelope protein o f the
SFFVp plays a role, not only in the constitutive activation of the EPOR with resultant EPO
independence (104) but also, in the block in EPO-induced differentiation observed in
Friend MEL cells (20, 29). This question was first approached by examining whether
DMSO induction o f maturation resulted in changes in gp55 expression and whether
DMSO/R1 cells demonstrated different expression of gp55. Attention was therefore turned
upon the synthesis and processing of the SFFVp env gene product in Friend MEL and
DMSO/R1 cells and upon the effects of induction of differentiation upon gp55 expression.
Increased SFFVp pp55 protein content, but not gp55 synthesis, in DMSO/R1 cells.
Metabolic labeling experiments (156-158) were conducted to examine the synthesis of
SFFVp gp55 in Friend MEL and DMSO/R1 cells, and the effect of DMSO treatment on this
synthesis was also examined (Figures 15 and 16). Western blot analysis (173) was
performed to measure the amount of total cellular gp55 in these cells (Figure 17). The
results of these studies strongly suggested that, while the SFFVp envelope glycoprotein
was not synthesized at a greater rate in DMSO/R1 cells than in parental MEL cells, gp55
was being degraded at a slower rate in the resistant subline, leading to accumulation of a
much higher level of total cellular gp55 protein in DMSO/R1 cells. This increased level of
gp55 in a DMSO-resistant MEL subline and the observation that DMSO-treated DMSO/R1
cells expressed more total gp55 protein than uninduced MEL cells were interesting
findings, given our hypothesis that gp55 plays a role in the block in EPO-induced
differentiation of Friend MEL cells.
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While there was no obvious explanation for the increased stability of synthesized
gp55 in DMSO/R1 cells, the increased amount of total cellular gp55 protein suggested a
possible explanation for the decreased number of cell surface EPORs observed on these
cells during binding studies. SFFVp gp55 has been shown to associate with the EPOR in
the RER, causing retendon of the cytokine receptor within the RER and increasing the halflife of newly synthesized receptor (122). Since more than 95% of the SFFVp env gene
product in Friend MEL cells remains in the RER due to defective intracellular transport of
the glycoprotein (27,116), DMSO/R1 cells, in most likelihood, contain a higher number of
gp55 polypeptides in their RERs. A higher number o f gp55 molecules may increase
retention of EPORs in the RERs of DMSO/R1 cells and thereby inhibit transport of the
receptors to the cell surface.
To determine if such a retention was occurring, the synthesis and intracellular
transport of EPORs in Friend MEL and DMSO/R1 cells were examined by pulse-chase
metabolic labeling and endoglycosidase H (endo H) treatment (166-168) of a-mEPOR
immunoprecipitates. Unfortunately, the rabbit polyclonal a-mEPOR antiserum that was
used did not prove an effective precipitator of the receptor in cellular lysate samples, despite
the trial of a number o f antibody dilutions. This ineffectiveness may have been due to low
numbers of EPORs in the lysates or to inadequate binding affinity of the antiserum for the
mEPOR. However, the antiserum was synthesized to the same peptide antigen that had
been reported to generate immunoprecipitation-usable antiserum (122).

SloaLrisgiadatign.Qf.SFFVp gp55 in Frignd.M El and.P M S Q/R 1 ,cells- Pulsechase metabolic labeling and endo H treatment (166-168) o f anti-gp55/gp70
immunoprecipitates demonstrated that the SFFVp env gene product existed primarily as an
immaturely glycosylated, endo H-sensitive 55 kDa glycoprotein which underwent little, if
any, detectable degradation during a 6 hour chase period following metabolic labeling
(Figures 18 and 19). There appeared to be some degradation of gp55 after a 6 hour chase
period in DMSO-treated MEL cells, suggesting that the decrease in total gp55 protein seen
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with Western blot analysis of these cells was due to faster degradation of synthesized gp55.
If synthesized gp55 protein in DMSO/R1 cells has^reater stability and a longer half-life
than in parental MEL cells, a much longer chase period will be necessary to detect such a
difference in degradative rates of the envelope glycoprotein. The duration of the chase
period in this set of experiments was too short to detect any degradation of gp55, much less
any difference between the stabilities of gp55 in the two cell lines.
Interestingly, F-MuLV gp70 appeared to be synthesized at an equal or slower rate
in both cell lines than was SFFVp gp55 and, unlike gp55, underwent significant
degradation during the chase period (Figures 18 and 19). Yet, Western blot analysis with
the same antiserum used in immunoprecipitation studies detected a markedly higher amount
of gp70 than of gp55 in both Friend and DMSO/R1 cells (Figure 17). Since a greater
quantity of one protein can not accumulate when it is synthesized at an equal or slower rate
and possesses a shorter half-life than the second protein, one of the observations is
probably the result o f experimental artifact. The most likely explanation is that the
polyclonal antiserum used in these investigations exhibits different binding affinities for
gp55 and gp70 under immunoprecipitation conditions and Western blot conditions. The
antiserum may immunoprecipitate gp70 less efficiently than gp55, or the antiserum may
bind gp70 more efficiently than gp55 on a Western blot. This question will be addressed
later in this section.
Transfection o f pRc/RSV-gp55 and pRc/RSV-antisense gp55 into Friend cells.
Although DMSO/R1 cells had been demonstrated to contain a greater amount o f gp55
protein than parental MEL cells, it was unclear whether this increased level of the SFFVp
env gene product produced the DMSO-resistant phenotype in clone DMSO/R1, whether
these two phenomena were correlated but not causally related, or whether these two
phenomena were entirely unrelated. To test the hypothesis that the envelope protein of the
SFFVp plays a role, not only in the constitutive activation of the EPOR (104, 115) but
also, in the block in EPO-induced differentiation observed in Friend MEL cells,
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transfection studies were performed to increase or decrease the level of total gp55 protein in
MEL cells. Electroporation (140,175-178) was used to stably transfect Friend cells with
vector alone (no insert), vector expressing the SFFVp gp55 cDNA in the sense orientation,
or vector expressing the gp55 cDNA in the antisense orientation (Figure 20). Cells were
selected in growth medium containing G-418 (180-182) and cloned by single cell sorting.
Western blot analysis (173) o f SFFVp gp55 was used to screen clones for
increased or decreased cellular content o f gp55 protein. This method of screening was
chosen because the relationship of interest was the one between the level of total cellular
gp55 protein, not o f mRNA expression or protein synthesis, and responsiveness to the
effects of DMSO. A clone (Tf-gp55) of pRc/RSV-gp55-transfected cells expressing an
increased level of gp55 protein similar to that seen in DMSO/R1 cells was chosen for
further study (Figure 21). Similarly, a clone (B7) of pRc/RSV-antisense gp55-transfected
cells expressing a decreased level of gp55 was selected for further study (Figure 22).
Transfection of the expression vector alone containing no DNA insert had no
significant effect on the growth characteristics or responsiveness to DMSO (Table 6). As
summarized in Table 6 and in the Results section, Tf-gp55 cells exhibited similar growth
characteristics as Friend cells, and exposure of Tf-gp55 cells to DMSO resulted in a similar
amount of growth inhibition as in parental MEL cells. In addition, DMSO-pretreated Tfgp55 cells responded to EPO with a similar increase in cell proliferation as was observed
with parental Friend cells. However, unlike its action upon Friend MEL cells, DMSO
treatment of Tf-gp55 cells did not confer cellular responsiveness to the differentiationinducing effects o f EPO (Table 7). These results suggested that the increased level of
SFFVp gp55 in DMSO/R1 cells was responsible for the cells' resistance to the restoration
by DMSO of cellular sensitivity to EPO's differentiation-inducing effects. However, these
results indicated that the increased level of gp55 in DMSO/R1 cells was not responsible for
the cells’ resistance to the differentiation-inducing effects of DMSO and to the restoration
by DMSO of sensitivity to the growth-stimulatory effects o f EPO.

Some other
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mechanism(s) must account for these two aspects of the resistant phenotype of clone
DMSO/R1.
Separation of the growth-stimulatory and differentiation-inducing effects o f EPO.
These results demonstrated that the stimulation o f proliferation and the induction of
differentiation by EPO are two separate processes. EPO was able to stimulate cell growth,
but not increased differentiation, in Tf-gp55 cells that had been pretreated with DMSO,
indicating that these two cellular pathways are not necessarily linked.

It makes

physiological sense for these two pathways to be connected, as the biological function of
EPO is to increase the number of circulating erythrocytes and, thus, the oxygen carrying
capacity of the blood (38,54). EPO increases the erythrocyte population by stimulating the
proliferation of erythroid progenitor cells, thereby increasing the erythroid cell pool as well
as replacing differentiating progenitors, and inducing the maturation of erythroid precursor
cells to mature, functional red blood cells (1,54). However, these results have shown that
the proliferation and maturation pathways downstream of the EPOR can be disconnected.
This separation had been suggested by the ability of gp55 to associate with and
constitutively activate a mitogenic signal, but not a differentiating signal, from the EPOR.
Interestingly, as evidenced by the ability of DMSO to induce the differentiation of
Tf-gp55 cells, but not to confer sensitivity to the maturation-inducing effects of EPO in the
same cells, the block in the EPO-induced differentiation of Friend cells does not seem to be
due simply to a block in tumor cell maturation. Tf-gp55 cells were induced to differentiate
to the same apparent extent as Friend cells, as evidenced by growth inhibition and Hb
production (20, 134, 206). Nevertheless, these transfected cells were unable to further
differentiate in response to EPO. Thus, the ability of a DMSO-treated MEL cell to respond
to EPO does not appear to be dependent solely upon the stage of differentiation of the
tumor cell. In normal erythroid progenitor cells, responsiveness to EPO does appear to be
dependent upon a cell's stage of development and the distance which the cell has traveled
along the pathway from pluripotent stem cell to mature erythrocyte (38,54). The increase
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in the level of gp55 protein in Tf-gp55 cells, however, resulted in continued blockage of
EPO-induced maturation despite DMSO-induced differentiation.
Transfection of MEL cells with pRc/RSV-antiscnsc tn?55 cDNA. O f greater interest
than transfection studies to increase gp55 protein content was the attempt to decrease the
level of gp55 by the transfection of a vector expressing gp55 cDNA in the antisense
direction. If the hypothesis that the gp55-EPOR interaction results in a block in EPOinduced differentiation is true, a significant decrease in cellular gp55, and thereby gp55EPOR interactions, should allow MEL cells to differentiate in response to EPO in the
absence of pretreatment with DMSO. However, the results obtained from these antisense
transfection studies did not fully support nor refute this hypothesis.
Clone B7, derived from MEL cells transfected with pRc/RSV-antisense gp55, was
hypersensitive to both the differentiadon-inducing and EPO-sensitizing effects o f DMSO,
compared to parental Friend cells (Table 8). DMSO-pretreated B7 cells responded to EPO
with increased stimuladon of both cell proliferation and further differentiation. However,
these cells contained only a partially decreased level of gp55 protein and were unresponsive
to EPO in the absence of DMSO. All further attempts to isolate pRc/RSV-antisense gp55transfected clones with more greatly decreased levels of gp55 were unsuccessful.
Whatever the role o f SFFVp gp55 in blocking MEL cell differentiation may be, gp55 is
known to be required for EPO independence of MEL cells (104,115). Thus, transfectants
in which the expression of gp55 is decreased to very low or nonexistent levels are likely to
be unable to grow in culture in the absence of EPO.
To address this concern, EPO was added to the selection medium and to the
medium in which clones were expanded after single cell sorting. Unfortunately, this
modification proved fruitless. Several clones which, in preliminary tests, appeared to
increase Hb production in response to EPO in the absence of DMSO (data not shown),
could not be maintained in culture despite repeated attempts. After a limited number of
passages, these very promising clones stopped growing and could not be maintained in
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culture.

While this inability to maintain viable populations o f these clones was

disappointing, this failure was not surprising given the dual effects of EPO upon cells of
the erythroid lineage (38, 54).

EPO that was added to support cell viability and

proliferation in transfectants with greatly decreased gp55 protein levels may have induced
these same cells to enter the maturation pathway and lose their capacity to self-replicate (1).
Thus, it was not unexpected that only cells in which gp55 expression remained above a
certain threshold level were able to be isolated from the antisense transfection studies.
These results indicated that SFFVp gp55 may play a role in blocking EPO-induced
differentiation, possibly through its association with the EPOR (104, 122). The question
of possible relationships between gp55 expression and cellular responsiveness to EPOinduced growth stimulation or DMSO-induced differentiation remains unclear. While no
changes were observed upon increased expression of gp55, increased sensitivity to the
maturation-inducing and EPO-sensitizing effects of DMSO accompanied a decrease in the
level of gp55 protein in clone B7. Clones Tf-gp55 and B7 may prove useful tools for the
study o f the signal transduction pathways used by the EPOR to generate mitogenic and
differentiation signals in the erythroid cell (38, 54, 55). Clone Tf-gp55, in particular,
offers a cell system in which the differentiating response to EPO has been dissociated from
the proliferative response to EPO. Studies may be conducted to examine if exposure to
EPO after DMSO pretreatment results in the activation of different intracellular messenger
systems than in Friend cells. In particular, activation of a certain messenger pathway in
Friend cells, but not in Tf-gp55 cells, may be valuable in identifying the possible
involvement of this pathway in the generation of a differentiation signal.

INTERACTION BETWEEN GP55 AND THE EPOR
Chemical crosslinking to_radioiodinated EPO. Chemical crosslinking was
performed with a number of different reagents, but none proved to be an efficient
crosslinker of radiolabeled EPO. Only a small fraction of the radiolabeled EPO that was
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bound to cells was crosslinked to protein, despite the use of several different reagents and
numerous attempts to optimize crosslinking conditions and minimize any hydrolysis of the
crosslinker. The binding of radiolabeled EPO was demonstrated to be specific by the
ability of excess cold EPO to compete for binding (Figure 23). Homobifunctional Nhydroxysuccinimide (NHS) esters (DSS, DST, BS^), which react with primary amines on
lysine or available amino-terminal amines, and a carbodiimide (EDC), which crosslinks an
amine to a carboxylic acid group, were tested (126-128, 190-198). The tested reagents
included both water-insoluble, membrane-permeable compounds (DSS, DST) and watersoluble, membrane-impermeable compounds (BS^, EDC / sulfo-NHS). None of these
compounds, however, crosslinked more than a small fraction o f receptor-bound 12^IrhEPO to cellular protein.
The ability o f a chemical crosslinker to covalently join a radiolabeled ligand to its
receptor or to a receptor-associated protein depends upon the chemical specificity and the
spacer arm length of the reagent. The chemical specificity of a crosslinking reagent resides
in the functional reactive group or groups which are contained in the reagent (214).
Different reactive groups couple to different amino acid residues, and only reagents with
the appropriate functional group(s) can crosslink two proteins. Additionally, the distance
between the targeted amino acid residues on the two proteins must be bridged by the
crosslinker in order for covalent linkage to occur (214). The inability of myriad attempts to
covalently link radioiodinated EPO to its receptor is, in all probability, due to a lack of
suitable amino acid residues on the two proteins that are in close enough physical proximity
to be joined by available crosslinking reagents. The crosslinking of radiolabeled EPO to
SFFVp gp55 in a Friend MEL cell line (115,123) indicated that gp55 must be associated
with the EPOR and that the spatial relationship of the bound EPO molecule and gp55
allowed the intermolecular distance to be bridged by a crosslinker.
As shown in Figures 23 to 25, radiolabeled EPO was crosslinked primarily to a
protein of a molecular weight of 60-65 kDa, which has been previously identified by other
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investigators as SFFVp gp55 and not the EPOR (123). A protein o f approximately 120
kDa was also crosslinked to 125I-rhEPO when a combination of DSS and DST was used
(Figure 25). This second protein may represent a dimer of gp55, as gp55 has been shown
to form disulfide-linked homodimers in Friend MEL cells (27,107, 115,117). Attempts
to positively identify the smaller and larger proteins by immunoprecipitation of 125I-rhEPOcrosslinked proteins from cellular lysates were unsuccessful. This lack o f success was
likely due to the very small amount o f EPO-crosslinked proteins present in the binding
mixture and the resultant inability to immunoprecipitate detectable amounts o f proteins.
Induction of MEL cell differentiation did not result in disappearance of either the
60-65 kDa or 120 kDa crosslinked protein. On the contrary, the amounts of the two EPOcrosslinked proteins appeared to have increased upon DMSO treatment, although this was
difficult to determine due to the faintness of the crosslinked bands. In addition, similar
amounts o f both crosslinked proteins were observed in DMSO/R1 cells, and DMSO
treatment seemed to have a similar effect on EPO-crosslinking in resistant cells as in
parental MEL cells.
These results were surprising for several reasons.

First, these findings

demonstrated that induction of differentiation by DMSO was not accompanied by
dissociation of SFFVp gp55 from the EPOR, as the putative gp55 protein was still
crosslinked to EPO after 4 days of DMSO treatment. Secondly, the amount o f ^1-rhEPOcrosslinked gp55 appeared to increase upon DMSO induction of differentiation, although
the number of receptors was shown to decrease from 180 to 110 receptors per cell over the
same time period. Similarly, comparable levels of EPO-crosslinking to DMSO/R1 cells
were observed, although binding studies demonstrated that DMSO/R1 cells express onethird the number of EPORs expressed by parental MEL cells.

Thus, while DMSO

induction of differentiation does not result in dissociation of SFFVp gp55 from the EPOR,
some other change in the EPOR complex may be occurring, as a model in which the EPOR
complex remains static does not fit the crosslinking results. In any case, crosslinking of
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EPO to gp55 must occur through interaction of EPO to the EPOR, since it has been
demonstrated that EPO does not bind to cells expressing gp55 but not the EPOR (57,115).
Differences between water-insoluble and water-soluble crosslinkers. Interestingly,
the amount o f ^ j^ E P O - c r o s s lin k e d gp55 was greater when a water-insoluble,
membrane-permeable reagent was used, either alone (DSS) or in combination with another
compound o f a similar class (DSS and DST), rather than a water-soluble, membraneimpermeable reagent (BS3 or the combination o f EDC and sulfo-NHS). O f note, the
reported crosslinking of radiolabeled EPO to SFFVp gp55 in MEL cells had been achieved
with DSS (123). Classically, surface membrane proteins are crosslinkable by both watersoluble and water-insoluble reagents, whereas integral membrane proteins are conjugable
by water-insoluble, but not water-soluble, reagents (214). The reason is obvious; watersoluble compounds are not able to permeate the membrane. Such an explanation does not
seem plausible in this situation, however, since EPO is known to bind to the exoplasmic
domain of its receptor (55,57). Thus, bound EPO must be on the exoplasmic surface of
the plasma membrane, rather than imbedded in the membrane, and should be reachable by
water-soluble crosslinkers. In addition, although little if any crosslinking was observed
with the combination of EDC and sulfo-NHS, the other water-soluble crosslinker, BS3,
was able to conjugate 125I-rhEPO to gp55.
Two other characteristics of the tested water-soluble reagents may explain their
inferior ability to crosslink radiolabeled EPO to gp55. First, EDC, being a carbodiimide
(195-197), is in an altogether different class of reagents from DSS, DST and BS3, which
are all homobifunctional NHS esters (126-128, 190-193). EDC can only crosslink an
amine on one protein to a carboxylic acid group on a second protein, whereas the NHS
esters crosslink a primary amine on one protein to a primary amine on a second (214).
Thus, an exposed carboxylic acid at the right distance from an amine may not be present on
the second protein.

Secondly, the spacer arm length of DST, 6.4 angstroms, is

considerably shorter than the spacer arm lengths o f DSS or BS3, which are both 11.4
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angstroms (214). Thus, the combination of DSS and DST may be able to each form one
crosslink, incorporating twice as much label as BS3 alone.
Cell surface labeling o f SFFVp gp55. Since the crosslinking o f EPO to gp55
appeared to increase with induction of differentiation, cell surface labeling studies (199203) were conducted to determine if cell surface expression of SFFVp gp55 increased with
DMSO treatment. A small amount of SFFVp gp60-65 was seen in Friend MEL cells,
indicative of the low percentage (2-5%) of the SFFVp env gene product that is transported
to the cell surface (Figure 27) (27, 116). Markedly decreased labeling of F-MuLV gp70,
and no SFFVp gp60-65, was observed in DMSO/R1 cells. Not only did the increased
level of SFFVp gp55 in DMSO/R1 cells not result in increased cell surface expression of
SFFVp gp60-65, DMSO/R1 cells exhibited markedly less surface gp60-65 than parental
MEL cells. The decrease in surface F-MuLV gp70 in DMSO/R1 cells was unexpected, as
this glycoprotein is not throught to have any role in the mitogenic activation of the EPOR or
in blockage of EPO-induced differentiation (27). However, the decreases in the the cell
surface expression of the two viral envelope glycoproteins in DMSO/R1 cells appeared
specific, as total labeled surface proteins did not change remarkably from parental MEL
cells (Figure 26).
While total cell surface labeled proteins increased upon exposure o f Friend MEL or
DMSO/R1 cells to DMSO (Figure 26), DMSO treatment of both cell lines resulted in
greater increases in surface labeling of both F-MuLV gp70 and the 60-65 kDa protein
thought to be the maturely glycosylated envelope form of SFFVp gp55 (Figure 27). In
addition, cell surface labeled protein gp55 was observed in DMSO-treated MEL cells but
not in DMSO-resistant cells exposed to DMSO. This result was quite surprising, as the 55
kDa form of the SFFVp env gene product normally represents immaturely glycosylated
protein that has not traversed the Golgi complex (27, 107, 116). This Finding suggested
that DMSO treatment may disrupt normal intracellular transport, resulting in transport of
immaturely glycosylated gp55 to the cell surface without carbohydrate processing.
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To explore alternative explanations for this observation, the mechanism of action of
lactoperoxidase-glucose oxidase radioiodination must be reviewed (199-203). In the
Enzymobead preparation used in these studies, the two enzymes are immobilized on
hydrophilic spheres several microns in diameter. The glucose oxidase generates hydrogen
peroxide from p-D-glucose, and lactoperoxidase catalyzes the peroxide oxidation o f labeled
iodide to 125l 2 . 125l2 reacts with cellular proteins to produce radioiodinated proteins.
Given the membrane perturbing effects of DMSO (211), it is conceivable that exposure of
MEL cells to DMSO may disrupt the plasma membrane to such an extent that a molecule
such as 12^l2 may diffuse through the plasma membrane to radioiodinate proteins that are
intracellular.

The size of the Enzymobead spheres precludes the possiblity of

intemalizadon of the spheres.
What argues against both proposed explanations, however, is the apparent relative
specificity of this increase in cell surface labeling of SFFVp gp55 and F-MuLV gp70. If
disruption of membrane protein transport or diffusion of 12^l2 into the cell was occurring,
then labeling of other immaturely glycosylated proteins or labeling of proteins not normally
expressed on the cell surface would be expected. However, although total cell surface
labeling increased with DMSO treatment, the same labeled bands were prominent in both
control and treated cells. Additionally, the increase in the viral envelope glycoproteins was
more pronounced than the increase in total surface proteins.
Similar experiments with clones Tf-gp55 and B7 demonstrated the apparent lack of
a relationship between total SFFVp gp55 content and surface expression of the envelope
protein (Figure 28). Both sense and antisense gp55-transfected cells exhibited similar
surface labeling of F-MuLV gp70 and SFFVp gp65 as did parental MEL cells. Although
both DMSO/R1 and Tf-gp55 cells showed increased total cellular SFFVp envelope
glycoprotein, the amount of cell surface gp65 was quite different in the two cell lines, with
clone Tf-gp55 expressing a similar amount as the parental Friend MEL clone as well as
clone B7. Similar to its effects upon Friend cells, DMSO increased labeling of both F-
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MuLV gp70 and SFFVp gp65 and induced the labeling of SFFVp gp55 in both transfected
clones. These results demonstrated no relationship between the level of cell surface SFFVp
gp60-65 and responsiveness to the differentiation-inducing and EPO-sensitizing effects of
DMSO.
Coimmunoprecipitation studies o f SFFVp gp55 and the EPOR. To more directly
determine if induction of MEL cell differentiation results in dissociation o f SFFVp gp55
from the EPOR, coimmunoprecipitation experiments were performed (Figures 29-33).
These studies took advantage of the difference between the sizes of the SFFVp env gene
product expressed on the cell surface (65 kDa) and in the RER (55 kDa) to determine which
of the two forms associated with the EPOR (27,116). The goat polyclonal a-MuLV gp70
antiserum more efficiently immunoprecipitated SFFVp gp55 than F-MuLV gp70, as
Western blotting demonstrated a higher ratio of gp55 to gp70 in immunoprecipitates than in
cellular lysates (Figure 29). This finding provided a possible explanation for the higher
ratio of gp70 to gp55 detected in Western blots than in immunoprecipitation of
metabolically labeled cellular lysates, despite the shorter half-life of gp70.
Figures 29 demonstrated that only the SFFVp env gene product, and not F-MuLV
gp70, associated with the EPOR, as immunoprecipitation of the EPOR did not coprecipitate
gp70. Both the cell surface gp65 form and the RER gp55 form coimmunoprecipitated with
the EPOR, and the amounts of the two forms that associated in parental MEL and
DMSO/R1 cells appeared to be similar. While only 2-5% o f the SFFVp env gene product
is expressed on the MEL cell surface in its mature 65 kDa form (27,116), approximately
equal amounts of gp65 and gp55 were coimmunoprecipitated with the EPOR, indicative
that the small amount of cell surface protein accounted for a significant fraction of the
SFFVp env gene product's interaction with the EPOR. Western blotting o f MEL and
DMSO/R1 cellular lysates with rabbit a-mEPOR antiserum detected a prominent band at
approximately 105 kDa (Figure 30). Whether this band represented an immunologically
related protein, perhaps a covalently linked homodimer of the receptor, or a protein
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nonspecifically recognized by rabbit antiserum was not determined. Such a determination
can be made by performing Western blot analysis of cellular lysate with rabbit preimmune
serum. Whatever the identity of this band, it was not recognized by the same rabbit amEPOR antiserum in immunoprecipitation studies and was not coprecipitated during
immunoprecipitation of SFFVp gp55.
Interestingly, bands of 60 kDa and 65 kDa, corresponding to the reported molecular
sizes of newly synthesized and maturely glycosylated EPOR, were far more prominent in
Western blots of a-mEPOR immunoprecipitates than of cellular lysates. This finding that
the rabbit a-mEPOR antiserum appeared to efficiently recognize and bind the EPOR in
cellular lysate samples was interesting, given the inability to detect significant levels of
metabolically labeled or cell surface labeled EPOR in earlier experiments. It is possible that
labeling of the EPOR with 35S-methionine or radioiodination with Na125I interfered, in
some way, with recognition of the receptor by the antiserum, resulting in this apparent
discrepancy in affinity of the a-mEPOR antiserum. The results depicted in Figure 31
demonstrated that the goat anti-rabbit secondary antibody directly recognized the denatured
immunoglobulin (Ig) heavy chain o f the rabbit a-mEPOR antibody, used in
immunoprecipitations, that had been subjected to SDS-PAGE and transferred to membrane.
It was somewhat surprising that a similar experiment showed that the rabbit anti-goat
secondary antibody did not recognize the denatured Ig heavy chain of the goat a-MuLV
gp70 antibody that had been subjected to SDS-PAGE and transferred (data not shown).
The results depicted in Figures 32 and 33 suggested that SFFVp gp55 and gp65 did
not dissociate from the mEPOR upon induction of MEL cell differentiation, as both forms
of the SFFVp env gene product were still coimmunoprecipitated with the EPOR (Figure
32). The amount of EPOR coimmunoprecipitated with the SFFVp envelope glycoproteins
did not change with exposure of Friend MEL or DMSO/R1 cells to DMSO, also suggestive
that the amount of association between the receptor and gp55 (and gp65) did not change
upon DMSO treatment. However, an important limitation of these coimmunoprecipitation
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studies must be kept in consideration when interpreting these results. The ability o f the amEPOR anti serum to coimmunoprecipitate SFFVp gp65 in a cellular lysate may represent a
true association of the two proteins ir. the living cell but may also represent an experimental
artifact arising from association in vitro after cellular lysis. The only true way to answer
this question is through careful fractionation of plasma membrane away from other
membrane compartments, including the RER, prior to examination of the SFFVp gp65EPOR interaction. Such an experiment has not been reported in the literature, probably due
to the extremely low number of EPORs expressed on the surface of MEL cells and the
accompanying technical difficulties associated with careful fractionation of cell membranes.

GP55 AND THE BLOCK IN EPO-INDUCED DIFFERENTIATION OF MEL CELLS
These investigations have attempted to examine the role of the SFFVp env gene
product, gp55 (27, 107, 111, 112), in the block in the EPO-induced differentiation of
Friend MEL cells. The ability of DMSO to induce maturation of Friend MEL cells (20) has
been studied to determine the effects of this maturation upon the relationship and interaction
between SFFVp gp55 and the EPOR.

An MEL subline that was resistant to the

differentiation-inducing and EPO-sensitizing effects o f DMSO, and that expressed greatly
increased amounts o f total cellular SFFVp gp55, was developed and studied to help
determine the changes in the interaction o f gp55 with the EPOR.
Increased expression of total cellular gpSS protein resulted in blockage of the ability
o f DMSO to restore sensitivity to EPO-induced differentiation. Such an increase, however,
did not result in blockage of the abilities of DMSO to induce maturation or to restore
sensitivity to EPO-induced proliferation. These distinctions are subtle but important points.
First, the induction o f MEL cell differentiation and the restoration of responsiveness to
EPO, or at least to the maturation-inducing effects of EPO, by DMSO are two separable
processes, indicating that the pathways are not identical. Thus, DMSO does not restore
EPO responsiveness merely by stimulating Friend cells to progress down the maturation
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pathway to a certain stage in development. Instead, DMSO must act on some other level to
permit the differentiation-induced cell to respond to EPO with further maturation.
Secondly, the abilities of EPO to stimulate proliferation and induce differentiation of
DMSO-treated Friend MEL are also separable events. If extrapolated to the function of
EPO in normal erythropoiesis, his latter distinction has wider implications, as EPO serves
dual, and seemingly contradictory, roles as mitogenic factor and differentiation inducer (38,
54). As discussed earlier in this section, the roles of EPO as growth stimulant and
maturation inducer fit physiologically, as proliferation and self-renewal of the erythroid
progenitor population is needed to replace precursors that have committed to terminal
differentiation and production of functional, end-stage erythrocytes (1). The SFFVp
envelope glycoprotein, gp55, binds to the EPOR and induces cell growth (104) but not
differentiation, indicative of the separation of the signaling pathways for these two
biological pathways. Clone Tf-gp55 represents an example in which that separation of
cellular events downstream of the EPOR is seen, not with a transforming viral envelope
glycoprotein but, with the natural ligand for the receptor, EPO.
The role o f SFFVp gp55 in the block in the EPO-induced differentiation of Friend
cells is, however, unclear. Coimmunoprecipitation and crosslinking studies indicated that
dissociation of gp55 or gp65, the cell surface form of the SFFVp env gene product, from
the EPOR does not appear to occur. These investigations have disproved the model that
had originally been proposed, that of DMSO’s acting upon the EPOR complex to dissociate
SFFVp gp55 from the receptor and thus "free" the receptor to transduce the mitogenic and
differentiating signals of EPO. However, DMSO may still alter the EPOR complex in such
a way that transduction of a maturation-inducing signal from the receptor can occur.
DMSO may perturb the plasma membrane, changing the gp55-EPOR complex enough that
a third protein, necessary to generate a differentiation signal, can bind to the EPOR. Such a
model is possible, especially given the change in receptor binding affinity seen upon
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DMSO treatment of Friend cells, which may be due to perturbation o f the plasma
membrane and EPOR conformation by DMSO.
Alternatively, DMSO may circumvent the gp55-EPOR complex entirely and induce
differentiation and restore EPO responsiveness at a different cellular site altogether. While
it is likely that DMSO induces MEL cell maturation through this manner, the restoration of
EPO responsiveness by this manner is more speculative, given the known interaction of
gp55 with the EPOR (104, 122) and the results observed with clone Tf-gp55. What that
cellular site may be is open to speculation, as DMSO has been demonstrated to exert a wide
range of effects upon cells, from membrane perturbations (211) to induction of a number of
second messenger systems, as reviewed in the Introduction section (46-53). DMSO may,
in fact, act upon several cellular systems which are all important in the induction of
differentiation. The study of DMSO as an inducer of MEL cell differentiation, and as a
restorer of EPO responsiveness, is greatly complicated by this range of nonspecific actions.
Thus, while SFFVp gp55 appears to be important in blocking the EPO-induced
differentiation of Friend MEL cells, the mechanism by which DMSO restores EPO
responsiveness remains unclear. The Friend cell system, while a fascinating model of
tumorigenesis and differentiation, is a system in which differentiation, particularly EPOinduced maturation, is difficult to study for a number of reasons. The low expression of
EPORs (55), the low level of cell surface SFFVp gp65 (27, 116), and the promiscuous
effects of the differentiation inducer DMSO (46-49,51-53,211) all contribute to complicate
the study of Friend MEL cell differentiation. However, unlike the study of EPO-induced
proliferation, which is readily studied in non-erythroid cell lines transfected to overexpress
the EPOR (104, 115), the investigation of erythroid differentiation must be performed in
erythroid cells, including the Friend system.
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SUMMARY
These studies have provided evidence that DMSO induces Friend cell differentiation
and restores EPO responsiveness at a cellular site downstream of EPOR expression and the
binding of EPO to its receptor. The results of the binding assays demonstrated that DMSO
does not restore EPO sensitivity through increased receptor expression, induction of a new
high-affinity class of receptor, or induction of cooperative binding. As demonstrated by
the transfection studies with clone Tf-gp55, restoration o f responsiveness to the
differentiating effects of EPO does not necessarily accompany DMSO-induced Friend cell
maturation and is not dependent solely upon the stage of maturation of the cell. Thus,
DMSO must restore EPO responsiveness through some mechanism other than induction of
differentiation. The same transfection studies provided evidence that EPO can induce a
mitogenic signal in the absence of a differentiation signal, demonstrating that these dual
effects of EPO are separable processes.
While clone DMSO/R1 exhibited an increased level of total cellular gp55 protein,
this increase did not appear to be the cause of the subline's resistance to the differentiating
effects o f DMSO. However, the transfection studies demonstrated that this increased
amount of gp55 is sufficient to maintain the block in EPO-induced differentiation despite
pretreatment of cells with DMSO. Although these investigations have provided evidence
that SFFVp gp55 plays a role in the block in the EPO-induced differentiation of Friend
MEL cells, the mechanism by which this block occurs and the mechanism by which DMSO
removes this block remain unclear. These studies have shown, however, that DMSO does
not induce the dissociation of gp55 from the EPOR in Friend cells.
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